ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
Recently Viewed
You have not visited any articles yet, Please visit some articles to see contents here.
CONTENT TYPES

Figure 1Loading Img

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer

View Author Information
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
*Phone: (650) 467-3214. E-mail: [email protected]
Cite this: J. Med. Chem. 2016, 59, 22, 10030–10066
Publication Date (Web):July 14, 2016
https://doi.org/10.1021/acs.jmedchem.6b00618
Copyright © 2016 American Chemical Society
Subscribed Access
Article Views
9461
Altmetric
-
Citations
LEARN ABOUT THESE METRICS
PDF (4 MB) OpenURL HONG KONG UNIV SCIENCE TECHLGY
Supporting Info (1)»

Abstract

In addition to each of the factors that govern the identification of a successful oncology drug candidate, drug discovery aimed at treating neurological cancer must also consider the presence of the blood–brain barrier (BBB). The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small molecules from freely reaching the brain, where neurooncologic malignancies reside. Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable. This Perspective discusses the unmet need for neurooncology treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clinical inhibitors of kinases that are of interest for the treatment of brain cancer.

Background

ARTICLE SECTIONS
Jump To

Neurooncology encompasses the study of tumors that originate in the brain (e.g., glioblastoma multiforme (GBM)) as well as brain metastases. In 2015, it was anticipated that more than 21 000 new cases of malignant brain and central nervous system (CNS) cancers would be diagnosed in the United States that year.(1) Among malignant brain tumors, the most common is GBM which has an associated poor prognosis (3-year survival rate 3–5%).(2) Despite the apparent unmet medical need, there has been little progress in developing new treatments for GBM. Most evaluations of chemotherapeutics in GBM have failed. Currently, the alkylating agents temozolomide (approved 2005) and the carmustine-based Gliadel wafer (approved 1996) are the only chemotherapeutics that are FDA approved for the treatment of newly diagnosed GBM. Other neurological cancers have similarly limited drug treatment options.
In addition to the need for more treatment options for primary brain tumors, metastasis of tumors to the CNS occurs from as many as 40% of peripheral tumors, with well over 100 000 cases per year.(3) When a kinase inhibitor is used for the treatment of peripheral disease, such CNS metastasis is a risk as a mechanism of emergent resistance if that inhibitor is not freely CNS penetrant. In this scenario, treatment of a tumor with drug is effective until disease progression occurs in the CNS, where drug concentrations are limited. As an example of the significance of the challenge presented by resistance due to CNS metastases, 14% of patients with HER2-positive breast cancer treated with pertuzumab had first evidence of disease progression due to CNS metastasis, evidently as a result of the inability of pertuzumab to cross the blood–brain barrier (BBB).(4) Unfortunately, as discussed below, this scenario is not limited to HER2-positive disease treated with a therapeutic antibody but also happens with numerous FDA approved small molecule kinase inhibitors that do not penetrate the CNS. For CNS metastases, prognosis is generally poor and chemotherapy is useful only in limited settings,(5) furthering the unmet need for new chemotherapeutics for malignancy in the CNS.
While primary brain tumors and brain metastases are distinct disease manifestations and may require targeting different drivers of disease, for the medicinal chemist, the approach to treating each of these indications requires the same considerations of the BBB, which typically limits small molecule penetration to the CNS where brain tumors reside. Furthermore, for both primary and secondary brain tumors there is biological rationale to develop BBB penetrating kinase inhibitors.
While there have been 32 kinase inhibitors approved for the treatment of cancers that reside outside the CNS, no kinase inhibitor has been approved for the treatment of primary CNS tumors, while alectinib (61) has recently received accelerated approval to treat patients including those with brain metastases. One reason for the lack of approved kinase inhibitors for treating brain tumors is that in order to effectively treat brain tumors, the kinase inhibitor must be capable of reaching its target. Therefore, the kinase inhibitor must effectively cross the BBB. As will be discussed below (and included as Supporting Information), the majority of approved kinase inhibitors and kinase inhibitors that have advanced to clinical study have no report of CNS penetration, reportedly limited CNS penetration, or CNS penetration that is expected to be limited due to the action of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp).
When considering potential therapeutics for the treatment of brain cancer, it is frequently asserted that because of disruption of the BBB by primary tumors or metastases in the brain, consideration of the BBB is not relevant. However, while it may be true that a tumor can disrupt the BBB, it generally does so just partially and significant literature reports indicate the importance of the BBB in limiting drug penetration to its intended target even when a tumor causes such partial disruption.(6) Additionally, GBM in particular is noted to grow in a diffuse manner in which a significant portion of the tumor grows behind an intact BBB, and so without effective drugs that are capable of freely crossing that barrier the tumor progresses.(7) That GBM grows in such a manner so as to remain behind an intact BBB punctuates the need for small molecules to be able to penetrate that barrier if they are to have potential to effectively treat that disease.
With an understanding of the importance of free BBB penetration for drugs targeting brain cancer, neurooncology medicinal chemistry programs have much in common with programs for other CNS diseases. Fortunately, in recent years there has been a much improved appreciation for the requirement to achieve sufficient free drug concentration in the brain, if that is where the target resides. A recent Perspective provides an excellent review of the concepts of free brain penetration that are essential to CNS and neurooncology programs alike and pertinent to the remainder of the discussion within.(8) Succinctly, it is important to note that it is critical that kinase inhibitors that are intended to treat brain tumors achieve therapeutically beneficial free drug concentrations in the brain. Indeed, a recent conference on CNS cancer drug discovery and development emphasized the need for neurooncology programs to focus on achieving free brain penetration.(9) To assess in preclinical studies whether effective therapeutic concentrations of a molecule cross the BBB, and therefore whether it has a realistic chance of achieving efficacy by the intended mechanism, some assessment of free brain or, as a surrogate, cerebral spinal fluid (CSF) concentrations is needed.(8) To assess the extent to which a small molecule freely penetrates the BBB (as opposed to just achieving a target free concentration in the brain), a comparison of free brain or CSF concentrations to free plasma concentrations is needed (Kp,uu). It is worth noting here that in the discussion of free brain penetration of clinical kinase inhibitors found below, the target therapeutic concentration is not often available, and so an assessment of free CNS penetration (Kp,uu or free brain-to-free plasma concentration ratios), where available, is utilized for an assessment. Where such values were available, we considered values of <0.1 to be low and evidence of significant limitation to free BBB penetration, whereas values of >0.3 demonstrate a significant degree of free CNS penetration.
In principle, therapeutic free concentration of drug might be able to penetrate the BBB even with very low Kp,uu values. In order for this to occur, however, there would need to be a corresponding increase in systemic exposure that might increase risk of unintended side effects. To illustrate, a kinase inhibitor with a Kp,uu of 0.1 would require 10 times the sytemic exposure to achieve a therapeutic benefit in the brain compared to a kinase inhibitor equivalent in all aspects except for a Kp,uu of 1.0. When targeting CNS disease, then, the importance of maximizing Kp,uu is a significant consideration and likely to impact the safety/tolerability of a molecule at doses required to achieve therapeutically beneficial free concentrations in the CNS.
With an understanding of the importance of achieving free CNS penetration with molecules intended for the treatment of brain cancers, a paramount requirement for achieving significant free drug concentrations behind the BBB is that the small molecules are not strong substrates of P-gp or Bcrp, efflux transporters highly expressed at the BBB.(8, 10) Small molecules that are significant substrates of P-gp are anticipated to have limited free CNS penetration, and in the discussion of clinical kinase inhibitors below, molecules that are reported to be P-gp substrates are suggested to likely have limited CNS penetration.
For medicinal chemists interested in kinase inhibitors to treat brain cancer, avoidance of P-gp transport must be a focus so as to maximize Kp,uu. Considerations in the design of kinase inhibitors (or any small molecule) to limit transporter mediated efflux include a number of physicochemical properties that can be prospectively calculated. Among the most critical properties to consider are the reported correlations between topological polar surface area (TPSA) and/or the number of hydrogen bond donors (HBD) and the likelihood of P-gp mediated efflux.(8) ATP-competitive small molecule kinase inhibitors generally employ hydrogen bonding interactions with the hinge of the kinase, and oftentimes multiple hydrogen bond donors are utilized.(11)
As a result of the common use of frequent hydrogen bond donors within kinase inhibitors, overcoming the physicochemical property restraints that predict efflux while maintaining other desirable attributes of kinase inhibitors, including potency, is a challenge. Indeed, a comparison of the median values of physicochemical properties of 119 CNS approved drugs(12) with those for the 34 kinase inhibitors approved for clinical use (all indications) reveals significant disparities (Table 1). Whereas CNS drugs have a median value of 1 HBD, approved kinase inhibitors have 2. Additionally, approved kinase inhibitors have a median TPSA value double that of approved CNS drugs. Kinase inhibitors also tend to have significantly higher MW and lipophilicity than CNS drugs.
Table 1. Comparison of Median Values of Physicochemical Properties for Kinase Inhibitors Approved for Clinical Use and 119 Drugs Approved for CNS Indications
median property valueapproved kinase inhibitors (n = 34)aCNS drugs (n = 119)b
cLogP4.22.8
cLogD7.43.61.7
TPSA (Å2)9145
HBD21
MW483305
pKa7.08.4
a

Kinase inhibitors approved for any indication through 2015.(13)

b

Marketed CNS drugs. Values obtained from ref 12.

For more than 30 years, kinase inhibitors have been the focus of significant pharmaceutical pursuit and the appeal of kinase inhibitors as potential therapeutics extends to the treatment of brain tumors and metastases.(14) While the nature of kinase inhibitors, particularly ATP competitive versions, may have some constraints on physical properties to achieve potency that are contrary to what is typical for CNS drugs, realizing potent kinase inhibitors that are capable of significant free brain penetration is possible. However, free brain penetration has not been a design consideration for many kinase inhibitor programs and in some cases may have been intentionally avoided.(15)
Even when intentionally seeking potent and freely BBB penetrant kinase inhibitors, there are, of course, limitations to available in vivo brain cancer disease models in which such molecules can be studied and none “fully reflects human gliomas.”(16) As an example, the U87 model of glioblastoma is a frequently studied GBM model used in orthotopic mouse xenograft studies. The use of the U87 model to assess whether or not a molecule has potential in the treatment of brain cancer is limited, however, as it is known to maintain a highly disrupted BBB, not relevant to clinical disease, and not to grow in the diffuse manner observed in human patients in which the tumor invades healthy brain with an intact BBB.(17) For this reason, the U87 and potentially other models may overestimate the likelihood that an agent may provide therapeutic benefit in human GBM patients. To understand whether the drug is capable of reaching its target in brain tissue, an evaluation of free brain-to-plasma ratios, free brain concentrations, change in brain concentration between wild-type mice and transporter knockout mice, or at least assessment of whether it is a substrate of P-gp or Bcrp is desirable.
The basis for the interest in kinase inhibitors to treat brain tumors begins with the underlying biology of CNS malignancy. In the following sections, individual kinase targets with relevance in CNS malignancy are introduced. In many cases kinase inhibitors have been studied in clinical trials of patients with brain tumors or metastases without success. However, in many of those cases limited CNS penetration of the kinase inhibitor may have contributed to a lack of efficacy. We identify clinical kinase inhibitors for the kinase targets, and within each section on a given kinase target, available data related to brain penetration of any clinical inhibitors of that target are summarized. In the few cases where BBB penetrating inhibitors of a kinase target for brain cancer are reported, the medicinal chemistry efforts leading to this profile are discussed. Ultimately, we summarize whether or not clinical brain penetrant inhibitors of kinase targets of interest for neurooncology are available. Finally, a comparison of the physical properties of clinical CNS penetrant kinase inhibitors for brain cancer with those that have limited CNS penetration reveals remarkable similarity, and disparity from properties of CNS drugs.

VEGFR and PDGFR

ARTICLE SECTIONS
Jump To

Inhibition of angiogenesis has been established as a beneficial approach to treating cancer, and the potential of this approach to cancer treatment extends to cancers in the CNS.(18) Targeting vascular endothelial growth factor receptors (VEGFRs) has been suggested to be of particular interest for the potential treatment of neurological tumors, as it is a known driver of angiogenesis in CNS tumors and found to be overexpressed in this setting, particularly the highly vascularized GBM.(19) Additionally, platelet derived growth factor receptor (PDGFR), a kinase frequently inhibited by VEGFR inhibitors, has been identified as a potential target for the treatment of GBM due to its high expression in this context.(20) Indeed, at least 14 inhibitors of VEGFR and/or PDGFR have been evaluated for their potential in the treatment of CNS tumors (Table 2), yet an unfortunate few would be expected to freely penetrate the BBB to reach such tumors.
Table 2. Structures and Key Properties for VEGFR and PDGFR Inhibitors Advanced to Clinical Study for Brain Cancera
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Cediranib (1, Table 2)(21) and pazopanib (2, Table 2)(22) have been studied in phase II and phase III trials in GBM patients but did not show a survival benefit.(23, 24) The diffuse nature of GBM vasculature growth would require effective penetration of brain tissue by the inhibitors to maximize efficacy. However, both cediranib and pazopanib have been reported to be substrates of both P-gp and Bcrp in vitro and these transporters were found to limit brain exposure in mice.(25, 26)
Like cediranib and pazopanib, sunitinib (3),(27) sorafenib (4),(28) nintedanib (5),(29) tivozanib (6),(30) and dovitinib (7)(31) were each ineffective in clinical GBM studies.(32-36) Sunitinib, sorafenib, and nintedanib each are likely to have limited CNS penetration, as they are substrates of P-gp and/or Bcrp, whereas data are not available for tivozanib or dovitinib.(37-39) Furthermore, for sorafenib, another study suggests that patients treated with renal cell carcinoma treated with sorafenib progress due to metastases only observed in the CNS, suggesting a sanctuary from drug due to lack of BBB penetration.(40)
Regorafenib (8, Table 2) demonstrated an effect in a rat model of glioblastoma(41) and, accordingly, advanced to clinical studies for the treatment of GBM.(42) While results are not available, efflux transport may limit free concentrations of regorafenib behind the BBB as the molecule is a substrate of P-gp and Bcrp and in P-gp/Bcrp knockout mice a 5.5-fold increase in brain concentration was achieved when compared to wild type mice at the same time point.(43)
The PDGFR-β, c-KIT, and Flt3 inhibitor tandutinib (9, Table 2) was found to be a substrate of both P-gp and Bcrp, which limits brain exposure in mice.(44) Still, tandutinib was advanced to a phase I clinical trial in patients with GBM. In that study, brain concentrations in 6 patients were determined, and a mean brain-to-plasma ratio (total) in these patients was determined to be 0.33. However, no free brain-to-free plasma ratios or free brain concentration data from subsequent studies have been reported, and so no conclusion can be made about whether or not sufficient target engagment was achieved.(45)
After demonstrating in vivo efficacy in three different orthotopic GBM models in mice,(46) axitinib (10, Table 2)(47) encouragingly demonstrated activity in a phase II study of patients with GBM.(48) However, it remains possible that the extent of benefit derived from axitinib treatment of GBM, where some tumor typically resides behind an intact BBB, may be limited due to the fact that axitinib is a significant substrate of P-gp and Bcrp. This was demonstrated in mouse pharmacokinetic studies in which P-gp/Bcrp knockout mice had 14- and 21-fold increases in brain concentration at 1 and 4 h postdose when compared to wild type mice.(49)
Vandetanib (11, Table 2)(50) and lenvatinib (12, Table 2)(51) are additional VEGFR inhibitors that have advanced to clinical studies to treat GBM(52, 53) despite being reported substrates of P-gp.(54, 55) The ability to achieve efficacious free concentrations in the brain is a concern as P-gp efflux is anticipated to limit drug penetration to portions of tumor where the BBB remains intact.
Whether or not vatalanib (13, Table 2)(56) is a substrate of P-gp or Bcrp in vitro has not been reported, and there are not reports of brain penetration of this molecule either preclinically or clinically. Vatalanib was studied in phase I clinical trials in patients with glioma or GBM, but development of the molecule was halted prior to complete assessment in this patient population.(57)
Cabozantinib (14, Table 2)(58) and brivanib (15, Table 2)(59) stand out among the VEGFR inhibitors discussed here, as they are reported to not be substrates of P-gp transport, suggestive of their potential in the neurooncology setting.(60, 61) To the best of our knowledge, there are no reports of preclinical in vivo studies describing free brain exposure or clinical study results evaluating brivanib for the treatment of CNS tumors. However, consistent with its lack of P-gp transport, cabozantinib has undergone a phase II study for the treatment of GBM and demonstrated some clinical and pharmacodynamic activity.(62)
Among the 15 VEGFR/PDGFR inhibitors discussed here and included in Table 2, just two have been reported to have minimal P-gp mediated efflux, of importance when targeting CNS malignancy. That two, cabozantinib and brivanib, are able to minimize P-gp transport demonstrates that it is possible to achieve with still potent kinase inhibitors and enables assessment of the validity of the hypothesis that inhibiting their targets might be an effective treatment approach for GBM.

EGFR

ARTICLE SECTIONS
Jump To

The initial success of the epidermal growth factor receptor (EGFR) inhibitors erlotinib (16, Table 3)(63) and gefitinib (17, Table 3)(64) in the treatment of EGFR mutant non-small-cell lung cancer (NSCLC) was followed by the approval of afatinib (18, Table 3)(65) and more recently osimertinib (19, Table 3).(66) In addition to their use in the treatment of NSCLC, erlotinib and gefitinib have been evaluated for the treatment of NSCLC brain metastases that harbor activating mutations of EGFR. Despite some reported benefit of EGFR inhibitor treatment of EGFR mutant NSCLC brain metastases,(67) it is also reported that such molecules are not as effective in the treatment of brain metastases as peripheral metastases, suggesting limited CNS penetration.(68) In this scenario, the inhibitor may be able to effectively treat some, or a portion of, individual metastases where the BBB is compromised, yet lesions behind the BBB continue to grow. Consistent with this theory, PET imaging of 11C-erlotinib showed accumulation of drug in a brain metastasis but not in normal brain tissue. These data suggest that where the BBB is intact, a “sanctuary” for tumor remains.(69) That erlotinib was not capable of freely crossing the BBB was also established in a preclinical model of glioma.(70) Gefitinib, afatinib, and osimertinib have each also been reported to be substrates of both P-gp and Bcrp, and so brain penetration of those EGFR inhibitors is expected to be limited.(71-73) Nevertheless, what free concentration of afatinib that is capable of reaching CNS metastases in EGFR mutant-positive NSCLC has demonstrated benefit clinically.(74)
Table 3. Structures and Key Properties for EGFR Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

The interest in EGFR inhibitors for treating CNS cancer extends beyond brain metastases in NSCLC to GBM treatment. In the most common and aggressive form of brain cancer, GBM, overexpression of EGFR is encountered in approximately 40% of patients and half of these have an associated extracellular mutation of EGFR (variant III).(75) These factors suggest the potential utility of a brain penetrant EGFR inhibitor. Several small molecule EGFR inhibitors, including gefitinib and erlotinib, have been approved for use in EGFR mutant NSCLC but, despite clinical study, have not resulted in approval for the treatment of gliomas.(76)
Investigation of brain penetrant inhibitors of EGFR would therefore be of interest. For rociletinib (20, Table 3)(77) no associated P-gp efflux or brain penetration data have been reported. However, recently there have been two reports of EGFR inhibitors that, while maintaining the quinazoline core of earlier EGFR inhibitors, were reportedly designed to effectively penetrate the BBB to allow for effective treatment of CNS disease. The first, NT113 (21, Table 3), a pan-ERBB inhibitor, demonstrated efficacy in intracranial GBM xeongrafts, including those with high EGFR vIII expression.(78) A limitation in the characterization of 21 is that, while brain-to-plasma ratios are reported, no free brain concentrations or free brain-to-free plasma ratios are reported, limiting the interpretation of just how effectively this molecule penetrates the BBB. Nevertheless, in intracranial GBM xenograft studies, 21 was more efficacious than either erlotinib or lapatinib, potentially indicating some improved degree of effective CNS penetration.
A second recently disclosed quinazoline-based clinical EGFR inhibitor intended to cross the BBB is AZD3759 (22, Table 3).(79) The disclosure of 22 describes the directed effort toward specifically identifying a brain penetrating inhibitor of EGFR for the treatment of CNS tumors, particularly CNS metastases that arise in the course of treatment of EGFR mutant NSCLC. In order to achieve the excellent brain penetration that 22 realizes compared to gefitinib (Figure 1), improving physical properties to reduce transporter mediated efflux was emphasized in the optimization effort. In this case, the number of rotatable bonds had an apparent correlation with efflux, and reduction of rotatable bonds, when compared to gefitinib, resulted in reduced transporter mediated efflux. Furthermore, the fluorine atom of gefitinib was moved to be positioned next to the NH of the aniline in 22 (Figure 1). This positioning allows for intramolecular interaction of the F atom with the NH, thereby “masking” the HBD, commonly associated with increased transporter mediated efflux. The structural modifications relative to gefitinib did not have an apparent detrimental impact on potency, as 22 and gefitinib are reported to have the same potency in a cellular assay employing an L858R EGFR mutant cell line, suggesting its potential in the treatment of NSCLC with EGFR mutant positive brain metastases. The team at AstraZeneca demonstrated the effective penetration of 22 across the BBB in preclinical species by reporting both Kpuu,brain and Kpuu,CSF values that show that the molecule achieves equivalent free concentrations on each side of the barrier in rats. The scientists at AstraZeneca went on to show extensive penetration of 22 into monkey brain in PET imaging studies. 22 also demonstrated remarkable efficacy in an in vivo model of brain metastasis. In this model, 22 clearly differentiates itself from erlotinib, which was not efficacious when administered at the same dose level as 22.

Figure 1

Figure 1. Structural modifications upon gefitinib (17), focused on reducing rotatable bonds and effective hydrogen bond donors, led to the freely BBB penetrating inhibitor of EGFR, 22.

While EGFR has been a long-standing target in GBM, previous molecules have not allowed for clinical conclusion on the validity of the target as transporter mediated efflux does not allow them to freely penetrate the BBB to where tumors reside. The recent emergence of 21 and, particularly, 22 highlights an exciting opportunity to study inhibition of a known driver of a significant percentage of GBM cases and NSCLC brain metastases. 21 and 22 are also part of a very limited set of kinase inhibitors reportedly specifically designed for the treatment of brain cancer.

PI3K/AKT/mTOR

ARTICLE SECTIONS
Jump To

In addition to targeting EGFR directly, another approach to treat GBM would be to target downstream kinases. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) kinases comprise one such pathway and are implicated in a significant percentage of GBM and neuroblastoma cases.(80-83) Targeting the PI3K/AKT/mTOR pathway is also suggested as a mechanism to treat human epidermal growth factor receptor 2 (HER2)-positive brain metastases.(84) As a result of this biological implication and the pursuit of inhibitors of this pathway for other tumors, a number of agents have advanced to clinical trials in GBM patients.(85) As the inhibitors of the PI3K/AKT/mTOR pathway have been reviewed in this context previously,(85) we provide here a brief summary organized according to primary target of the inhibitor.
Of the many PI3K/mTOR inhibitors that have entered clinical study, GDC-0084 (25),(86) buparlisib (26),(87) PX-866 (28),(88) pilaralisib (29),(89) and XL765 (30)(90) have been part of trials specifically for GBM (Table 4).(83) Buparlisib has also advanced to clinical studies for the treatment of breast cancer patients with brain metastases.(91) However, among these, only 25 was apparently designed to ensure significant free brain penetration.
Table 4. Structures and Key Properties for PI3K Inhibitors Advanced to Clinical Study for Brain Cancer or FDA Approveda
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

In order to realize 25, a program was initiated to purposefully identify a PI3K/mTOR inhibitor capable of crossing the BBB so that it would be amenable to treating GBM. These studies began with GNE-493 (23)(92) as a starting point which was a potent inhibitor of PI3K and mTOR but was a substrate of P-gp and Bcrp (Figure 2).(86) In order to realize brain penetrant analogs, the importance of reducing the number of hydrogen bond donors in 23 was identified as critical. To further predict the likelihood of P-gp and Bcrp mediated efflux, as well as metabolic stability, in silico evaluations were used to prospectively evaluate designs. From these efforts GNE-317 (24, Figure 2) was first identified which demonstrated that a brain penentrant PI3K inhibitor differentiated from a PI3K inhibitor that does not penetrate the BBB (2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno[3,2-d]pyrimidine (GDC-0941),(93) not shown) in that it had a PD effect in normal brain tissue and had improved efficacy in in vivo brain tumor models.(94)24 was found to have unacceptable projected human clearance and so was further optimized to 25 (Figure 2), a molecule that is of comparable potency and has similar ability to cross the BBB to 24 but was projected to have more desirable human pharmacokinetic properties. The ability of 25 to potently inhibit PI3K/mTOR signaling in the brain, along with its desirable projected human pharmacokinetic profile, led to its advancement to clinical trials for the treatment of GBM.

Figure 2

Figure 2. Modifications of PI3K/mTOR inhibitors that resulted in the discovery of 25, a brain penetrating inhibitor with desirable metabolic stability.

The report of the discovery of buparlisib (26) does not indicate that achieving brain penetration was a design consideration.(87) However, in subsequent reports buparlisib has been reported to effectively cross the BBB and inhibit PI3K pathway signaling in preclinical(95) and early clinical studies in patients with recurrent GBM.(96) Unfortunately and despite inhibition of PI3K signaling in patient tumors, there was not substantial efficacy. Additionally, buparlisib has been reported to cause mood changes, a side effect not observed with other PI3K inhibitors in the clinical setting.(84) The structurally related dual PI3K/mTOR inhibitor PQR309 (27) is reported to not be a substrate of P-gp(97) and achieves equivalent brain and plasma concentrations,(98) although free concentrations were not reported.
The inhibitors 28, pilaralisib (29), and 30 have each progressed to clinical trials for the treatment of GBM, but there has not been a report of whether brain penetration was a design consideration or if these molecules penetrate the BBB.
The PI3K and PI3K/mTOR inhibitors discussed above inhibit each of the class I PI3K isoforms (α, β, δ, and γ). However, the only as yet approved PI3K inhibitor is idelalisib (31), a selective inhibitor of the δ isoform of PI3K.(99) Idelalisib is approved for the treatment of chronic lymphocytic leukemia. We were unable to identify any indications that CNS tumor progression is a mechanism of resistance to idelalisib. This is a potential risk, as idelalisib is reported to not penetrate the BBB,(100) consistent with the disclosure that it is a substrate of both P-gp and Bcrp.(101)
Among mTOR inhibitors, the mTORC1 inhibitors everolimus (32), temsirolimus (33), and sirolimus (34) are FDA approved agents (Table 5).(102) Each of these molecules has been studied in patients with GBM but has not provided benefit.(83) Perhaps insufficient brain penetration is a contributing factor to the lack of efficacy, as everolimus and sirolimus are reported to be substrates of P-gp (and temsirolimus is a prodrug of sirolimus).(103)
Table 5. Structures and Key Properties for mTOR Inhibitors Advanced to Clinical Study for Brain Cancera
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

AZD2014 (35)(104) and CC-223 (36)(105) are mTORC1/2 inhibitors that have advanced to GBM clinical trials.(106, 107) For 35, there is no indication of whether the molecule penetrates the BBB.(108) In a clinical study of 36, GBM tumor-to-plasma ratios ranged from 16% to 77%.(107) However, it is not possible to ascertain if sufficient concentrations to expect efficacy are achieved as free concentrations were not reported, including where the BBB is intact.
Most encouraging of the clinical mTOR inhibitors from the perspective of trying to treat brain cancer, palomid 529 (37) has been reported to effectively cross the BBB as brain concentrations were similar in pharmacokinetic experiments comparing wild type mice and P-gp knockout mice.(109) This makes 37 one of a small set of clinical kinase inhibitors (the only apparent mTOR inhibitor) where limited brain penetration would not be a principal factor in limiting conclusion on the value of a target.
In addition to the inhibition of PI3K and mTOR, inhibition of AKT has received significant attention in this pathway.(110) Among the clinical AKT inhibitors perifosine (38),(111) 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one (MK-2206, 125),(112) PBI-05204 (39),(113) 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693),(114) uprosertib,(115) XL-418 (structure not disclosed), (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one (GDC-0068),(116) and 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ-092),(117) we were only able to identify some indication of the likelihood of brain penetration, or advancement to a clinical study for use in brain cancer, for perifosine and 39 (Table 6). Ultimately, the allosteric AKT inhibitor perifosine was part of a trial in GBM patients but did not demonstrate efficacy,(83) consistent with limited (total) brain penetration preclinically.(118) In a preclinical study of 39, significant total brain concentrations were achieved in rats but no assessment of free concentration was determined.(119) Additionally, for 125, a trial of GBM patients was deemed not suitable due to “questions regarding the ability of the drug to pass through the blood–brain barrier”.(83)
Table 6. Structures and Key Properties for Select AKT Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Achieving brain penetration was not an apparent design consideration for any clinical AKT inhibitor, and no clinical AKT inhibitor is conclusively capable of achieving signficant free brain concentrations, suggesting opportunity remains for AKT inhibitors that might be used to treat brain cancers.

FGFR

ARTICLE SECTIONS
Jump To

Fibroblast growth factor receptor (FGFR) kinase has been suggested as a potential target for the treatment of brain cancer,(120, 121) and numerous FGFR inhibitors have entered clinical development.(122) As many of the FGFR inhibitors are nonselective, with many inhibiting VEGFR and PDGFR (discussed above), the focus of this section is limited to selective FGFR inhibitors that have entered clinical development (Table 7).(123) Those inhibitors include AZD4547 (40),(124) infigratinib (41),(125) erdafitinib (42),(126) CH5183284 (43),(127) and ARQ 087 (structure not available). Of these, infigratinib has advanced to clinical studies in patients with GBM.(128) However, we were unable to identify any data that suggest infigratinib is capable of penetrating the BBB. Similarly, we were unable to identify data informing the potential of erdafitinib, 40, or 43 to freely cross the BBB. On the other hand and of interest for its potential for the treatment of brain cancer, ARQ 087 was reported to achieve free brain-to-free plasma concentration ratios of about 0.1 in rats.(129)
Table 7. Structures and Key Properties for FGFR Inhibitors Advanced to Clinical Studya
compdprimary kinase targetHBDTPSA (A2)cLogPMWpreclinical assessment of brain penetration
40FGFR3914.4464no data reported
41FGFR2954.7560no data reported
42FGFR1774.3447no data reported
43FGFR41053.4356no data reported
CNS drugs*N/A1452.8305 
a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

IGF-1R

ARTICLE SECTIONS
Jump To

Type I insulin growth factor receptor (IGF-1R) has been identified as a potential target for the treatment of brain cancers,(120, 130) and numerous IGF-1R inhibitors have advanced to clinical trials.(131) Among the clinical IGF-1R inhibitors (Table 8) linsitinib (44),(132) BMS-754807 (45),(133) BVP-51004 (46),(134) XL-228 (47),(135) and INSM-18 (48),(136) there is no indication that achieving CNS penetration was a design consideration. 45 was demonstrated to have limited total brain penetration in mouse studies,(137) and 48 is believed to be a substrate of P-gp.(138) We were unable to identify data related to efflux transport or brain penetration of the other IGF-1R inhibitors. Unfortunately, the available data suggest that no clinical IGF-1R inhibitors are suitable to evaluate whether inhibition of this target would be beneficial for brain cancer treatment.
Table 8. Structures and Key Properties for IGF-1R Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

CDKs

ARTICLE SECTIONS
Jump To

In addition to aberrant EGFR and PI3K signaling pathways, activation of cyclin-dependent kinases (CDK) 4 and 6 is observed in a majority of GBM cases.(82, 139) Furthermore, CDK4/6 amplification is frequently observed in diffuse intrinsic pontine gliomas, a cancer of the brainstem.(140) Among CDK4/6 inhibitors, palbociclib (49, Table 9)(141) is approved for the treatment of hormone-receptor positive breast cancer. Regarding its potential for the treatment of brain cancer, palbociclib was demonstrated to provide a survival benefit in a genetic mouse model of brainstem glioma.(142) Preclinical studies in three intracranial mouse models of GBM showed that palbociclib was efficacious either as a single agent or in combination with radiation.(143) However, palbociclib was found at 25-fold higher concentration in tumor than in normal brain tissue, suggesting that the molecule has limited penetration into the brain and the BBB is compromised at the core of the tumor but not in normal brain tissue. Therefore, despite the reports of efficacy in brain cancer models, palbociclib may have free brain concentrations below what is needed for efficacy in tumors where the BBB is intact. This would be consistent with being a substrate of P-gp,(144) and ultimately an assessment of free brain concentrations or Kpuu,brain is necessary to draw a conclusion about the merits of palbociclib for use in brain cancer.
Table 9. Structures and Key Properties for CDK4/6 Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Like palbociclib, abemaciclib (50)(145) is reported to be a substrate of both P-gp and Bcrp.(146) However, in mice and rats, Kpuu,brain is measurable at at least 0.2 and, while perhaps a model of modest utility, abemaciclib demonstrated efficacy in an orthotopic U87 GBM model in rats.(146, 147) While there is potential to further increase free brain penetration, given that some free brain exposure is attained with abemaciclib, it is encouraging that a trial studying abemaciciblib in breast cancer, non-small-cell lung cancer, or melanoma patients with brain metastases is currently enrolling.(148) To the best of our knowledge, there is no evidence of brain penetration for other CDK4/6 inhibitors, including the clinical inhibitor ribociclib (51).(149)
In addition to the potential of CDK4/6 inhibition in the treatment of brain cancer, inhibition of CDK1 and CDK2 has been suggested as having potential application in the treatment of GBM.(150) The CDK inhibitors that have advanced to the clinic that inhibit CDK1/2 tend to be broad spectrum CDK inhibitors (Table 10).(149)
Table 10. Structures and Key Properties for CDK1/2 Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Flavopiridol (52, Table 10)(151) has been shown to inhibit GBM tumor models in mice, including in the intracranial setting.(152) However, the value of the in vivo efficacy may be limited by a compromised BBB, as flavopiridol is a substrate of both P-gp and Bcrp and significantly increased brain exposure is observed in P-gp/Bcrp knockout mice than in wild type mice.(153)
Seliciclib (53, Table 10) was reported to achieve a brain-to-plasma ratio (AUC) of 0.3 after a 25 mg/kg oral dose to rats.(154) However, this only considers the total concentrations, and the free concentration ratio is likely to be lower as seliciclib is a reported substrate of P-gp.(155)
Dinaciclib (54, Table 10)(156) has demonstrated potential utility in in vitro studies to treat GBM;(157) however, we were unable to identify any data suggesting whether or not this molecule is likely to penetrate the BBB.
Despite inhibition of neuroblastoma tumor cell growth in the in vitro setting,(158) SNS-032 (55, Table 10) is a substrate of P-gp and brain penetration is limited in wild type mice compared to P-gp knockout mice.(159)
AT7519 (56, Table 10)(160) appears to be a substrate of P-gp as it has less of an effect on P-gp overexpressing cell lines.(161) We were not able to determine if R547 (57)(162) and AZD5438 (58)(163) are capable of crossing the BBB or are substrates of efflux transporters. Furthermore, we were unable to identify any indication that achieving CNS penetration was a design consideration in the discovery of any of the inhibitors of the CDKs 1 and 2. Taken together, there remains an apparent lack of a CNS penetrating CDK1/2 inhibitor if clinical assessment of this target for the treatment of GBM is to be assessed.

ALK

ARTICLE SECTIONS
Jump To

Outside primary brain tumors, there is a growing recognition of the ability of peripheral tumors to escape therapy via metastasis to the brain. As a result, there are emerging best-in-class opportunities for kinase inhibitors that prevent resistance in that manner. An example of this phenomenon is seen in the case of anaplastic lymphoma kinase (ALK) fusion positive NSCLC.(164) Crizotinib (59)(165) was the first ALK inhibitor to show remarkable benefit to ALK-positive NSCLC patients.(166) Unfortunately, disease progression on crizotinib therapy is inevitable. In fact, in the phase I and II trials of crizotinib in ALK-positive NSCLC, the most common mechanism of progression on therapy has been reported to be through CNS metastases.(167, 166) Crizotinib has poor free brain penetration, consistent with significant P-gp mediated efflux in vitro, which likely allows for metastases to find “sanctuary” in the CNS allowing for disease progression.(168, 169) As a result of relapse through CNS metastases, as well as resistance mechanisms including kinase domain mutations, there has been a substantial effort in identifying next-generation ALK inhibitors, which have been reviewed elsewhere.(170)
Among the many next-generation inhibitors (Table 11), several have been reported to be potentially effective in controlling CNS disease in ALK-positive NSCLC. In a small set of patients in a phase I trial, ceritinib (60)(171) was reported to achieve responses in patients with brain metastases, including patients who had progressed on crizotinib.(172) For ceritinib, medicinal chemistry optimization did not apparently focus on achieving free brain exposure.(171)
Table 11. Structures and Key Properties for ALK Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

While, to the best of our knowledge, P-gp transport or free brain penetration was not apparently a factor in the design of the molecule, alectinib (61)(173) is reported to be efficacious in preclinical models of brain metastases and, aiding in the positive interpretation of the efficacy results, alectinib is reportedly not a substrate of P-gp.(174) Most significantly, alectinib has been reported to achieve responses in patients with CNS disease that did not respond to crizotinib, indicating some degree of brain penetration.(175)
Entrectinib (62)(176) is reportedly capable of crossing the BBB in preclinical species, although free brain concentrations were not reported. Encouragingly, a clinical report of a NSCLC patient with brain metastases who had a response to entrectinib suggests that the molecule may achieve significant free CNS penetration.(177)
ASP3026 (63)(178) was reported to achieve a brain-to-plasma ratio (AUC0–24h) of 0.72 in mice.(179) Free brain-to-plasma ratios were not reported, however. Brigatinib (64)(180) is another next-generation ALK inhibitor that has some preliminary indication of efficacy in a cohort of 10 crizotinib resistant patients with brain metastases.(181) Brigatinib was able to achieve a response in a mouse intracranial tumor model, and 11C brigatinib was visualized within the tumor. However, in these studies, the extent to which the BBB was compromised was not reported and higher concentrations of brigatinib were observed in the intracranial tumor than in normal brain tissue.(181) While insufficient preclinical data exist to understand the extent to which free brigatinib is capable of penetrating the BBB, very encouraging clinical data are emerging showing that brigatinib is effective in treating ALK-positive brain metastases, where crizotinib was ineffective, suggesting meaningful CNS penetration of brigatinib in these patients.(182)
X-376 (65)(183) and X-396 (structure not disclosed, 126) are additional ALK inhibitors. 126 is reported to have a brain-to-plasma ratio in mice comparable to that of crizotinib (a P-gp substrate with low CNS exposure in humans). However, the investigators suggest that due to the greater potency of 126, there may be potential for efficacy in the CNS setting.(183) No reports of free brain levels are reported, however.
While each of the aforementioned next-generation ALK inhibitors (Table 10) may hold potential for treating ALK-positive malignancy, there is insufficient preclinical data to demonstrate that these molecules lack transporter mediated efflux and/or achieve significant free brain exposure.
PF-06463922 (66, Table 11)(169) clearly stands out among the next generation ALK inhibitors, as achieving free brain penetration was an evident design consideration. 66, which has activity against both EML4-ALK fusion proteins and crizotinib resistant ALK mutants, was designed to be a brain penetrant ALK inhibitor by reducing P-gp transport.(169)
As resistance to crizotinib is acquired through various kinase mutations as well as CNS metastases, the Pfizer program sought to achieve a molecule that would simultaneously overcome both of those resistance mechanisms.(169) Initial analogs capable of potently inhibiting crizotinib resistant ALK mutations did not achieve a desirable balance of potency with physicochemical properties that allowed for both good metabolic stability and low P-gp mediated efflux. Crystallographic information was utilized to design subsequent ALK inhibitors with improved lipophilic efficiency. The “U-shape” that ligands adopted in a cocrystal structure with ALK inspired macrocyclic analogs. A 12-membered ring lactam was found to improve human liver microsomal stability and reduce P-gp efflux when compared to its acyclic counterpart (66 vs 67, Figure 3). Rather than focusing on the influence of single physicochemical properties on P-gp mediated efflux, the Pfizer group emphasizes the need for multiparameter optimization due to an interplay of the influence of numerous physicochemical properties on efflux. In particular, HBD, log D, and MW were each considered in parallel. In these studies, acyclic analogs had higher levels of P-gp mediated efflux than the macrocycles with comparable MW, log D, and HBD. 66, like the other macrocycles as well as acyclic analogs described, takes advantage of an intramolecular hydrogen bond between the aminopyridine and the adjacent ether oxygen. This intramolecular hydrogen bond may effectively mask a HBD. The authors also suggest that the macrocycles may have reduced efflux relative to acyclic analogs due to a reduced number of rotatable bonds and a 10% smaller solvent-accessible surface area.(169) Ultimately, 66 achieves a free brain-to-free plasma AUC ratio of 0.2 after oral administration in rats.

Figure 3

Figure 3. Macrocyclization led to improved metabolic stability, potency, and reduced P-gp mediated efflux in this series of ALK inhibitors.

In summary, ALK is one of a few kinase targets, along with PI3K, EGFR, and PLK (below), where discovery programs have been reportedly directed specifically at achieving brain penetrating inhibitors. With such an ALK inhibitor undergoing clinical study currently, evaluation of the clinical hypothesis can take place.

HER2

ARTICLE SECTIONS
Jump To

A parallel to the resistance to initial ALK inhibitors via brain metastasis is observed in the treatment of HER2-positive breast cancer with antibody therapeutics. Among patients treated with trastuzamab (Herceptin), CNS metastases emerge in approximately 30% of patients.(184) Lapatinib (68, Table 12) is approved as a small molecule HER2/EGFR inhibitor,(185) but preclinical studies showed that therapeutic concentrations were not achieved in brain metastases,(186) suggesting that lapatinib does not effectively cross the BBB and would not be expected to be efficacious in that setting. Furthermore, a study of brain-to-plasma concentration ratios in mice shows that lapatinib is a substrate of P-gp and Bcrp.(187) Indeed, in the clinical setting lapatinib was found to have variable and limited penetration into HER2-positive brain metastases.(188, 91) Aside from lapatinib, at least a dozen additional small molecule inhibitors of HER2 have been reported to have advanced to clinical study (Table 12).(189)
Table 12. Structures and Key Properties for HER2 Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Among the HER2 inhibitors that have advanced to clinical studies, neratinib (69),(190) a pan-HER inhibitor, and tucatinib (70)(191) have advanced to trials for breast cancer patients with brain metastases. Unfortunately, a phase II trial of neratinib in patients with HER2-positive brain metastases was not successful. The lack of efficacy attained in the trial may be due in part to the noted lack of CNS penetration of neratinib, determined in preclinical studies(192) and consistent with a report that it is a P-gp substrate.(193) For tucatinib, on the other hand, an active metabolite is reported to achieve brain-to-plasma concentration ratios ranging from 0.5 to 2.1 across several time points after a 75 mg/kg oral dose in mice.(194) While only total concentration ratios were reported, and so a true indication of free brain penetration is not available, in other studies tucatinib was capable of inhibiting p-HER2 in mouse brain tissue, demonstrating some extent of free exposure. Additionally, tucatinib achieved a survival benefit in mice in an intracranial HER2-positive xenograft study.(191)
TAK-285 (71)(195) is a clinical inhibitor of HER2 and EGFR that has been demonstrated to be capable of penetrating the BBB in preclinical studies. In rats, the free brain-to-free plasma (AUC) ratio was 0.24 after a 75 mg/kg oral dose.(196) Additionally, 71 was demonstrated to not be a substrate of P-gp and to confer efficacy in a mouse model of HER2-positive brain metastases.(197) Taken together, the data are supportive of evaluating 71 in the clinical treatment of patients HER2-positive brain metastases.
Dacomitinib (72)(198) inhibits epidermal growth factor receptors and other tyrosine kinases. A clinical study is looking at the safety and effectiveness of using dacomitinib to treat HER2-positive breast cancer patients with progressive brain metastases (NCT02047747). Unfortunately, there are apparently no data available on whether dacomitinib is a substrate of efflux transporters that are expressed at the BBB.
The pan-HER inhibitor AC480 (73)(199) was utilized in a study of patients with GBM in which the tumor was surgically resected after drug administration. This study showed that 73 had concentrations in the tumor and brain that were greater than in plasma, although no indication of free concentrations has been reported that would help to interpret whether efficacy could have been expected.(200)
The HER2/EGFR/VEGFR inhibitor AEE788 (74)(201) was of interest for the treatment of brain cancers. In preclinical studies, 74 had activity against medulloblastoma cell lines and a xenograft (flank).(202) While 74 was reported to confer a survival benefit in an orthotopic model of glioblastoma in mice, we were not able to identify reports of whether 74 is an efflux transporter substrate or if it is capable of free brain penetration.(203) Unfortunately, a phase I trial of 74 enrolling GBM patients needed to be discontinued due to toxicity of the molecule without benefit.(204)
Pelitinib (75)(205) is another HER2/EGFR inhibitor that has advanced to clinical studies but is reported to be a substrate of Bcrp which might limit its CNS exposure.(206) The HER2 inhibitor CP-724,714 (76)(207) was reported to be a substrate of both P-gp and Bcrp and, accordingly, would not be expected to be able to effectively cross the BBB.(208)
CUDC-101 (77),(209) sapitinib (78),(210) and AST1306 (79)(211) have advanced to clinical trials, but we were unable to identify whether or not these molecules are substrates of efflux transporters or whether they are capable of free penetration of the BBB.
The data available for tucatinib and 71 demonstrate that brain penetrant inhibitors of HER2, which would be of evident interest in the treatment of HER2-positive brain metastases, are achievable, and it is encouraging that a potential treatment for HER2-positive brain metastases may be realized.

b-Raf/MEK

ARTICLE SECTIONS
Jump To

Historically, melanoma patients have a high frequency (>90%) of brain metastasis development, and once present, these patients typically survive for less than 6 months.(212) Recently, inhibitors of the V600E mutation of b-Raf (vemurafenib (80)(213) and dabrafenib (81)(214)) and mitogen activated protein kinase (MEK) inhibitors (cobimetinib (85)(215) and trametinib (86)(216)), along with the combination of dabrafenib and trametinib, have received approval for the treatment of melanoma. As b-Raf (including V600E mutant) and MEK inhibitors are used in the treatment of melanoma, it is important to consider how effectively these agents cross the BBB to either treat or prevent CNS metastases.(217) Additionally, b-Raf(218) and MEK(219) have been identified as potential targets for primary brain tumors. At least seven Raf inhibitors(220) and more than a dozen MEK inhibitors(221) have entered clinical studies.
Among the clinical Raf inhibitors (Table 13), there have been conflicting reports of clinical response of CNS metastases to vemurafenib (80)(222) or dabrafenib (81)(223) therapy, ranging from ineffective at treating brain metastases to a case of a complete response. Both vemurafenib and dabrafenib have been reported to be substrates of P-gp and Brcp and, furthermore, achieve little free brain penetration in mouse studies.(224, 225) The varied reports and modest clinical response rates could be attributed to inconsistent disruption of the BBB, and potentially greater rates of response could be achieved if a b-Raf inhibitor were capable of free brain penetration.
Table 13. Structures and Key Properties for b-Raf Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Raf-265 (82)(226) does not apparently effectively cross the BBB, as that molecule conferred efficacy in a mouse tumor model when implanted in a flank but not when implanted intracranially.(227) We were unable to identify any information suggesting whether or not the clinical Raf inhibitors encorafenib (83),(228) XL281 (structure not disclosed), RO5212054 (structure not disclosed), ARQ-736 (84),(229) or its active metabolite, are capable of penetrating the BBB or are efflux transporter substrates. Together, the available data suggest that a BBB penetrating Raf inhibitor remains elusive, yet there would be significant potential value for such an inhibitor in treating cancers that metastasize to the brain.
The approved MEK inhibitors cobimetinib (85, Table 14) and trametinib (86, Table 14) have each also been reported to have limited free brain penetration in mice due to P-gp and Bcrp mediated efflux.(230, 224) Additionally, neither cobimetinib nor trametinib inhibited pERK in normal brain tissue in mice after oral administration despite inhibition in the periphery, further illustrating a lack of CNS penetration by these molecules.(231) Furthermore, when coadministered, dabrafenib and trametinib had low mouse brain exposure as well.(224)
Table 14. Structures and Key Properties for MEK Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Among the other clinical MEK inhibitors,(221) we were unable to identify any data that would suggest that GDC-0623 (87), binimetinib (88), selumetinib (89), CI-1040 (90), TAK-733 (91), RO5126766 (92), or WX-554 (structure not disclosed) would be likely to penetrate the BBB. Nevertheless, selumatinib and binimetinib have been studied clinically for the treatment of brain cancers.(232, 233)
The MEK inhibitor PD0325901 (93)(221) inhibited tumor growth in a LN229 intracranial glioblastoma mouse xenograft tumor model study.(219) Additionally, that 93 is capable of penetrating the BBB in rats was demonstrated by significant inhibition of pERK in normal brain tissue after oral administration of the drug. This molecule was found to have neurologic toxicities clinically, and with the hope to avoid similar toxicities, refametinib (94) and RO4987655 (95) were reportedly designed specifically to not penetrate the BBB.(234, 235) Accordingly, despite substantial peripheral exposure in rat or mouse studies, inhibition of pERK in brain tissue by those molecules was negligible. Likewise, AZD8330 (96)(221) is reported to achieve minimal CNS penetration in rats.(236)
Pimasertib (97)(221) has been reported to inhibit pERK in mouse brain tissue, indicating some degree of CNS penetration.(237) Consistent with those results, pimasertib was reported to not be a substrate of efflux transporters.(238)
E6201 (98),(239) an inhibitor of MEK and other kinases, has been shown to achieve total brain-to-plasma concentration ratios of 4.8–6.4 in rodents, although free concentrations were not reported. To support the suggestion that some 98 is free to engage its target in mouse brains, the molecule demonstrated a survival benefit in a mouse model of brain metastases.(240)
While in no case was achieving free brain penetration of a MEK inhibitor a reported design consideration, two clinical MEK inhibitors discussed above have achieved significant CNS concentration in preclinical studies. Worth noting, those two MEK inhibitors (93 and 97) each have a dihydroxy hydroxamate moiety (the only two among those in Table 14) and have four nominal hydrogen bond donors. It is therefore curious that the physical properties of 93 and 97 are so inconsistent with the median values of marketed CNS drugs in the HBD category, which is known to have a substantial impact on P-gp efflux. However, both 93 and 97 have the potential for multiple intramolecular hydogen bonding interactions which could reduce both the effective HBD count and polarity of these molecules. While the brain penetrant MEK inhibitors offer opportunity to study their benefit in patients with brain cancer, 93 also highlights the additional risk that brain penetration of small molecule drugs adds to to an already difficult development path. Both on- and off-target activities in the brain have the potential to render a drug less tolerated, potentially limiting the ability of such a molecule to benefit patients with peripheral malignancy.

PLK1/Aurora Kinases

ARTICLE SECTIONS
Jump To

Both Polo-like kinase (PLK)(241) and Aurora kinases have been suggested as targets for the treatment of brain cancers.(242, 243) Among the PLK1 inhibitors that have advanced to the clinic (Table 15), volasertib (99),(244) BI 2536 (100),(245) GSK 461364 (101),(246) rigosertib (102),(247) and NMS-P937 (103)(248) have been shown to be substrates of P-gp, and therefore, CNS penetration is expected to be limited.
Table 15. Structures and Key Properties for PLK Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

The PLK1 inhibitor TAK-960 (104, Table 15), however, was reportedly selected among other analogs because it had reduced P-gp mediated efflux, suggesting the potential for CNS penetration.(249) In the discovery of 104, it was noted that incorporation of a substituent capable of acting as a hydrogen bond acceptor adjacent to an amide, effectively eliminating a hydrodgen bond donor via intramolecular hydrogen bond, was essential to reduce P-gp mediated efflux (Figure 4).

Figure 4

Figure 4. Reducing effective HBD count by intramolecular hydrogen bonding reduced P-gp efflux among a set of PLK1 inhibitors.

At least 15 Aurora kinase inhibitors have advanced to clinical studies.(250) We were unable to identify considerations of achieving CNS exposure in the discovery of those molecules. Among those Aurora kinase inhibitors that have entered clinical studies, any discussion of potential BBB penetration is limited to tozasertib (105)(250) and alisertib (106)(250) (Table 16) which were each reported to inhibit tumor growth in orthotopic GBM models in mice, which is insufficient to understand the extent to which those molecules are capable of freely penetrating the BBB.(243, 251)
Table 16. Structures and Key Properties for Clinical Aurora Inhibitors for Which BBB Penetration Data Are Availablea
compdprimary kinase targetHBDTPSA (A2)cLogPMWpreclinical assessment of brain penetration
105pan-Aurora31024.8465insufficient data
106Aurora A21056.2519insufficient data
CNS drugs*N/A1452.8305 
a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

PKC

ARTICLE SECTIONS
Jump To

Protein kinase C (PKC) has been identified as a potential target for the treatment of GBM.(252) Among the small molecule PKC inhibitors that have entered clinical studies for the treatment of cancer (Table 17) are bryostatin (107), enzastaurin (108), midostaurin (109), and UCN-01 (110).(253) Among these, enzastaurin was part of a trial for the treatment of GBM,(254) as well as for the treatment of brain metastases from lung cancer,(255) but in each case it did not demonstrate significant benefit. Along with enzastaurin, we were unable to identify any data suggesting whether or not bryostatin or midostaurin is capable of penetrating the BBB or is a substrate of efflux transporters P-gp or Bcrp.
Table 17. Structures and Key Properties for PKC Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

The PKC inhibitor 110 achieved total brain-to-plasma concentration ratios of 0.5–1.0 at five different time points after a 3.5 mg/kg dose to rats.(256) However, free concentrations are not reported, and so a proper interpretation of free brain penetration is not available from this study. Additionally, 110 is a reported substrate of P-gp, anticipated to limit CNS penetration.(257)

ABL and Src

ARTICLE SECTIONS
Jump To

The discovery of imatinib (111, Table 18)(258) has rightfully been heralded as a remarkable success story in targeted therapeutics for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). Despite initial responses, however, in addition to the emergence of resistance mutations,(259) brain metastases lead to progression on imatinib therapy in nearly 20% of patients.(260) Such CNS resistance likely emerges due to the poor ability of imatinib to cross the BBB, demonstrated both preclinically and clinically, as it is a P-gp and Bcrp substrate.(261)
Table 18. Structures and Key Properties for Abl or Src Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

Dasatinib (112, Table 18) was discovered as a next-generation Bcr-Abl inhibitor that potently inhibits imatinib resistant mutant forms of the enzyme.(262) Dasatinib also inhibits Src, among other kinases,(263) which has been identified as a potential target for the treatment of GBM as well as a target for patients with brain metastases.(264) Like imatinib, dasatinib is a substrate of both P-gp and Bcrp which limits its brain penetration.(265) Yet, despite approximately 10% (total) brain penetration (relative to plama) in an intracranial mouse model of Ph+ CML, dasatinib was able to demonstrate a therapeutic benefit. The authors attribute the efficacy to the exceptional potency of dasatinib against the relevant enzymes driving tumor growth.(266) In a small clinical study, all of the 11 evaluable patients with CNS chronic myeloid leukemia responded to dasatinib therapy. Also, of 22 patients from whom CSF samples were obtained, dasatinib was detectable in 6 of those patients, with CSF-to-plasma (total) of 0.05–0.28.(266) These encouraging results suggest that a CNS penetrant Bcr-Abl inhibitor has potential for significant clinical benefit.
Adding to data suggesting the benefit of CNS penetrant Bcr-Abl inhibitors, bosutinib (113) is another inhibitor of Bcr-Abl and Src family kinases, along with other kinases.(263) In rats, bosutinib has been reported to achieve brain-to-plasma ratios ranging from 2.0 to 0.4; however there was not an accounting for free concentrations, so interpretation is limited. Yet bosutinib is reported to not be a significant substrate of P-gp or Bcrp.(267) While there has been a report of a patient with ALL, which includes the CNS, who achieved a response to bosutinb,(268) a phase II clinical trial of bosutinib in patients with GBM was halted early due to lack of benefit.(269)
Nilotinib (114) has been reported to be a substrate of P-gp,(270) and achieving CNS penetration was not a reported consideration in its discovery.(271) Despite this, in a small clinical study of four patients with CNS progression of CML, nilotinib was able to achieve a median CSF-to-plasma (total) ratio of 0.53%. With plasma protein binding reported to be 98% for nilotinib, this would translate to an approximately 26% CSF-to-free plasma ratio.(272) Along with the apparent CNS penetration, 3 of the 4 patients had a clinical response to nilotinib.(272) Further suggestive of some CNS penetration of both nilotinib and bosutinib are reports describing the use of these molecules in preclinical models of neurodegeneration in which pharmacodynamic modulation changes are observed in rodent brains.(273)
In the initial report describing the discovery of the Bcr-Abl inhibitor ponatinib (115), brain penetration was not reported as a design consideration.(274) Still, the authors suggest that ponatinib is capable of crossing the BBB, as in a mouse study, a brain/plasma concentration ratio of 1.6 was achieved. As total (as opposed to free) concentrations were used to calculate the ratio, little conclusion can be drawn about how effectively ponatinib is capable of crossing the BBB based on that data. Suggesting that the action of P-gp and Bcrp actually does limit penetration of ponatinib across the BBB is a study comparing brain and plasma exposure in both wild type and P-gp/Bcrp knockout mice. In this study, the AUCbrain in the transporter knockout mice was 18-fold higher than in wild type mice.(275)
Bafetinib (116)(276) is a Bcr-Abl/Lyn inhibitor that has advanced to clinical study for the treatment of brain cancers. Unfortunately, in a clinical study monitoring brain concentrations by microdialysis, bafetinib was demonstrated to not effectively cross the BBB.(277) Consistent with the clinical findings, preclinical studies demonstrated that efficacy in a preclinical CNS cancer model was significantly improved with coadministration of a P-gp inhibitor, implying bafetinib is a significant substrate of that transporter.(278)
While achieving CNS penetration is not discussed as a design consideration in the discovery of saracatinib (117),(279) in preclinical studies it was reported to achieve brain-to-plasma concentration ratios of about 0.5 and CSF-to-plasma ratios of about 0.2.(280) The brain and plasma concentrations reported were total (as opposed to free), and so there is a limit to the interpretation of brain penetration of this agent. However, in a clinical study evaluating saracatinib in Alzheimer’s patients, CSF-to-free plasma ratios were about 0.3, indicating some ability of this molecule to freely reach the CNS.(281)

c-Met

ARTICLE SECTIONS
Jump To

Inhibition of c-Met has been suggested as a possible approach to treat brain cancer.(282) The clinical c-Met inhibitor foretinib (118)(283) has been reported to achieve brain-to-plasma ratios approaching 0.2 in mice; however, only total concentrations were reported.(284) SGX523 (119),(285) a c-Met inhibitor, was reported to confer efficacy in an orthotopic U87 xenograft model.(286) However, no indication of the extent of brain penetration of the molecule or whether it is a substrate of efflux transporters is available, and so a conclusion on the expected potential utility of this molecule for the treatment of CNS malignancy cannot be drawn. Although numerous other nominal c-Met inhibitors have entered clinical trials,(287) we were unable to identify any indication that these molecules(288) achieve brain penetration (Table 19).
Table 19. Structures and Key Properties for Clinical c-Met Inhibitors for Which Discussion of Brain Penetration Was Found in the Literaturea
compdprimary kinase target(s)HBDTPSA (A2)cLogPMWpreclinical assessment of brain penetration
118MET, RON, Axl, VEGFR21114.2633insufficient data
119MET0732.6359insufficient data
CNS drugs*N/A1452.8305 
a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

FAK/Pyk2

ARTICLE SECTIONS
Jump To

Focal-adhesion kinase (FAK) and proline rich tyrosine kinase 2 (Pyk2) have been implicated as potential targets for the treatment of brain cancers.(289) Additionally, four FAK or FAK/Pyk2 inhibitors have advanced to clinical study (Table 20).(290) For PF-562,271 (120),(291) defactinib (121),(292) and PND-1186 (122)(293) we were unable to to identify any reported characteristics that would indicate whether the molecule is capable of penetrating the BBB. GSK-2256098 (123)(294) is reported to have “poor” penetration of the BBB in rodent PK studies. By PET, in human GBM patients, significant brain and tumor concentrations relative to blood are reported but nonspecific binding was not apparently factored.(295) Taken together, it appears that potential opportunity remains for the identification of a FAK and Pyk2 inhibitor that is capable of reaching brain tumors behind the BBB.
Table 20. Structures and Key Properties for FAK/Pyk2 Inhibitors Advanced to Clinical Studya
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs.(12)

TGFβ-R

ARTICLE SECTIONS
Jump To

Inhibition of transforming growth factor receptor β (TGFβ-R) kinase activity has been identified as a potential mechanism to treat glioblastoma.(296) The TGF-β inhibitors galunisertib and TEW-7197 (structure not disclosed) have been reported to have advanced to clinical trials.(297) However, considerations of brain penetration are not reported for these molecules.

PIM1 Kinase

ARTICLE SECTIONS
Jump To

PIM1 kinase has been identified as a potential target for the treatment of GBM.(298) The PIM inhibitors N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine (SGI-1776),(299)N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (LGH447),(300) and (R,Z)-5-((2-(3-aminopiperidin-1-yl)-[1,1′-biphenyl]-3-yl)methylene)thiazolidine-2,4-dione (AZD-1208)(301) have advanced to clinical trials, but we were unable to identify data suggesting whether or not these molecules are substrates of efflux transport or are capable of freely penetrating the BBB.

BTK

ARTICLE SECTIONS
Jump To

Ibrutinib (124)(302) (Table 21) is an inhibitor of Bruton’s tyrosine kinase (BTK) that has been approved for use in some hematological cancers including mantle cell lymphoma (MCL). While rare, CNS metastases can arise in patients with MCL. In a small study, each of three patients with CNS involvement in MCL responded to ibrutinib (two with complete response of CNS lesions).(303) Futhermore, in the two patients evaluated, concentrations in the CSF were significant and expected to be efficacious. The CSF-to-blood ratios ranged from 1% to 7%, but free plasma concentrations would likely indicate a greater free percentage of CNS penetration. Consistent with the free exposure in the CSF, ibrutinib is reported to not be a substrate of P-gp,(304) an encouraging aspect of this molecule for the treatment, or prevention, of CNS progression of hematological malignancies for which it is used.
Table 21. Structure and Key Properties for the BTK Inhibitor Ibrutiniba
Table a

Properties for 119 marketed CNS drugs are included for comparison. *Median value of 119 marketed CNS drugs(12)

Other Kinases

ARTICLE SECTIONS
Jump To

Numerous other kinases have been suggested to be of potential interest as targets for the treatment of brain cancer. Ataxia telangiectasia mutated (ATM),(305) Mer, and Axl(306) are among kinases that have been reported as potential targets for brain cancer but for which no discussion of brain penetration for clinical molecules exists or no molecule has advanced to clinical study for brain cancer treatment.

Conclusion

ARTICLE SECTIONS
Jump To

In the above sections, the availability of data suggesting whether or not kinase inhibitors of various targets have the potential for free CNS penetration and, therefore, potential in the treatment of brain tumors is discussed. Among the kinases examined here that have a biological rationale to be targeted with inhibitors for the treatment of brain cancers, a distinct minority have CNS penetrant inhibitors that have advanced to clinical study (Table 22). Furthermore, while CNS penetrant inhibitors are available for some kinases, their evaluation has not yet concluded, so no conclusion on the validity of the hypotheses of inhibiting their targets to treat brain cancer can yet be drawn.
Table 22. Kinases of Interest for Brain Cancer and Whether or Not CNS Penetrating Clinical Inhibitors Are Available
kinase targets with CNS penetrant clinical inhibitors availablekinase targets without known CNS penetrant clinical inhibitors
EGFRVEGFR
Pl3K/mTORAKT
CDK4/6lGF-1R
ALKCDK1/2
HER2b-RAF
MEKPLK1
Abl/SrcAurora
BTKPKC
 c-MET
 FAK/Pyk2
 TGFR-β
 PlM1
 ATM
 Mer
 AXL
 FGFR
It is important to note that only evidence of free CNS penetration or lack of P-gp/Bcrp transport of clinical inhibitors was considered in determining whether a kinase target has a tool to assess it as a target for treatment of CNS tumors (i.e., its categorization in Table 22). In reality, many other additional variables impact evaluation of a hypothesis clinically (e.g., PK, selectivity profile, safety, extent of free brain penetration, etc.), and so even for targets where CNS penetrant clinical inhibitors are available, lack of benefit may be encountered in the clinic for other reasons. Therefore, for each indicated kinase target discussed here, opportunity may remain for additional or improved inhibitors that are specifically designed to treat brain cancers, even where a brain penetrant inhibitor already exists and for which a known liability might be addressed. The paucity of CNS penetrant kinase inhibitors also limits study of combinations of brain penetrant kinase inhibitors, which may be a necessary treatment approach for certain tumors.(307)
Of the kinase inhibitors included in the above discussion, we identified 68 as having evidently limited CNS penetration (n = 48; molecules that achieve low free or total brain concentrations or are reported substrates of P-gp/Bcrp) or where some CNS penetration was evident/anticipated (n = 20; molecules that achieve meaningul free brain concentrations or are reportedly not substrates of P-gp/Bcrp).(308) In Table 23 we compare the physicochemical properties of kinase inhibitors identified in the discussion above as CNS penetrating to those that have limited CNS penetration, as well as 119 marketed CNS drugs. There is remarkable similarity in the median values of cLogP, cLogD7.4, TPSA, HBD, and MW among the two categories of kinase inhibitors (mean values are also very similar). The only significant differentiation between the two classes of kinase inhibitors was in the calculated pKa category (which can affect HBD count for those sufficiently basic), where CNS penetrating kinase inhibitors have a lower median pKa than either kinase inhibitors that do not cross the BBB or CNS drugs. Possibly affecting the quality of the data set and preventing emergence of additional differentiation in the properties between the groups, however, is a lack of free-brain-to-free-plasma drug concentration ratios for most molecules. That is, perhaps additional data and application of more stringent criteria to designate molecules as CNS penetrating might yield different results. Additionally, as discussed next, there are limitations to the use of calculated physical properties that might conceal actual differences between molecules. Also, while rare, there is a potential for species differences in P-gp to affect the interpretation of reported data.
Table 23. Comparison of Median Values of Physicochemical Properties for Kinase Inhibitors Discussed above That Are (a) Reported or Predicted (Based on Efflux Transport Data) To Have Limited CNS Penetration or (b) Reported To Have Significant Free CNS Penetration and/or No Significant P-gp or Bcrp Effluxa
 kinase inhibitors 
median property valuelimited CNS penetration (n = 48)bCNS penetrating (n = 20)bCNS drugs (n = 119)c
cLogP4.34.12.8
cLogD7.43.33.41.7
TPSA (Å2)929845
HBD221
MW479483305
c_pKa8.36.58.4
a

Median values of marketed CNS drugs are included for comparison.

b

Kinase inhibitors CNS penetration categorization assigned based on data in discussions above. A complete list of the kinase inhibitors assigned to each category and their calculated physicochemical properties is provided in Supporting Information.

c

Marketed CNS drugs. Values obtained from ref 12.

There are very few reports of the design of kinase inhibitors specifically for the treatment of brain cancer. We identified only five molecules, 21, 22, 25, 66, and 104, for which achieving brain penetration was a design intent. In the discovery of three of those five molecules (22, 66, and 104), intramolecular hydrogen bonds were utilized to effectively mask at least 1 HBD, which would not be accounted for in the calculated properties of those molecules. Furthermore, such intramolecular hydrogen bonds would also affect effective polar surface area. It is possible that other CNS penetrant kinase inhibitors also, whether intentionally or not, employ such a mechanism to avoid efflux transport to achieve their penetration (e.g., 93 and 97). Regardless, this is an approach that is worth consideration on kinase programs requiring CNS penetration.
As drug discovery programs have increased their appreciation for what consitutes meaningful (free) brain penetration in recent years, the potential for this understanding to impact the discovery of new treatments of brain cancer is evident. Over the previous decades, a large number of kinase inhibitors advanced to clinical study for brain cancer treatment where, given the understanding of CNS penetration available today, negative outcomes were predictable given limited free access of the drug to its target. In fact, such studies should now be considered unjustified.
Treating primary brain tumors with kinase inhibitors requires brain penetrant versions of those molecules and opportunity abounds for the pharmaceutical industry to treat these already significant unmet needs. Additionally, as kinase inhibitors are approved for the treatment of peripheral cancers, the emergence of brain metastases is expected when the treatments are not BBB penetrant (e.g., ALK, HER2, EGFR, etc.). Whereas in discovery programs brain penetration might be considered a liability for potential CNS safety reasons, limiting brain penetration might ultimately result in a resistance mechanism clinically via brain metastasis. In this scenario, best-in-class opportunities may emerge where brain penetrating kinase inhibitors can be realized. Whether for primary brain cancers or brain metastases, that so few kinase inhibitors have been reportedly designed to achieve CNS penetration suggests that the lack of advancement in the treatment of brain cancers has been at least in part due to lack of directed effort with an appreciation of free drug principles. At the same time, that CNS penetrant inhibitors of various kinases have been identified, and specifically designed and realized, demonstrates that success in this area can be achieved, even if the physicochemical properties of kinase inhibitors and those of CNS drugs at first appear at odds. The clear medical need, biological rationale, and improved appreciation for free drug principles provide an impetus and framework to properly approach the challenge of discovering and developing kinase inhibitors for brain cancer.

Supporting Information

ARTICLE SECTIONS
Jump To

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.6b00618.

  • Calculated physicochemical properties of FDA approved kinase inhibitors and of discussed inhibitors that are capable of penetrating the BBB or have limited CNS penetration (PDF)

Terms & Conditions

Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

Author Information

ARTICLE SECTIONS
Jump To

  • Corresponding Author
    • Timothy P. Heffron - Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States Email: [email protected]
    • Notes
      The author declares no competing financial interest.

    Biography

    ARTICLE SECTIONS
    Jump To

    Timothy P. Heffron

    Timothy P. Heffron is a Senior Scientist at Genentech. As a medicinal chemist and chemistry and research team leader, Timothy has contributed to the advancement of programs directed toward treatments for neurooncology, oncology (including cancer immunotherapy), neurology, and ophthalmology indications. Timothy has contributed to seven molecules that have advanced to clinical development, four of which came under his leadership as a chemistry team leader, including taselisib (phase III). Timothy completed his undergraduate studies in chemistry at Yale University and his doctoral studies at The Massachusetts Institute of Technology.

    Acknowledgment

    ARTICLE SECTIONS
    Jump To

    Cyrus Khojasteh, Xingrong Liu, and Alan Olivero are acknowledged for their helpful comments in the preparation of this Perspective.

    Abbreviations Used

    GBM

    glioblastoma multiforme

    CNS

    central nervous system

    BBB

    blood–brain barrier

    CSF

    cerebral spinal fluid

    P-gp

    P-glycoprotein

    Bcrp

    breast cancer resistance protein

    HBD

    hydrogen bond donor

    TPSA

    topological polar surface area

    VEGFR

    vascular endothelial growth factor receptor

    PDGFR

    platelet derived growth factor receptor

    EGFR

    epidermal growth factor receptor

    PI3K

    phosphoinositide 3-kinase

    AKT

    protein kinase B

    mTOR

    mammalian target of rapamycin

    HER2

    human epidermal growth factor receptor 2

    FGFR

    fibroblast growth factor receptor

    IGF-1R

    type I insulin growth factor receptor

    CDK

    cyclin-dependent kinase

    ALK

    anaplastic lymphoma kinase

    MEK

    mitogen activated protein kinase

    PLK

    Polo-like kinase

    PKC

    protein kinase C

    Ph+

    Philadelphia chromosome positive

    CML

    chronic myeloid leukemia

    ALL

    acute lymphoblastic leukemia

    FAK

    focal-adhesion kinase

    Pyk2

    proline rich tyrosine kinase 2

    TGFβ-R

    transforming growth factor receptor β

    BTK

    Bruton’s tyrosine kinase

    MCL

    mantle cell lymphoma

    ATM

    ataxia telangiectasia mutated

    References

    ARTICLE SECTIONS
    Jump To

    This article references 308 other publications.

    1. 1
      Ostrom, Q. T.; Gittleman, H.; Farah, P.; Ondracek, A.; Chen, Y.; Wolinsky, Y.; Stroup, N. E.; Kruchko, C.; Barnholtz-Sloan, J. S. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010 Neuro-Oncology 2013, 15 (Suppl. 2) 1 56 DOI: 10.1093/neuonc/not151
    2. 2
      Krex, D.; Klink, B.; Hartmann, C.; von Deimling, A.; Pietsch, T.; Simon, M.; Sabel, M.; Steinbach, J. P.; Heese, O.; Reifenberger, G.; Weller, M.; Schackert, G. Long-term survival with glioblastoma multiforme Brain 2007, 130, 2596 2606 DOI: 10.1093/brain/awm204
    3. 3
      Patchell, R. A. The management of brain metastases Cancer Treat. Rev. 2003, 29, 533 540 DOI: 10.1016/S0305-7372(03)00105-1
    4. 4
      Swain, S. M.; Baselga, J.; Miles, D.; Im, Y.-H.; Quah, C.; Lee, L. F.; Cortes, J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA Ann. Oncol. 2014, 25, 1116 1121 DOI: 10.1093/annonc/mdu133
    5. 5
      (a) Mehta, M. P.; Paleologos, N. A.; Mikkelsen, T.; Robinson, P. D.; Ammirati, M.; Andrews, D. W.; Asher, A. L.; Burri, S. H.; Cobbs, C. S.; Gaspar, L. E.; Kondziolka, D.; Linskey, M. E.; Loeffler, J. S.; McDermott, M.; Olson, J. J.; Patchell, R. A.; Ryken, T. C.; Kalkanis, S. N. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline J. Neuro-Oncol. 2010, 96, 71 83 DOI: 10.1007/s11060-009-0062-7
      (b) Owonikoko, T. K.; Arbiser, J.; Zelnak, A.; Shu, H.-K. G.; Shim, H.; Robin, A. M.; Kalkanis, S. N.; Whitsett, T. G.; Salhia, B.; Tran, N. L.; Ryken, T.; Moore, M. K.; Egan, K.; Olson, J. J. Current approaches to the treatment of metastatic brain tumors Nat. Rev. Clin. Oncol. 2014, 11, 203 222 DOI: 10.1038/nrclinonc.2014.25
    6. 6
      (a) Steeg, P. S.; Camphausen, K. A.; Smith, Q. R. Brain metastases as preventive and therapeutic targets Nat. Rev. Cancer 2011, 11, 352 363 DOI: 10.1038/nrc3053
      (b) Sledge, G. W. Heading in a new direction: drug permeability in breast cancer brain metastasis Clin. Cancer Res. 2010, 16, 5605 5607 DOI: 10.1158/1078-0432.CCR-10-2502
      (c) Lockman, P. R.; Mittapalli, R. K.; Taskar, K. S.; Rudraraju, V.; Gril, B.; Bohn, K. A.; Adkins, C. E.; Roberts, A.; Thorsheim, H. R.; Gaasch, J. A.; Huang, S.; Palmien, D.; Steeg, P. S.; Smith, Q. R. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer Clin. Cancer Res. 2010, 16, 5664 5678 DOI: 10.1158/1078-0432.CCR-10-1564
      (d) Henson, J. W.; Cordon-Cardo, C.; Posner, J. B. P-glycoprotein expression in brain tumors J. Neuro-Oncol. 1992, 14, 37 43 DOI: 10.1007/BF00170943
      (e) Demeule, M.; Shedid, D.; Beaulieu, E.; Del Maestro, R. F.; Moghrabi, A.; Ghosn, P. B.; Moumdijian, R.; Berthelet, F.; Beliveau, R. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors Int. J. Cancer 2001, 93, 62 66 DOI: 10.1002/ijc.1306
    7. 7
      (a) Claes, A.; Idema, A. J.; Wesseling, P. Diffuse glioma growth: a guerrila war Acta Neuropathol. 2007, 114, 443 448 DOI: 10.1007/s00401-007-0293-7
      (b) Agarwal, S.; Sane, R.; Oberoi, R.; Ohlfest, J. R.; Elmquist, W. F. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain Expert Rev. Mol. Med. 2011, 13, e17 DOI: 10.1017/S1462399411001888
      (c) Kuratsu, J.; Itoyama, Y.; Uemura, S.; Ushio, Y. Regrowth patterns of glioma—cases of glioma regrew away from the original tumor Gan No Rinsho 1989, 35, 1255 1260
      (d) Silbergeld, D. L.; Chicoine, M. R. Isolation and characterization of human malignant glioma cells from histologically normal brain J. Neurosurg. 1997, 86, 525 531 DOI: 10.3171/jns.1997.86.3.0525
      (e) Lucio-Eterovic, A. K.; Piao, Y.; de Groot, J. F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Clin. Cancer Res. 2009, 15, 4589 4599 DOI: 10.1158/1078-0432.CCR-09-0575
    8. 8
      Rankovic, Z. CNS Drug Design: Balancing physicochemical properties for optimal brain exposure J. Med. Chem. 2015, 58, 2584 2608 DOI: 10.1021/jm501535r
    9. 9
      Levin, V. A.; Tonge, P. T.; Gallo, J. M.; Birtwistle, M. R.; Dar, A. C.; Iavarone, A.; Paddison, P. J.; Heffron, T. P.; Elmquist, W. F.; Lachowicz, J. E.; Johnson, T. W.; White, F. M.; Sul, J.; Smith, Q. R.; Shen, W.; Sarkaria, J. N.; Samala, R.; Wen, P. Y.; Berry, D. A.; Petter, R. C. CNS anticancer drug discovery and development conference white paper Neuro-Oncology 2015, 17, vi1 vi26 DOI: 10.1093/neuonc/nov169
    10. 10
      (a) Sun, H.; Dai, H.; Shaik, N.; Elmquist, W. F. Drug efflux transporters in the CNS Adv. Drug Delivery Rev. 2003, 55, 83 105 DOI: 10.1016/S0169-409X(02)00172-2
      (b) He, H.; Lyons, K. A.; Shen, X.; Yao, Z.; Bleasby, K.; Chan, G.; Hafey, M.; Li, X.; Xu, S.; Salituro, G. M.; Cohen, L. H.; Tang, W. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure Xenobiotica 2009, 39, 687 693 DOI: 10.1080/00498250903015402
      (c) Kodaira, H.; Kusuhara, H.; Fujita, T.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate J. Pharmacol. Exp. Ther. 2011, 339, 935 944 DOI: 10.1124/jpet.111.180398
    11. 11
      Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the “gatekeeper door”: exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681 2694 DOI: 10.1021/jm901443h
    12. 12
      (a) Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420 434 DOI: 10.1021/cn100007x
      (b) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435 449 DOI: 10.1021/cn100008c
    13. 13
      (a)

      For inhibitors approved through 2014:

      Wu, P.; Nielsen, T. E.; Clausen, M. H. FDA-approved small-molecule kinase inhibitors Trends Pharmacol. Sci. 2015, 36, 422 439 DOI: 10.1016/j.tips.2015.04.005
      (b)

      For inhibitors approved in 2015:

      http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm (accessed June 12, 2016) .
    14. 14
      Bridges, A. J. Chemical inhibitors of protein kinases Chem. Rev. 2001, 101, 2541 2572 DOI: 10.1021/cr000250y
    15. 15
      Cole, S.; Bagal, S.; El-Kattan, A.; Fenner, K.; Hay, T.; Kempshall, S.; Lunn, G.; Varma, M.; Stupple, P.; Speed, W. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration Xenobiotica 2012, 42, 11 27 DOI: 10.3109/00498254.2011.617847
    16. 16
      Huszthy, P. C.; Daphu, I.; Niclou, S. P.; Stieber, D.; Nigro, J. M.; Sakariassen, P.; Miletic, H.; Thorsen, F.; Bjerkvig, R. In vivo models of primary brain tumors: pitfalls and perspectives Neuro-Oncology 2012, 14, 979 993 DOI: 10.1093/neuonc/nos135
    17. 17
      Lee, J.; Kotilarova, S.; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N. M.; Pastorino, S.; Purow, B. W.; Christopher, N.; Zhang, W.; Park, J. K.; Fine, H. A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 2006, 9, 391 403 DOI: 10.1016/j.ccr.2006.03.030
    18. 18
      Jain, R. K.; di Tomaso, E.; Duda, D. G.; Loeffler, J. S.; Sorensen, A. G.; Batchelor, T. T. Angiogenesis in brain tumors Nat. Rev. Neurosci. 2007, 8, 610 622 DOI: 10.1038/nrn2175
    19. 19
      (a) Huang, H.; Held-Feindt, J.; Buhl, R.; Mehdorn, H. M.; Mentlein, R. Expression of VEGF and its receptors in different brain tumors Neurol. Res. 2005, 27, 371 377 DOI: 10.1179/016164105X39833
      (b) Tuettenberg, J.; Friedel, C.; Vajkoczy, P. Angiogenesis in malignant glioma-a target for antitumor therapy? Crit. Rev. Oncol. Hematol. 2006, 59, 181 193 DOI: 10.1016/j.critrevonc.2006.01.004
    20. 20
      Barrios, C. H.; Viola, F. S.; Coutinho, L. M.; Paglioli, E. Determination of expression of platelet derived growth factor receptors (PDGFR) in astrocytic tumors J. Clin. Oncol. 2006, 24 (Suppl.) 11518
    21. 21
      Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. J.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H. P.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jurgensmeier, J. M.; Ogilvie, D. J. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res. 2005, 65, 4389 4400 DOI: 10.1158/0008-5472.CAN-04-4409
    22. 22
      Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; Hunter, R. N.; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor J. Med. Chem. 2008, 51, 4632 4640 DOI: 10.1021/jm800566m
    23. 23
      Mulholland, P.; Batchelor, T. T.; Neyns, B. A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients Proc. ESMO Ann. Oncol. 2010, 21, LBA7
    24. 24
      Iwamoto, F. M.; Lamborn, K. R.; Robins, H. I.; Mehta, M. P.; Chang, S. M.; Butowski, N. A.; DeAngelis, L. M.; Abrey, L. E.; Zhang, W.-T.; Prados, M. D.; Fine, H. A. Phase II trial of pazopanib (GW786034), and oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06–02) Neuro Oncol. 2010, 12, 855 861 DOI: 10.1093/neuonc/noq025
    25. 25
      Wang, T.; Agarwal, S.; Elmquist, W. F. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier J. Pharmacol. Exp. Ther. 2012, 341, 386 395 DOI: 10.1124/jpet.111.190488
    26. 26
      Minocha, M.; Khurana, V.; Qin, B.; Pal, D.; Mitra, A. K. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib Int. J. Pharm. 2012, 436, 127 134 DOI: 10.1016/j.ijpharm.2012.05.038
    27. 27
      Atkins, M.; Jones, C. A.; Kirkpatrick, P. Sunitinib maleate Nat. Rev. Drug Discovery 2006, 5, 279 280 DOI: 10.1038/nrd2012
    28. 28
      Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discovery 2006, 5, 835 844 DOI: 10.1038/nrd2130
    29. 29
      Roth, G. J.; Binder, R.; Colbatzky, F.; Dallinger, C.; Schlenker-Herceq, R.; Hilberg, F.; Wollin, S. L.; Kaiser, R. Nintedanib: from discovery to the clinic J. Med. Chem. 2015, 58, 1053 1063 DOI: 10.1021/jm501562a
    30. 30
      Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; Suzuki, R.; Kubo, K.; Shibuya, M.; Isae, T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties Cancer Res. 2006, 66, 9134 9142 DOI: 10.1158/0008-5472.CAN-05-4290
    31. 31
      Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.; Jazan, E. M.; Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier, K.; Wiesmann, M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.; Heise, C. C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.; Jansen, J. M.; Wernette-Hammond, M. E.; Harris, A. L. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors J. Med. Chem. 2009, 52, 278 292 DOI: 10.1021/jm800790t
    32. 32
      (a) Balana, C.; Gil, M. J.; Reynes, G.; Capellades, J.; Ribalta, T.; Gallego, O.; Segura, P. P.; Verger, E. A phase II multicentric study of sunitinib administered as upfront therapy in glioblastoma: a study by the GEINO group J. Clin. Oncol. 2012, 30, 2045
      (b) Kreisl, T. N.; Smith, P.; Sul, J.; Salgado, C.; Iwamoto, F. M.; Shih, J. H.; Fine, H. A. Continuous daily sunitinib for recurrent glioblastoma J. Neuro-Oncol. 2013, 111, 41 48 DOI: 10.1007/s11060-012-0988-z
      (c) Reardon, D. A.; Vredenburgh, J. J.; Coan, A.; Desjardins, A.; Peters, K. B.; Gururangan, S.; Sathornsumetee, S.; Rich, J. N.; Herndon, J. E.; Friedman, H. S. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma J. Neuro-Oncol. 2011, 105, 621 627 DOI: 10.1007/s11060-011-0631-4
    33. 33
      (a) Lee, E. Q.; Kuhn, J.; Lamborn, K. R.; Abrey, L.; DeAngelis, L. M.; Lieberman, F.; Robins, H. I.; Chang, S. M.; Yung, W. K. A.; Drappatz, J.; Mehta, M. P.; Levin, V. A.; Aldape, K.; Dancey, J. E.; Wright, J. J.; Prados, M. D.; Cloughesy, T. F.; Gilbert, M. R.; Wen, P. Y. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 Neuro-Oncology 2012, 14, 1511 1518 DOI: 10.1093/neuonc/nos264
      (b) Hainsworth, J. D.; Ervin, T.; Friedman, E.; Priego, V.; Murphy, P. B.; Clark, B. L.; Lamar, R. E. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme Cancer 2010, 116, 3663 3669 DOI: 10.1002/cncr.25275
    34. 34
      Muhic, A.; Poulsen, H. S.; Sorensen, M.; Grunnet, K.; Lassen, U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme J. Neuro-Oncol. 2013, 111, 205 212 DOI: 10.1007/s11060-012-1009-y
    35. 35
      Cai, X.; Chandra, V.; Ou, Y.; Emblem, K. E.; Muzikansky, A.; Evans, J.; Kalpathy-Cramer, J.; Dietrich, J.; Chi, A. S.; Wen, P. Y.; Rosen, B. R.; Batchelor, T.; Gerstner, E. R.; Martinos, A. A. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma J. Clin. Oncol. 2015, 33 (Suppl.) 2025
    36. 36
      Ahluwalia, M. S.; Papadantonakis, N.; Venur, V. A.; Schilero, C.; Peereboom, D. M.; Stevens, G.; Rosenfeld, S.; Vogelbaum, M. A.; Elson, P.; Nixon, A. B.; McCrae, K. Phase II trial of dovitinib in recurrent glioblastoma J. Clin. Oncol. 2015, 33 (Suppl.) 2050
    37. 37
      (a) Oberoi, R. K.; Mittapalli, R. K.; Fisher, J.; Elmquist, W. F. Sunitinib LC-MS/MS assay in mouse plasma and brain tissue: application in CNS distribution studies Chromatographia 2013, 76, 1657 1665 DOI: 10.1007/s10337-013-2528-1
      (b) Tang, S. C.; Lagas, J. S.; Lankheet, N. A. G.; Poller, B.; Hillebrand, M. J.; Rosing, H.; Bejinen, J. H.; Schinkel, A. H. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration Int. J. Cancer 2012, 130, 223 233 DOI: 10.1002/ijc.26000
    38. 38
      (a) Lagas, J. S.; van Waterschoot, R. A. B.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation Mol. Cancer Ther. 2010, 9, 319 326 DOI: 10.1158/1535-7163.MCT-09-0663
      (b) Agarwal, S.; Sane, R.; Ohlfest, J. R.; Elmquist, W. F. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain J. Pharmacol. Exp. Ther. 2011, 336, 223 233 DOI: 10.1124/jpet.110.175034
      (c) Asakawa, C.; Ogawa, M.; Kumata, K.; Fujinaga, M.; Kato, K.; Yamasaki, T.; Yui, J.; Kawamura, K.; Hatori, A.; Fukumura, T.; Zhang, M.-R. [11C]Sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice Bioorg. Med. Chem. Lett. 2011, 21, 2220 2223 DOI: 10.1016/j.bmcl.2011.03.002
    39. 39
      Hussar, D. A.; Jeon, M. M. Naloxegol oxalate, pirfenidone, and nintedanib J. Am. Pharm. Assoc. 2015, 55, 461 463 DOI: 10.1331/JAPhA.2015.15523
    40. 40
      Helgason, H. H.; Mallo, H. A.; Droogendijk, H.; Haanen, J. G.; van der Veldt, A. A. M.; van den Eertwegh, A. J.; Boven, E. Brain metastases in patients with renal cell cancer receiving new targeted treatment J. Clin. Oncol. 2008, 26, 152 154 DOI: 10.1200/JCO.2007.13.5814
    41. 41
      Wilhelm, S. M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C. A.; Schutz, G.; Thierauch, K. H.; Zopf, D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int. J. Cancer 2011, 129, 245 255 DOI: 10.1002/ijc.25864
    42. 42
      EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003722-41 (accessed June 9, 2016) .
    43. 43
      Kort, A.; Durmus, S.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Pharm. Res. 2015, 32, 2205 2216 DOI: 10.1007/s11095-014-1609-7
    44. 44
      Yang, J. J.; Milton, M. N.; Liao, M.; Liu, N.; Wu, J. T.; Gan, L.; Balani, S. K.; Lee, F. W.; Prakash, S.; Xia, C. Q. P-glycloprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor Drug Metab. Lett. 2010, 4, 202 212 DOI: 10.2174/187231210792928279
    45. 45
      Supko, J. G.; Grossman, S. A.; Peereboom, D. M.; Chowdhary, S.; Lesser, G. J.; Nabors, L. B.; Mikkelsen, T.; Desideri, S.; Batchelor, T. T. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma J. Clin. Oncol. 2009, 27 (15s) 2039
    46. 46
      Lu, L.; Saha, D.; Martuza, R. L.; Rabkin, S. D.; Wakimoto, H. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma J. Neuro-Oncol. 2015, 121, 91 100 DOI: 10.1007/s11060-014-1612-1
    47. 47
      Zakharia, Y.; Zakharia, K.; Rixe, O. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma Expert Opin. Drug Discovery 2015, 10, 925 935 DOI: 10.1517/17460441.2015.1045411
    48. 48
      Neyns, B.; Duerinck, J.; Du Four, S.; Bouttens, F.; Verschaeve, V.; Everaert, H.; Van Binst, A. Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma J. Clin. Oncol. 2014, 32 (Suppl.) 2018
    49. 49
      Poller, B.; Iusuf, D.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics Drug Metab. Dispos. 2011, 39, 729 735 DOI: 10.1124/dmd.110.037317
    50. 50
      Sim, M. W.; Cohen, M. S. The discovery and development of vandetanib for the treatment of thyroid cancer Expert Opin. Drug Discovery 2014, 9, 105 114 DOI: 10.1517/17460441.2014.866942
    51. 51
      Matsui, J.; Yamamoto, Y.; Funahashi, Y.; Tsuruoka, A.; Watanabe, T.; Wakabayashi, T.; Uenaka, T.; Asada, M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition Int. J. Cancer 2008, 122, 664 671 DOI: 10.1002/ijc.23131
    52. 52
      (a) Drappatz, J.; Norden, A. D.; Wong, E. T.; Doherty, L. M.; LaFrankie, D. C.; Ciampa, A.; Kesari, S.; Sceppa, C.; Gerard, M.; Phan, P.; Schiff, D.; Batchelor, T. T.; Ligon, K. L.; Young, G.; Muzikansky, A.; Weiss, S. E.; Wen, P. Y. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma Int. J. Radiat. Oncol., Biol., Phys. 2010, 78, 85 90 DOI: 10.1016/j.ijrobp.2009.07.1741
      (b) Chheda, M. G.; Wen, P. Y.; Hochberg, F. H.; Chi, A. S.; Drappatz, J.; Eichler, A. F.; Yang, D.; Beroukhim, R.; Norden, A. D.; Gerstner, E. R.; Betensky, R. A.; Batchelor, T. T. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study J. Neuro-Oncol. 2015, 121, 627 634 DOI: 10.1007/s11060-014-1680-2
      (c) Kreisl, T. N.; McNeill, K. A.; Sul, J.; Iwamoto, F. M.; Shih, J.; Fine, H. A. A phase I/II trial of vandetanib for patients with recurrent malignant glioma Neuro-Oncology 2012, 14, 1519 1526 DOI: 10.1093/neuonc/nos265
      (d) Subbiah, V.; Berry, J.; Roxas, M.; Guha-Thakurta, N.; Subbiah, I. M.; Ali, S. M.; McMahon, C.; Miller, V.; Cascone, T.; Pai, S.; Tang, Z.; Heymach, J. V. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases Lung Cancer 2015, 89, 76 79 DOI: 10.1016/j.lungcan.2015.04.004
    53. 53
      Reardon, D. A.; Pan, E.; Fan, J.; Mink, J.; Barboriak, D. P.; Vrendenburgh, J. J.; Desjardins, A.; Peters, K.; O’Brien, J. P.; Wen, P. Y. A phase 2 trial of the multitargeted kinase inhibitor lenvatinib (E7080) in patients with recurrent glioblastoma (GBM) and disease progression following prior bevacizumab treatment Ann. Oncol. 2012, 23 (Suppl. 9) 417PD
    54. 54
      Minocha, M.; Khurana, V.; Qin, B.; Pal, D.; Mitra, A. K. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors Int. J. Pharm. 2012, 434, 306 314 DOI: 10.1016/j.ijpharm.2012.05.028
    55. 55
      Shumaker, R. C.; Aluri, J.; Fan, J.; Martinez, G.; Thompson, G. A.; Ren, M. Effect of fifampicin on the pharmacokinetics of lenvatinib in healthy adults Clin. Drug Invest. 2014, 34, 651 659 DOI: 10.1007/s40261-014-0217-y
    56. 56
      Banerjee, S.; Zvelebil, M.; Furet, P.; Mueller-Vieira, U.; Evans, D. B.; Dowsett, M.; Martin, L. A. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase Cancer Res. 2009, 69, 4716 4723 DOI: 10.1158/0008-5472.CAN-08-4711
    57. 57
      (a) Gerstner, E. R.; Eichler, A. F.; Plotkin, S. R.; Drappatz; Doyle, C. L.; Xu, L.; Duda, D. G.; Wen, P. Y.; Jain, R. K.; Batchelor, T. T. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide J. Neuro-Oncol. 2011, 103, 325 332 DOI: 10.1007/s11060-010-0390-7
      (b) Brandes, A. A.; Stupp, R.; Hau, P.; Lacombe, D.; Gorlia, T.; Tosoni, A.; Mirimanoff, R. O.; Kros, J. M.; van den Bent, M. J. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma Eur. J. Cancer 2010, 46, 348 354 DOI: 10.1016/j.ejca.2009.10.029
      (c) Reardon, D. A.; Egorin, M. J.; Desjardins, A.; Vredenburgh, J. J.; Beumer, J. H.; Lagattuta, T. F.; Gururangan, S.; Herndon, J. E.; Salvado, A. J.; Friedman, H. S. Phase I pharmacokinetic study of the VEGFR tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma Cancer 2009, 115, 2188 2198 DOI: 10.1002/cncr.24213
    58. 58
      Yakes, F. M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A. D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y. C.; Joly, A. H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol. Cancer Ther. 2011, 10, 2298 2308 DOI: 10.1158/1535-7163.MCT-11-0264
    59. 59
      Bhide, R. S.; Cai, Z. W.; Zhang, Y. Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L. J.; Borzilleri, R. M.; Zheng, X.; Wu, L. I.; Barrish, J. C.; Kim, S. H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R.; Kukral, D.; Hunt, J. T.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D’Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor J. Med. Chem. 2006, 49, 2143 2146 DOI: 10.1021/jm051106d
    60. 60
      Highlights of Prescribing Information. COMETRIQ. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf (accessed June 12, 2016) .
    61. 61
      Marathe, P. H.; Kamath, A. V.; Zhang, Y.; D’Arienzo, C.; Bhide, R.; Fargnoli, J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate Cancer Chemother. Pharmacol. 2009, 65, 55 66 DOI: 10.1007/s00280-009-1002-0
    62. 62
      (a) De Groot, J. F.; Prados, M.; Urquhart, T.; Robertson, S.; Yaron, Y.; Sorensen, A. G.; Norton, A.; Batchelor, T.; Drappatz, J.; Wen, P. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse J. Clin. Oncol. 2009, 27 (15s) 2047
      (b) Wen, P. Y.; Prados, M.; Schiff, D.; Reardon, D. A.; Cloughesy, T.; Mikkelsen, T.; Batchelor, T.; Drappatz, J.; Chamberlain, M. C.; De Groot, J. F. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) J. Clin. Oncol. 2010, 28, 2006
    63. 63
      Dowell, J.; Minna, J. D.; Kirkpatrick, P. Erlotinib hydrochloride Nat. Rev. Drug Discovery 2005, 4, 13 14 DOI: 10.1038/nrd1612
    64. 64
      Muhsin, M.; Graham, J.; Kirkpatrick, P. Gefitinib Nat. Rev. Drug Discovery 2003, 2, 515 516 DOI: 10.1038/nrd1136
    65. 65
      Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gieterma, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors Br. J. Cancer 2008, 98, 80 85 DOI: 10.1038/sj.bjc.6604108
    66. 66
      Finlay, M. R. V.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M. R.; Bradbury, R. H.; Brown, S. J.; Butterworth, S.; Campbell, A.; Chorley, C.; Colclough, N.; Cross, D. A. E.; Currie, G. S.; Grist, M.; Hassall, L.; Hill, G. B.; James, D.; James, M.; Kemmitt, P.; Klinowska, T.; Lamont, G.; Lamont, S. G.; Martin, N.; McFarland, H. L.; Mellor, M. J.; Orme, J. P.; Perkins, D.; Perkins, P.; Richmond, G.; Smith, P.; Ward, R. A.; Waring, M. J.; Whittaker, D.; Wells, S.; Wrigley, G. L. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor J. Med. Chem. 2014, 57, 8249 8267 DOI: 10.1021/jm500973a
    67. 67
      (a) Bartolotti, M.; Franceschi, E.; Brandes, A. A. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer Expert Rev. Anticancer Ther. 2012, 12, 1429 1435 DOI: 10.1586/era.12.121
      (b) Shimato, S.; Mitsudomi, T.; Kosaka, T.; Yatabe, Y.; Wakabayashi, T.; Mizuno, M.; Nakahara, N.; Hatano, H.; Natsume, A.; Ishii, D.; Yoshida, J. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib Neuro-Oncology 2006, 8, 137 144 DOI: 10.1215/15228517-2005-002
      (c) Porta, R.; Sanchez-Torres, J. M.; Paz-Ares, L.; Massuti, B.; Reguart, N.; Mayo, C.; Lianes, P.; Queralt, C.; Guillem, V.; Salinas, P.; Catot, S.; Isla, D.; Pradas, A.; Gurpide, A.; de Castro, J.; Polo, E.; Puig, T.; Taron, M.; Colomer, R.; Rosell, R. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Eur. Respir. J. 2011, 37, 624 631 DOI: 10.1183/09031936.00195609
      (d) Grommes, C.; Oxnard, G. R.; Kris, M. G.; Miller, V. A.; Pao, W.; Holodny, A. I.; Clarke, J. L.; Lassman, A. B. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer Neuro-Oncology 2011, 13, 1364 1369 DOI: 10.1093/neuonc/nor121
      (e) Jackman, D. M.; Holmes, A. J.; Lindeman, N.; Wen, P. Y.; Kesari, S.; Borras, A. M.; Bailey, C.; de Jong, F.; Janne, P. A.; Johnson, B. E. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib J. Clin. Oncol. 2006, 24, 4517 4520 DOI: 10.1200/JCO.2006.06.6126
      (f) Park, S. J.; Kim, H. T.; Lee, D. H.; Kim, K. P.; Kim, S.-W.; Suh, C.; Lee, J. S. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer. 2012, 77, 556 560 DOI: 10.1016/j.lungcan.2012.05.092
    68. 68
      Noronha, V.; Joshi, A.; Gokarn, A.; Sharma, V.; Patil, V.; Janu, A.; Purandare, N.; Chougule, A.; Jambhekar, N.; Prabhash, K. The importance of brain metastasis in EGFR mutation positive NSCLC patients Chemother. Res. Pract. 2014, 2014, 856156 DOI: 10.1155/2014/856156
    69. 69
      Weber, B.; Winterdahl, M.; Memon, A.; Sorensen, B. S.; Keiding, S.; Sorensen, L.; Nexo, E.; Meldgaard, P. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor J. Thorac. Oncol. 2011, 6, 1287 1289 DOI: 10.1097/JTO.0b013e318219ab87
    70. 70
      Agarwal, S.; Manchanda, P.; Vogelbaum, M. A.; Ohlfest, J. R.; Elmquist, W. F. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma Drug Metab. Dispos. 2013, 41, 33 39 DOI: 10.1124/dmd.112.048322
    71. 71
      Agarwal, S.; Sane, R.; Gallardo, J. L.; Ohlfest, J. R.; Elmquist, W. F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux J. Pharmacol. Exp. Ther. 2010, 334, 147 155 DOI: 10.1124/jpet.110.167601
    72. 72
      Peters, S.; Zimmerman, S.; Adjei, A. A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions Cancer Treat. Rev. 2014, 40, 917 926 DOI: 10.1016/j.ctrv.2014.06.010
    73. 73
      Highlights of Prescribing Information. TAGRISSO. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf Accessed June 12, 2016.
    74. 74
      Hoffknecht, P.; Tufman, A.; Wehler, T.; Pelzer, T.; Wiewrodt, R.; Schutz, M.; Serke, M.; Stohlmacher-Williams, J.; Marten, A.; Huber, R. M.; Dickgreber, N. J. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease J. Thorac. Oncol. 2015, 10, 156 163 DOI: 10.1097/JTO.0000000000000380
    75. 75
      Hatanpaa, K. J.; Burma, S.; Zhao, D.; Habib, A. A. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance Neoplasia 2010, 12, 675 684 DOI: 10.1593/neo.10688
    76. 76
      (a) Mellinghoff, I. K.; Wang, M. Y.; Vivanco, I.; Haas-Kogan, D. A.; Zhu, S.; Dia, E. Q.; Lu, K. V.; Yoshimoto, K.; Huang, J. H. Y.; Chute, D. J.; Riggs, B. L.; Horvatch, S.; Liau, L. M.; Cavanee, W. K.; Rao, P. N.; Beroukhim, R.; Peck, T. C.; Lee, J. C.; Sellers, W. R.; Stokoe, D.; Prados, M.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N. Engl. J. Med. 2005, 353, 2012 2024 DOI: 10.1056/NEJMoa051918
      (b) Rich, J. N.; Reardon, D. A.; Peery, T.; Dowell, J. M.; Quinn, J. A.; Penne, K. L.; Wikstrand, C. J.; Van Duyn, L. B.; Dancey, J. E.; McLendon, R. E.; Kao, J. C.; Stenzel, T. T.; Rasheed, B. K. A.; Tourt-Uhlig, S. E.; Herndon, J. E.; Vredenburgh, J. J.; Sampson, J. H.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S. Phase II trial of gefitinib in recurrent glioblastoma J. Clin. Oncol. 2004, 22, 133 142 DOI: 10.1200/JCO.2004.08.110
    77. 77
      Walter, A. O.; Sjin, R. T.; Haringsma, H. J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovsky, A.; Labenski, M.; Zhu, Z.; Wang, Z.; Sheets, M.; St Martin, T.; Karp, R.; van Kalken, D.; Chaturvedi, P.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W.; Lin, K.; Jaw-Tsai, S.; Raponi, M.; Van Dyke, T.; Etter, J.; Weaver, Z.; Pao, W.; Singh, J.; Simmons, A. D.; Harding, T. C.; Allen, A. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discovery 2013, 3, 1404 1415 DOI: 10.1158/2159-8290.CD-13-0314
    78. 78
      (a) Yoshida, Y.; Ozawa, T.; Butowski, N.; Shen, W.; Brown, D.; Pederson, H.; James, D. Preclinical evaluation of NT-113, a novel ERBB inhibitor optimized for CNS biodistribution Neuro-Oncology 2013, 15 (Suppl.) ET-00
      (b) Yoshida, Y.; Ozawa, T.; Yao, T.-W.; Shen, W.; Brown, D.; Parsa, A. T.; Raizer, J. J.; Cheng, S.-Y.; Stegh, A. H.; Mazar, A. P.; Giles, F. J.; Sarkaria, J. N.; Butowski, N.; Nicolaides, T.; James, C. D. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification Mol. Cancer Ther. 2014, 13, 2919 2929 DOI: 10.1158/1535-7163.MCT-14-0306
    79. 79
      Zeng, Q.; Wang, J.; Cheng, Z.; Chen, K.; Johnstrom, P.; Varnas, K.; Li, D. Y.; Yang, Z. F.; Zhang, X. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor J. Med. Chem. 2015, 58, 8200 8215 DOI: 10.1021/acs.jmedchem.5b01073
    80. 80
      Ströbele, S.; Schneider, M.; Schneele, L.; Siegelin, M. D.; Nonnenmacher, L.; Zhou, S.; Karpel-Massle, G.; Westhoff, M.-A.; Halatsch, M.-E.; Debatin, K.-M. A potential role for the inhibition of PI3K signaling in glioblastoma therapy PLoS One 2015, 10, e0131670 DOI: 10.1371/journal.pone.0131670
    81. 81
      Akhavan, D.; Cloughesy, T. F.; Mischel, P. S. mTOR signaling in glioblastoma: lessons learned from bench to bedside Neuro-Oncology 2010, 12, 882 889 DOI: 10.1093/neuonc/noq052
    82. 82
      The Cancer Genome Atlas Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 2008, 455, 1061 1068 DOI: 10.1038/nature07385
    83. 83
      Westhoff, M.-A.; Karpel-Massler, G.; Brühl, O.; Enzenmüller, S.; La Ferla-Brühl, K.; Siegelin, M. D.; Nonnenmacher, L.; Debatin, K.-M. A critical evaluation of PI3K inhibition in glioblastoma and neruoblastoma therapy Mol. Cell. Ther. 2014, 2, 32 DOI: 10.1186/2052-8426-2-32
    84. 84
      Mohd Sharial, M. S. N.; Crown, J.; Hennessy, B. T. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer Ann. Oncol. 2012, 23, 3007 3016 DOI: 10.1093/annonc/mds200
    85. 85
      Wen, P. Y.; Lee, E. Q.; Reardon, D. A.; Ligon, K. L.; Yung, W. K. A. Current clinical development of PI3K pathway inhibitors in glioblastoma Neuro-Oncology 2012, 14, 819 829 DOI: 10.1093/neuonc/nos117
    86. 86
      Heffron, T. P.; Ndubaku, C. O.; Salphati, L.; Alicke, B.; Cheong, J.; Drobnick, J.; Edgar, K.; Gould, S. E.; Lee, L. B.; Lesnick, J. D.; Lewis, C.; Nonomiya, J.; Pang, J.; Plise, E. G.; Sideris, S.; Wallin, J.; Wang, L.; Zhang, X.; Olivero, A. G. Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR ACS Med. Chem. Lett. 2016, 7, 351 356 DOI: 10.1021/acsmedchemlett.6b00005
    87. 87
      Burger, M. T.; Pecchi, S.; Wagman, A.; Ni, Z.-J.; Knapp, M.; Hendrickson, T.; Atallah, G.; Pfister, K.; Zhang, Y.; Bartulis, S.; Frazier, K.; Ng, S.; Smith, A.; Verhagen, J.; Haznedar, J.; Huh, K.; Iwanowicz, E.; Xin, X.; Menezes, D.; Merritt, H.; Lee, I.; Wiesmann, M.; Kaufman, S.; Crawford, K.; Chin, M.; Bussiere, D.; Shoemaker, K.; Zaror, I.; Maira, S.-M.; Voliva, C. F. Identification of NVP-BKM120 as a potent, selective, orally bioavailable Class I PI3 kinase inhibitor for treating cancer ACS Med. Chem. Lett. 2011, 2, 774 779 DOI: 10.1021/ml200156t
    88. 88
      Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol. Cancer Ther. 2004, 3, 763 772
    89. 89
      Foster, P.; Yamaguchi, K.; Hsu, P. P.; Qian, F.; Du, X.; Wu, J.; Won, K. A.; Yu, P.; Jaeger, C. T.; Zhang, W.; Marlowe, C. K.; Keast, P.; Abulafia, W.; Chen, J.; Young, J.; Plonowski, A.; Yakes, F. M.; Chu, F.; Engell, K.; Bentzien, F.; Lam, S. T.; Dale, S.; Yturralde, O.; Matthews, D. J.; Lamb, P.; Laird, A. D. The selective PI3K inhibitor XL147 (SAR245408) inhibits tumor growth and survival and potentiates the activity of chemotherapeutic agents in preclinical models Mol. Cancer Ther. 2015, 14, 931 940 DOI: 10.1158/1535-7163.MCT-14-0833
    90. 90
      Yu, P.; Laird, A. D.; Du, X.; Wu, J.; Won, K.; Yamaguchi, K.; Hsu, P. P.; Qian, F.; Jaeger, C. T.; Zhang, W.; Buhr, C. A.; Shen, P.; Abulafia, W.; Chen, J.; Young, J.; Plonowski, A.; Yakes, F. M.; Chu, F.; Lee, M.; Bentzien, F.; Lam, S. T.; Dale, S.; Matthews, D. J.; Lamb, P.; Foster, P. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway Mol. Cancer Ther. 2014, 13, 1078 1091 DOI: 10.1158/1535-7163.MCT-13-0709
    91. 91
      Lin, N. U. Targeted therapies in brain metastases Curr. Treat. Options Neurol. 2014, 16, 276 DOI: 10.1007/s11940-013-0276-z
    92. 92
      Sutherlin, D. P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W. W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V.; Wan, N. C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B.-Y. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer J. Med. Chem. 2010, 53, 1086 1097 DOI: 10.1021/jm901284w
    93. 93
      Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J. Med. Chem. 2008, 51, 5522 5532 DOI: 10.1021/jm800295d
    94. 94
      (a) Heffron, T. P.; Salphati, L.; Alicke, B.; Cheong, J.; Dotson, J.; Edgar, K.; Goldsmith, R.; Gould, S. E.; Lee, L. B.; Lesnick, J. D.; Lewis, C.; Ndubaku, C. O.; Nonomiya, J.; Olivero, A. G.; Pang, J.; Plise, E. G.; Sideris, S.; Trapp, S.; Wallin, J.; Wang, L.; Zhang, X. The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase a J. Med. Chem. 2012, 55, 8007 8020 DOI: 10.1021/jm300867c
      (b) Salphati, L.; Heffron, T. P.; Alicke, B.; Nishimura, M.; Barck, K.; Carano, R. A.; Cheong, J.; Edgar, K.; Greve, J.; Kharbanda, S.; Koeppen, H.; Lau, S.; Lee, L. B.; Pang, J.; Plise, E. G.; Pokorny, J. L.; Reslan, H. B.; Sarkaria, J. N.; Wallin, J. J.; Zhang, X.; Gould, S. E.; Olivero, A. G.; Phillips, H. S. Targeting the PI3K pathway in the brain – efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier Clin. Cancer Res. 2012, 18, 6239 6248 DOI: 10.1158/1078-0432.CCR-12-0720
    95. 95
      Maira, M.; Schnell, C.; Lollini, P.; Chouaid, C.; Schmid, P.; Nanni, P.; Lam, D.; Di Tomaso, E.; C. Massacesi, C.; Rodon, J. Preclinical and preliminary clinical activity of NVP-BKM-120, an oral pan-class I PI3K inhibitor, in the brain Ann. Oncol. 2012, 23 (Suppl.) 1675
    96. 96
      Wen, P. Y.; Yung, W. K. A.; Mellinghoff, I. K.; Ramkissoon, S.; Alexander, B. M.; Rinne, M. L.; Colman, H.; Omuro, A. M. P.; DeAngelis, L. M.; Gilbert, M. R.; De Groot, J. F.; Cloughesy, T. F.; Chi, A. S.; Lee, E. Q.; Nayak, L.; Betchelor, T.; Chang, S. M.; Prados, M.; Reardon, D. A.; Ligon, K. Phase II trial of the phosphatidylinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma J. Clin. Oncol. 2014, 32 (Suppl.) 2019
    97. 97
      Cmiljanovic, V.; Cmiljanovic, N.; Marone, R.; Beaufils, F.; Zhang, X.; Zvelebil, M.; Hebeisen, P.; Lang, M.; Mestan, J.; Melone, A.; Bohnacker, T.; Gaudio, E.; Tarantelli, C.; Bertoni, F.; Ritschard, R.; Pretre, V.; Wicki, A.; Fabbro, D.; Hillmann, P.; Williams, R.; Giese, B.; Wymann, M. P. Abstract 2664: PQR309: structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor Cancer Res. 2015, 75 (Suppl.) 2664 DOI: 10.1158/1538-7445.AM2015-2664
    98. 98
      Cmiljanovic, V.; Ettlin, R. A.; Beaufils, F.; Dieterle, W.; Hillmann, P.; Mestan, J.; Melone, A.; Bohnacker, T.; Lang, M.; Cmiljanovic, N.; Giese, B.; Hebeisen, P.; Wymann, M. P.; Fabbro, D. Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability Cancer Res. 2015, 75 (Suppl.) 4514 DOI: 10.1158/1538-7445.AM2015-4514
    99. 99
      Lannutti, B. J.; Meadows, S. A.; Herman, S. E. M.; Kashishian, A.; Steiner, B.; Johnson, A. J.; Byrd, J. C.; Tyner, J. W.; Loriaux, M. M.; Deininger, M.; Druker, B. J.; Puri, K. D.; Ulrich, R. G.; Giese, N. A. CAL-101, a p100d selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 2011, 117, 591 594 DOI: 10.1182/blood-2010-03-275305
    100. 100
      Janssens, A. Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice Belg. J. Hematol. 2015, 6, 216 224
    101. 101
      Highlights of Prescribing Information. Zydelig. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf (accessed June 12, 2016) .
    102. 102
      Benjamin, D.; Colombi, M.; Moroni, C.; Hall, M. H. Rapamycin passes the torch: a new generation of mTOR inhibitors Nat. Rev. Drug Discovery 2011, 10, 868 880 DOI: 10.1038/nrd3531
    103. 103
      Crowe, A.; Lemaire, M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin Pharm. Res. 1998, 15, 1666 1672 DOI: 10.1023/A:1011940108365
    104. 104
      Pike, K. G.; Malagu, K.; Hummersone, M. G.; Menear, K. A.; Duggan, H. M.; Gomez, S.; Martin, N. M.; Ruston, L.; Pass, S. L.; Pass, M. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014 Bioorg. Med. Chem. Lett. 2013, 23, 1212 1216 DOI: 10.1016/j.bmcl.2013.01.019
    105. 105
      Mortensen, D. S.; Perrin-Ninkovic, S. M.; Shevlin, G.; Zhao, J.; Packard, G.; Bahmanyar, S.; Correa, M.; Elsner, J.; Harris, R.; Lee, B. G. S.; Papa, P.; Parnes, J. S.; Riggs, J. R.; Sapienza, J.; Tehrani, L.; Whitefield, B.; Apuy, J.; Bisonette, R. R.; Gamez, J. C.; Hickman, M.; Khambatta, G.; Leisten, J.; Peng, S. X.; Richardson, S. J.; Cathers, B. E.; Canan, S. S.; Moghaddam, M. F.; Raymon, H. K.; Worland, P.; Narla, R. K.; Fultz, K. E.; Sankar, S. Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223 J. Med. Chem. 2015, 58, 5323 5333 DOI: 10.1021/acs.jmedchem.5b00626
    106. 106
      https://clinicaltrials.gov/ct2/show/NCT02619864 (accessed June 12, 2016) .
    107. 107
      Varga, A.; Mita, M. M.; Wu, J. J.; Nemunaitis, J. J.; Cloughesy, T. F.; Mischel, P. S.; Bendell, J. C.; Shih, K. C.; Paz-Ares, L. G.; Mahipal, A.; Delord, J.-P.; Kelley, R. K.; Soria, J.-C.; Wong, L.; Xu, S.; James, A.; Wu, X.; Chopra, R.; Hege, K.; Muster, P. N. Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors J. Clin. Oncol. 2013, 31 (Suppl.) 2606
    108. 108
      Basu, B.; Dean, E.; Puglisi, M.; Greystoke, A.; Ong, M.; Burke, W.; Cavallin, M.; Bigley, G.; Womack, C.; Harrington, E. A.; Green, S.; Oelmann, E.; de Bono, J. S.; Ranson, M.; Banerji, U. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014 Clin. Cancer Res. 2015, 21, 3412 3419 DOI: 10.1158/1078-0432.CCR-14-2422
    109. 109
      Lin, F.; Buil, L.; Sherris, D.; Beijnen, J. H.; van Tellingen, O. Dual mTORC1 and mTORC2 inhibitor Palmoid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2 Int. J. Cancer 2013, 133, 1222 1234 DOI: 10.1002/ijc.28126
    110. 110

      For AKT inhibitors that have entered clinical studies see the following:

      (a) Pal, S. K.; Reckamp, K.; Yu, H.; Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer Expert Opin. Invest. Drugs 2010, 19, 1355 1366 DOI: 10.1517/13543784.2010.520701
      (b) Rodon, J.; Dienstmann, R.; Serra, V.; Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials Nat. Rev. Clin. Oncol. 2013, 10, 143 153 DOI: 10.1038/nrclinonc.2013.10
    111. 111
      Hilgard, P.; Klenner, T.; Stekar, J.; Nossner, G.; Kutscher, B.; Engel, J. D-21266, a new heterocyclic alkylphospholipid with antitumor activity Eur. J. Cancer 1997, 33, 442 446 DOI: 10.1016/S0959-8049(97)89020-X
    112. 112
      Hirai, H.; Sootome, H.; Nakatsuru, Y.; Miyama, K.; Taguchi, S.; Tsujioka, K.; Ueno, Y.; Hatch, H.; Majumder, P. K.; Pan, B. S.; Kotani, H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo Mol. Cancer Ther. 2010, 9, 1956 1967 DOI: 10.1158/1535-7163.MCT-09-1012
    113. 113
      Dunn, D. E.; He, D. N.; Yang, P.; Johansen, M.; Newman, R. A.; Lo, D. C. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models J. Neurochem. 2011, 119, 805 814 DOI: 10.1111/j.1471-4159.2011.07439.x
    114. 114
      Heerding, D. A.; Rhodes, N.; Leber, J. D.; Clark, T. J.; Keenan, R. M.; Lafrance, L. V.; Li, M.; Safonov, I. G.; Takata, D. T.; Venslavsky, J. W.; Yamashita, D. S.; Choudhry, A. E.; Copeland, R. A.; Lai, Z.; Schaber, M. D.; Tummino, P. J.; Strum, S. L.; Wood, E. R.; Duckett, D. R.; Eberwein, D.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Zhang, S.; Minthorn, E. A.; Concha, N. O.; Warren, G. L.; Kumar, R. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase J. Med. Chem. 2008, 51, 5663 5679 DOI: 10.1021/jm8004527
    115. 115
      Dumble, M.; Crouthamel, M.; Zhang, S.; Schaber, M.; Levy, D.; Robell, K.; Liu, Q.; Figueroa, D. J.; Minthorn, E. A.; Seefeld, M. A.; Rouse, M. B.; Rabindran, S. K.; Heerding, D. A.; Kumar, R. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor PLoS One 2014, 9, e100880 DOI: 10.1371/journal.pone.0100880
    116. 116
      Blake, J. F.; Xu, R.; Bencsik, J. R.; Xiao, D.; Kallan, N. C.; Schlachter, S.; Mitchell, I. S.; Spencer, K. L.; Banka, A. L.; Wallace, E. M.; Gloor, S. L.; Martinson, M.; Woessner, R. D.; Vigers, G. P.; Brandhuber, B. J.; Liang, J.; Safina, B. S.; Li, J.; Zhang, B.; Chabot, C.; Do, S.; Lee, L.; Oeh, J.; Sampath, D.; Lee, B. B.; Lin, K.; Liederer, B. M.; Skelton, N. J. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors J. Med. Chem. 2012, 55, 8110 8127 DOI: 10.1021/jm301024w
    117. 117
      Lapierre, J.-M.; Eathiraj, S.; Vensel, D.; Liu, Y.; Bull, C. O.; Cornell-Kennon, S.; Iimura, S.; Kelleher, E. W.; Kizer, D. E.; Koerner, S.; Makhija, S.; Matsuda, A.; Moussa, M.; Namdev, N.; Savage, R. E.; Szwaya, J.; Volckova, E.; Westlund, N.; Wu, H.; Schwartz, B. Discovery of 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor J. Med. Chem. 2016, 59, 6455 6469 DOI: 10.1021/acs.jmedchem.6b00619
    118. 118
      Vink, S. R.; Schellens, J. H.; van Blitterswijk, W. J.; Verheij, M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid Invest. New Drugs 2005, 23, 279 286 DOI: 10.1007/s10637-005-1436-0
    119. 119
      Dunn, D. E.; He, D. N.; Yang, P.; Johansen, M.; Newman, R. A.; Lo, D. C. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models J. Neurochem. 2011, 119, 805 814 DOI: 10.1111/j.1471-4159.2011.07439.x
    120. 120
      Newton, H. B. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors Expert Rev. Anticancer Ther. 2003, 3, 595 614 DOI: 10.1586/14737140.3.5.595
    121. 121
      Singh, D.; Chan, J. M.; Zoppoli, P.; Niola, F.; Sullivan, R.; Castano, A.; Liu, E. M.; Reichel, J.; Porrati, P.; Pellegatta, S.; Qiu, K.; Gao, Z.; Ceccarelli, M.; Riccardi, R.; Brat, D. J.; Guha, A.; Aldape, K.; Golfinos, J. G.; Zagzag, D.; Mikkelsen, T.; Finocchiaro, G.; Lasorella, A.; Rabadan, R.; Iavarone, A. Transofrming fusions of FGFR and TACC genes in human glioblastoma Science 2012, 337, 1231 1235 DOI: 10.1126/science.1220834
    122. 122
      (a) Shaw, A. T.; Hsu, P. P.; Awad, M. M.; Engleman, J. A. Tyrosine kinase gene rearrangements in epithelial malignancies Nat. Rev. Cancer 2013, 13, 772 787 DOI: 10.1038/nrc3612
      (b) Dieci, M. V.; Arnedos, M.; Andre, F.; Soria, J. C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives Cancer Discovery 2013, 3, 264 279 DOI: 10.1158/2159-8290.CD-12-0362
    123. 123
      Brooks, A. N.; Kilgour, E.; Smith, P. D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer Clin. Cancer Res. 2012, 18, 1855 1862 DOI: 10.1158/1078-0432.CCR-11-0699
    124. 124
      Gavine, P. R.; Mooney, L.; Kilgour, E.; Thomas, A. P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M. J.; Brooks, A. N.; Klinowska, T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family Cancer Res. 2012, 72, 2045 2056 DOI: 10.1158/0008-5472.CAN-11-3034
    125. 125
      Guagnano, V.; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M. R.; Schnell, C.; Schmid, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Graus Porta, D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase J. Med. Chem. 2011, 54, 7066 7083 DOI: 10.1021/jm2006222
    126. 126
      Angibaud, P. R.; Mevellec, L.; Saxty, G.; Adelinet, C.; Akkari, R.; Berdini, V.; Bonnet, P.; Bourgeois, M.; Bourdrez, X.; Cleasby, A.; Colombel, H.; Csoka, I.; Embrechts, W.; Freyne, E.; Gilissen, R.; Jovcheva, E.; King, P.; Lacrampe, J.; Lardeau, D.; Ligny, Y.; Mcclue, S.; Meerpoel, L.; Newell, D. R.; Page, M.; Papanikos, A.; Pasquier, E.; Pilatte, I.; Poncelet, V.; Querolle, O.; Rees, D. C.; Rich, S.; Roux, B.; Sement, E.; Simonnet, Y.; Squires, M.; Tronel, V.; Verhulst, T.; Vialard, J.; Willems, M.; Woodhead, S. J.; Wroblowski, B.; Murray, C. W.; Perera, T. Abstract 4748: Discovery of JNJ-42756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment based approach Cancer Res. 2014, 74 (Suppl.) 4748 DOI: 10.1158/1538-7445.AM2014-4748
    127. 127
      Nakanishi, Y.; Akiyama, N.; Tsukaguchi, T.; Fujii, T.; Sakata, K.; Sase, H.; Isobe, T.; Morikami, K.; Shindoh, H.; Mio, T.; Ebiike, H.; Taka; Naoki, N.; Aoki, Y.; Ishii, N. The fibroblast growth factor receptor genetic status as a potential predictor for the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor Mol. Cancer Ther. 2014, 13, 2547 2558 DOI: 10.1158/1535-7163.MCT-14-0248
    128. 128
      https://clinicaltrials.gov/ct2/show/NCT01975701 (accessed June 12, 2016) .
    129. 129
      Savage, R. E.; Hall, T.; Schwartz, B. ARQ 087, a novel pan FGFR-inhibitor crosses the BBB (blood brain barrier) and distributes to the brain of rats Eur. J. Cancer 2014, 50 (Suppl. 6) 50 DOI: 10.1016/S0959-8049(14)70271-0
    130. 130
      Elmlinger, M. W.; Deininger, M. H.; Schuett, B. S.; Meyermann, R.; Duffner, F.; Grote, E. H.; Ranke, M. B. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade Endocrinology 2001, 142, 1652 1658 DOI: 10.1210/endo.142.4.8084
    131. 131
      Chen, H. X.; Sharon, E. IGF-1R as an anti-cancer target—trials and tribulations Aizheng 2013, 32, 242 252 DOI: 10.5732/cjc.012.10263
    132. 132
      Mulvihill, M. J.; Cooke, A.; Rosenfeld-Franklin, M.; Buck, E.; Foreman, K.; Landfair, D.; O’Connor, M.; Pirritt, C.; Sun, Y.; Yao, Y.; Arnold, L. D.; Gibson, N. W.; Ji, Q. S. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor Future Med. Chem. 2009, 1, 1153 1171 DOI: 10.4155/fmc.09.89
    133. 133
      Carboni, J. M.; Wittman, M.; Yang, Z.; Lee, F.; Greer, A.; Hurlburt, W.; Hillerman, S.; Cao, C.; Cantor, G. H.; Dell-John, J.; Chen, C.; Discenza, L.; Menard, K.; Li, A.; Trainor, G.; Vyas, D.; Kramer, R.; Attar, R. M.; Gottardis, M. M. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR Mol. Cancer Ther. 2009, 8, 3341 3349 DOI: 10.1158/1535-7163.MCT-09-0499
    134. 134
      Vasilcanu, D.; Girnita, A.; Girnita, L.; Vasilcanu, R.; Axelson, A.; Larsson, O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway Oncogene 2004, 23, 7854 7862 DOI: 10.1038/sj.onc.1208065
    135. 135
      Guz, N. R.; Leuser, H.; Goldman, E. Process development and multikilogram syntheses of XL228 utilizing a regioselective isoxazole formation and a selective SNAr reaction to a pyrimidine core Org. Process Res. Dev. 2013, 17, 1066 1073 DOI: 10.1021/op400137m
    136. 136
      Rodon, J.; De Santos, V.; Ferry, R. J.; Kurzrock, R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials Mol. Cancer Ther. 2008, 7, 2575 2588 DOI: 10.1158/1535-7163.MCT-08-0265
    137. 137
      Halvorson, K. G.; Barton, K. L.; Schroeder, K.; Misuraca, K. L.; Hoeman, C.; Chung, A.; Crabtree, D. M.; Cordero, F. J.; Singh, R.; Spasojevic, I.; Berlow, N.; Pal, R.; Becher, O. J. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent PLoS One 2015, 10, e0118926 DOI: 10.1371/journal.pone.0118926
    138. 138
      Boston-Howes, W.; Williams, E. O.; Bogush, A.; Scolere, M.; Pasinelli, P.; Trotti, D. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis Exp. Neurol. 2008, 213, 229 237 DOI: 10.1016/j.expneurol.2008.06.010
    139. 139
      Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.-H.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.-M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K. N.; Shinjo, S. M. O.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmiqiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme Science 2008, 321, 1807 1812 DOI: 10.1126/science.1164382
    140. 140
      (a) Paugh, B. S.; Broniscer, A.; Qu, C.; Miller, C. P.; Zhang, J.; Tatevossian, R. G.; Olson, J. M.; Geyer, J. R.; Chi, S. N.; da Silva, N. S.; Onar-Thomas, A.; Baker, J. N.; Gajjar, A.; Ellison, D. W.; Baker, Z. J. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma J. Clin. Oncol. 2011, 29, 3999 4006 DOI: 10.1200/JCO.2011.35.5677
      (b) Warren, K. E.; Killian, K.; Suuriniemi, M.; Wang, Y.; Quezado, M.; Meltzer, P. S. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas Neuro-Oncology 2012, 14, 326 332 DOI: 10.1093/neuonc/nor190
    141. 141
      Toogood, P. L.; Harvey, P. J.; Repine, J. T.; Sheehan, D. J.; VanderWel, S. N.; Zhou, H.; Keller, P. R.; McNamara, D. J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M. R.; Fry, D. W. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 J. Med. Chem. 2005, 48, 2388 2406 DOI: 10.1021/jm049354h
    142. 142
      Barton, K. L.; Misuraca, K.; Cordero, F.; Dobrikova, E.; Min, H. D.; Gromeier, M.; Kirsch, D. G.; Becher, O. J. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma PLoS One 2013, 8, e77639 DOI: 10.1371/journal.pone.0077639
    143. 143
      Michaud, K.; Solomon, D. A.; Oermann, E.; Kim, J.-S.; Zhong, W.-Z.; Prados, M. D.; Ozawa, T.; James, C. D.; Waldman, T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts Cancer Res. 2010, 70, 3228 3238 DOI: 10.1158/0008-5472.CAN-09-4559
    144. 144
      Parrish, K. E.; Pokorny, J. L.; Mittapalli, R. K.; Bakken, K.; Sarkaria, J. N.; Elmquist, W. F. Efflux transporters at the blood-brain barrier limit delivery and efficacy of CDK4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model J. Pharmacol. Exp. Ther. 2015, 355, 264 271 DOI: 10.1124/jpet.115.228213
    145. 145
      Gelbert, L. M.; Cai, S.; Lin, X.; Sanchez-Martinez, C.; del Prado, M.; Lallena, M. J.; Torres, R.; Ajamie, R. T.; Wishart, G. N.; Flack, R. S.; Neubauer, B. L.; Young, J.; Chan, E. M.; Iversen, P.; Cronier, D.; Kreklau, E.; de Dios, A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Invest. New Drugs 2014, 32, 825 837 DOI: 10.1007/s10637-014-0120-7
    146. 146
      Raub, T. J.; Wishart, G. N.; Kulanthaivel, P.; Staton, B. A.; Ajamie, R. T.; Sawada, G. A.; Gelbert, L. M.; Shannon, H. E.; Sanchez-Martinez, C.; De Dios, A. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft Drug Metab. Dispos. 2015, 43, 1360 1371 DOI: 10.1124/dmd.114.062745
    147. 147
      Sanchez-Martinez, C.; Gelbert, L. M.; Shannon, H.; De Dios, A.; Staton, B. A.; Ajamie, R. T.; Sawada, G.; Wishart, G. N.; Raub, T. J. Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts Mol. Cancer Ther. 2011, 10, B234 DOI: 10.1158/1535-7163.TARG-11-B234
    148. 148
      https://clinicaltrials.gov/ct2/show/NCT02308020 (accessed June 12, 2016) .
    149. 149
      Asghar, U.; Witkiewicz, A. K.; Turner, N. C.; Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy Nat. Rev. Drug Discovery 2015, 14, 130 146 DOI: 10.1038/nrd4504
    150. 150
      Cheng, C. K.; Gustafson, W. C.; Charron, E.; Houseman, B. T.; Zunder, E.; Goga, A.; Gray, N. S.; Pollok, B.; Oakes, S. A.; James, C. D.; Shokat, K. M.; Weiss, W. A.; Fan, Q. W. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 12722 12727 DOI: 10.1073/pnas.1202492109
    151. 151
      Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials Invest. New Drugs 1999, 17, 313 320 DOI: 10.1023/A:1006353008903
    152. 152
      Newcomb, E. W.; Tamasdan, C.; Entzminger, Y.; Arena, E.; Schnee, T.; Kim, M.; Crisan, D.; Lukyanov, Y.; Miller, D. C.; Zagzag, D. Flavopiridol inhibits the growth of GL261 gliomas in vivo Cell Cycle 2004, 3, 218 222 DOI: 10.4161/cc.3.2.667
    153. 153
      Zhou, L.; Schmidt, K.; Nelson, F. R.; Zelesky, V.; Troutman, M. D.; Feng, B. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice Drug Metab. Dispos. 2009, 37, 946 955 DOI: 10.1124/dmd.108.024489
    154. 154
      Vita, M.; Abdel-Rehim, M.; Olofsson, S.; Hassan, Z.; Meurling, L.; Siden, A.; Siden, M.; Pettersson, T.; Hassan, M. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat Eur. J. Pharm. Sci. 2005, 25, 91 103 DOI: 10.1016/j.ejps.2005.02.001
    155. 155
      Rajnai, Z.; Mehn, D.; Beery, E.; Okyar, A.; Jani, M.; Toth, G. K.; Fulop, F.; Levi, F.; Krajcsi, P. ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor Drug Metab. Dispos. 2010, 38, 2000 2006 DOI: 10.1124/dmd.110.032805
    156. 156
      Paruch, K.; Dwyer, M. P.; Alvarez, C.; Brown, C.; Chan, T. Y.; Doll, R. J.; Keertikar, K.; Knutson, C.; McKittrick, B.; Rivera, J.; Rossman, R.; Tucker, G.; Fischmann, T.; Hruza, A.; Madison, V.; Nomeir, A. A.; Wang, Y.; Kirschmeier, P.; Lees, E.; Parry, D.; Sqambellone, N.; Seghezzi, W.; Schultz, L.; Shanahan, F.; Wiswell, D.; Xu, X.; Zhou, Q.; James, R. A.; Paradkar, V. M.; Park, H.; Rokosz, L. R.; Stauffer, T. M.; Guzi, T. J. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases ACS Med. Chem. Lett. 2010, 1, 204 208 DOI: 10.1021/ml100051d
    157. 157
      Jane, E. P.; Premkumar, D. R.; Cavaleri, J. M.; Sutera, P. A.; Rajasekar, T.; Pollack, I. F. Dinaciclib, a cyclin-dependent kinase inhibitor promotes proteasomal degradation of Mcl-1 and enhances glioma cell lines J. Pharmacol. Exp. Ther. 2016, 356, 354 365 DOI: 10.1124/jpet.115.230052
    158. 158
      Loschmann, N.; Michaelis, M.; Rothweiler, F.; Zehner, R.; Cinati, J.; Voges, Y.; Sharifi, M.; Riecken, K.; Meyer, J.; von Deimling, A.; Fichter, I.; Ghafourian, T.; Westermann, F.; Cinatl, J. Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs Transl. Oncol. 2013, 6, 685 696 DOI: 10.1593/tlo.13544
    159. 159
      Kamath, A. V.; Chong, S.; Chang, M.; Marthe, P. H. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats Cancer Chemother. Pharmacol. 2005, 55, 110 116 DOI: 10.1007/s00280-004-0873-3
    160. 160
      Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.; Feltell, R. E.; Lewis, E. J.; McMenamin, R. L.; Navarro, E. F.; O’Brien, M. A.; O’Reilly, M.; Reule, M.; Saxty, G.; Seavers, L. C.; Smith, D. M.; Squires, M. S.; Trewartha, G.; Walker, M. T.; Woolford, A. J. Identification of N-(4-piperidinyl)-4-(2,6-dichlorbenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design J. Med. Chem. 2008, 51, 4986 4999 DOI: 10.1021/jm800382h
    161. 161
      Cihalova, D.; Staud, F.; Ceckova, M. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 trasporters and their potential to overcome multidrug resistance in vitro Cancer Chemother. Pharmacol. 2015, 76, 105 116 DOI: 10.1007/s00280-015-2772-1
    162. 162
      Chu, X. J.; DePinto, W.; Bartkovitz, D.; So, S. S.; Vu, B. T.; Packman, K.; Lukacs, C.; Ding, Q.; Jiang, N.; Wang, K.; Goelzer, P.; Yin, X.; Smith, M. A.; Higgins, B. X.; Chen, Y.; Xiang, Q.; Moliterni, J.; Kaplan, G.; Graves, B.; Lovey, A.; Fotouhi, N. Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity J. Med. Chem. 2006, 49, 6549 6560 DOI: 10.1021/jm0606138
    163. 163
      Byth, K. F.; Thomas, A.; Hughes, G.; Forder, C.; McGregor, A.; Geh, C.; Oakes, S.; Green, C.; Walker, M.; Newcombe, N.; Green, S.; Growcott, J.; Barker, A.; Wilkinson, R. W. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts Mol. Cancer Ther. 2009, 8, 1856 1866 DOI: 10.1158/1535-7163.MCT-08-0836
    164. 164
      Zhang, I.; Zaorsky, N. G.; Palmer, J. D.; Mehra, R.; Lu, B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer Lancet Oncol. 2015, 16, e510 e521 DOI: 10.1016/S1470-2045(15)00013-3
    165. 165
      Cui, J. J.; Tran-Dube, M.; Shen, H.; Nambu, M.; Kung, P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342 6363 DOI: 10.1021/jm2007613
    166. 166
      Camidge, D. R.; Bang, Y.-J.; Kwak, E. L.; Iafrate, A. J.; Varella-Garcia, M.; Fox, S. B.; Riely, G. J.; Solomon, B.; Ou, S.-H. I.; Kim, D.-W.; Salgia, R.; Fidias, P.; Engelman, J. A.; Gandhi, L.; Janne, P. A.; Costa, D. B.; Shapiro, G. I.; LoRusso, P.; Ruffner, K.; Stephenson, P.; Tang, Y.; Wilner, K.; Clark, J. W.; Shaw, A. T. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol. 2012, 13, 1011 1019 DOI: 10.1016/S1470-2045(12)70344-3
    167. 167
      Otterson, G. A.; Riely, G. J.; Shaw, A. T.; Crino, L.; Kim, D.-W.; Marins, R.; Salgia, R.; Zhou, C.; Solomon, B. J.; Wilner, K. D.; Polli, A.; Tang, Y.; Bartlett, C. H.; Ou, S.-H. I. Clinical characteristics of ALK+ NSCLC patients treated with crizotnib beyond disease progression: potential implications for management J. Clin. Oncol. 2012, 30 (Suppl.) 7600
    168. 168
      Costa, D. B.; Kobayashi, S.; Pandya, S. S.; Yeo, W.-L.; Shen, Z.; Tan, W.; Wilner, K. D. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib J. Clin. Oncol. 2011, 29, e443 445 DOI: 10.1200/JCO.2010.34.1313
    169. 169
      Johnson, T. W.; Richardson, P. F.; Bailey, S.; Brooun, A.; Burke, B. J.; Collins, M. R.; Cui, J. J.; Deal, J. G.; Deng, Y.-L.; Dinh, D.; Engstrom, L. D.; He, M.; Hoffman, J.; Hoffman, R. L.; Huang, Q.; Kania, R. S.; Kath, J. C.; Lam, H.; Lam, J. L.; Le, P. T.; Lingardo, L.; Liu, W.; McTigue, M.; Palmer, C. L.; Sach, N. W.; Smeal, T.; Smith, G. L.; Stewart, A. E.; Timofeevski, S.; Zhu, H.; Zhu, J.; Zou, H. Y.; Edwards, M. P. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations J. Med. Chem. 2014, 57, 4720 4744 DOI: 10.1021/jm500261q
    170. 170
      Awad, M. M.; Shaw, A. T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond Clin. Adv. Hematol. Oncol. 2014, 12, 429 439
    171. 171
      Marsilje, T. H.; Pei, W.; Chen, B.; Lu, W.; Uno, T.; Jin, Y.; Jiang, T.; Kim, S.; Li, N.; Warmuth, M.; Sarkisova, Y.; Sun, F.; Steffy, A.; Pferdekamper, A. C.; Li, A. G.; Joseph, S. B.; Kim, Y.; Liu, B.; Tuntland, T.; Cui, X.; Gray, N. S.; Steensma, R.; Wan, Y.; Jiang, J.; Chopiuk, G.; Li, J.; Gordon, W. P.; Richmond, W.; Johnson, K.; Chang, J.; Groessl, T.; He, Y.-Q.; Phimister, A.; Aycinena, A.; Lee, C. C.; Bursulaya, B.; Karanewsky, D. S.; Seidel, H. M.; Harris, J. L.; Michellys, P.-Y. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J. Med. Chem. 2013, 56, 5675 5690 DOI: 10.1021/jm400402q
    172. 172
      (a) Shaw, A. T.; Kim, D. W.; Mehra, R.; Tan, D. S. W.; Felip, E.; Chow, L. Q. M.; Camidge, D. R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, M.; Liu, G.; Santoro, A.; Lau, Y. Y.; Goldwasser, M.; Boral, A. L.; Engelman, J. A. Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med. 2014, 370, 1189 1197 DOI: 10.1056/NEJMoa1311107
      (b) Kim, D.-W.; Mehra, R.; Tan, D. S.-W.; Felip, E.; Chow, L. Q. M.; Camidge, D. R.; Vansteenkiste, J. F.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, M. H.; Liu, G.; Santoro, A.; Geraldes, M.; Boral, A.; Yovine, A. J.; Shaw, A. T. Ceritinib in advanced anaplastic lymphoma (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial J. Clin. Oncol. 2014, 32 (Suppl.) 8003
      (c) Shaw, A.; Mehra, R.; Tan, D. S. W.; Felip, E.; Chow, L. Q.; Camidge, D. R.; Vansteenkiste, J. R.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B.; Wolf, J.; Thomas, M.; Schuler, M.; Liu, G.; Santoro, A.; Geraldes, M.; Boral, A. L.; Yovine, A.; Kim, D. Evaluation of ceritinib-treated patients (pts) with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 Study Ann. Oncol. 2014, 25 (Suppl. 4) iv455 iv456
    173. 173
      Kinoshita, K.; Asoh, K.; Furuichi, N.; Ito, T.; Kawada, H.; Hara, S.; Ohwada, J.; Miyagi, T.; Kobayashi, T.; Takanashi, K.; Tsukaguchi, T.; Sakamoto, H.; Tsukuda, T.; Oikawa, N. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802) Bioorg. Med. Chem. 2012, 20, 1271 1280 DOI: 10.1016/j.bmc.2011.12.021
    174. 174
      Kodama, T.; Hasegawa, M.; Takanashi, K.; Sakurai, Y.; Kondoh, O.; Sakamoto, H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases Cancer Chemother. Pharmacol. 2014, 74, 1023 1028 DOI: 10.1007/s00280-014-2578-6
    175. 175
      (a) Gadgeel, S. M.; Gandhi, L.; Riely, G. J.; Chiappori, A. A.; West, H. L.; Azada, M. C.; Morcos, P. N.; Lee, R.-M.; Garcia, L.; Yu, L.; Boisserie, F.; Di Laurenzio, L.; Golding, S.; Sato, J.; Yokoyama, S.; Tanaka, T.; Ou, S.-H. I. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Lancet Oncol. 2014, 15, 1119 1128 DOI: 10.1016/S1470-2045(14)70362-6
      (b) Ajimizu, H.; Kim, Y. H.; Mishima, M. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib Med. Oncol. 2015, 32, 3 DOI: 10.1007/s12032-014-0477-7
      (c) Gainor, J. F.; Sherman, C. A.; Willoughby, K.; Logan, J.; Kennedy, E.; Brastianos, P. K.; Chi, A. S.; Shaw, A. T. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib J. Thorac. Oncol. 2015, 10, 232 236 DOI: 10.1097/JTO.0000000000000455
    176. 176
      Menichincheri, M.; Ardini, E.; Magnaghi, P.; Avanzi, N.; Banfi, P.; Bossi, R.; Buffa, L.; Canevari, G.; Ceriani, L.; Colombo, M.; Corti, L.; Donati, D.; Fasolini, M.; Felder, E.; Fiorelli, C.; Fiorentini, F.; Galvani, A.; Isacchi, A.; Borgia, A. L.; Marchionni, C.; Nesi, M.; Orrenius, C.; Panzeri, A.; Pesenti, E.; Rusconi, L.; Saccardo, M. B.; Vanotti, E.; Perrone, E.; Orsini, P. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor J. Med. Chem. 2016, 59, 3392 3408 DOI: 10.1021/acs.jmedchem.6b00064
    177. 177
      Farago, A. F.; Le, L. P.; Zheng, Z.; Muzikansky, A.; Drilon, A.; Patel, M.; Bauer, T. M.; Liu, S. V.; Ou, S. I.; Jackman, D.; Costa, D. B.; Multani, P. S.; Li, G. G.; Hornby, Z.; Chow-Maneval, E.; Luo, D.; Lim, J. E.; Iafrate, A. J.; Shaw, A. T. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer J. Thorac. Oncol. 2015, 10, 1670 1674 DOI: 10.1097/01.JTO.0000473485.38553.f0
    178. 178
      Mori, M.; Ueno, Y.; Konagai, S.; Fushiki, H.; Shimada, I.; Kondoh, Y.; Saito, R.; Mori, K.; Shindou, N.; Soga, T.; Sakagami, H.; Furutani, T.; Doihara, H.; Kudoh, M.; Kuromitsu, S. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice Mol. Cancer Ther. 2014, 13, 329 340 DOI: 10.1158/1535-7163.MCT-13-0395
    179. 179
      Fushiki, H.; Saito, R.; Jitsuoka, M.; Shimada, I.; Kondoh, Y.; Sakagami, H.; Funatsu, Y.; Noda, A.; Murakami, Y.; Miyoshi, S.; Ueon, Y.; Konagai, S.; Soga, T.; Nishimura, S.; Mori, M.; Kuromitsu, S. Abstract 2678: First demonstration of in vivo PET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor Cancer Res. 2013, 73 (Suppl.) 2678 DOI: 10.1158/1538-7445.AM2013-2678
    180. 180
      Huang, W. S.; Liu, S.; Zou, D.; Thomas, M.; Wang, Y.; Zhou, T.; Romero, J.; Kohlmann, A.; Li, F.; Qi, J.; Cai, L.; Dwight, T. A.; Xu, Y.; Xu, R.; Dodd, R.; Toms, A.; Parillon, L.; Lu, X.; Anjum, R.; Zhang, S.; Wang, F.; Keats, J.; Wardwell, S. D.; Ning, Y.; Xu, Q.; Moran, L. E.; Mohemmad, Q. K.; Jang, H. G.; Clackson, T.; Narashimhan, N. I.; Rivera, V. M.; Zhu, X.; Dalgarno, D.; Shakespeare, W. C. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of analplastic lymphoma kinase J. Med. Chem. 2016, 59, 4948 4964 DOI: 10.1021/acs.jmedchem.6b00306
    181. 181
      Gettinger, S. N.; Bazhenova, L.; Salgia, R.; Langer, C. J.; Gold, K. A.; Rosell, R.; Shaw, A. T.; Weiss, G. J.; Narasimhan, N. I.; Dorer, D. J.; Rivera, V. M.; Clackson, T.; Haluska, F. G.; Camidge, D. R. Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer J. Thorac. Oncol. 2013, 8 (Suppl. 2) S296
    182. 182
      Camidge, D. R.; Bazhenova, L.; Salgia, R.; Langer, C. J.; Gold, K. A.; Rosell, R.; Shaw, A. T.; Weiss, G. J.; Narasimhan, N. I.; Dorer, D. J.; Rivera, V. M.; Clackson, T. P.; Conlan, M. G.; Kerstein, D.; Haluska, F. G.; Gettinger, S. N. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC) J. Clin. Oncol. 2015, 33 (Suppl.) 8062
    183. 183
      Lovly, C. M.; Heuckmann, J. M.; de Stanchina, E.; Chen, H.; Thomas, R. K.; Liang, C.; Pao, W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Cancer Res. 2011, 71, 4920 4931 DOI: 10.1158/0008-5472.CAN-10-3879
    184. 184
      Lin, N. U.; Dieras, V.; Paul, D.; Lossignol, D.; Christodoulou, C.; Stemmler, H.-J.; Roche, H.; Liu, M. C.; Greil, R.; Ciruelos, E.; Loibl, S.; Gori, S.; Wardley, A.; Yardley, D.; Brufsky, A.; Blum, J. L.; Rubin, S. D.; Dharan, B.; Steplewski, K.; Zembryki, D.; Oliva, C.; Roychowdhury, D.; Paoletti, P.; Winer, E. P. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin. Cancer Res. 2009, 15, 1452 1459 DOI: 10.1158/1078-0432.CCR-08-1080
    185. 185
      Medina, P. J.; Goodin, S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin. Ther. 2008, 30, 1426 1447 DOI: 10.1016/j.clinthera.2008.08.008
    186. 186
      Taskar, K. S.; Rudraraju, V.; Mittapalli, R. K.; Samala, R.; Thorsheim, H. R.; Lockman, J.; Gril, B.; Hua, E.; Palmieri, D.; Polli, J. W.; Castellino, S.; Rubin, S. D.; Lockman, P. R.; Steeg, P. S.; Smith, Q. R. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer Pharm. Res. 2012, 29, 770 781 DOI: 10.1007/s11095-011-0601-8
    187. 187
      Polli, J. W.; Olson, K. L.; Chism, J. P.; St. John-Williams, L.; Yeager, R. L.; Woodard, S. M.; Otto, V.; Castellino, S.; Demby, V. E. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016 Drug Metab. Dispos. 2009, 37, 439 442 DOI: 10.1124/dmd.108.024646
    188. 188
      Morikawa, A.; Peereboom, D. M.; Thorsheim, H. R.; Samala, R.; Balyan, R.; Murphy, C. G.; Lockman, P. R.; Simmons, A.; Weil, R. J.; Tabar, V.; Steeg, P. S.; Smith, Q. R.; Seidman, A. D. Capcitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study Neuro-Oncology 2015, 17, 289 295 DOI: 10.1093/neuonc/nou141
    189. 189
      Schroeder, R. L.; Stevens, C. L.; Sridhar, J. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer Molecules 2014, 19, 15196 15212 DOI: 10.3390/molecules190915196
    190. 190
      Feldinger, K.; Kong, A. Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer: Targets Ther. 2015, 7, 147 162 DOI: 10.2147/BCTT.S54414
    191. 191
      Dinkel, V.; Anderson, D.; Winski, S.; Winkler, J.; Koch, K.; Lee, P. A. Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice Cancer Res. 2012, 72 (Suppl.) 852 DOI: 10.1158/1538-7445.AM2012-852
    192. 192
      Freedman, R. A.; Gelman, R. S.; Wefel, J. S.; Melisko, M. E.; Hess, K. R.; Connolly, R. M.; Van Poznak, C. H.; Niravath, P. A.; Puhalla, S. L.; Ibrahim, N.; Blackwell, K. L.; Liu, M. C.; Lowe, A.; Agar, N. Y. R.; Ryabin, N.; Farooq, S.; Lawler, E.; Rimawi, M. F.; Krop, I. E.; Wolff, A. C.; Winer, E. P.; Lin, N. U. Translational Breast Cancer Research Consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases J. Clin. Oncol. 2016, 34, 945 952 DOI: 10.1200/JCO.2015.63.0343
    193. 193
      Roche, S.; Pedersen, K.; Dunne, G.; Collins, D.; Devery, A.; Crown, J.; Clynes, M.; O’Connor, R. Pharmacological interactions of TKIs with the P-gp drug transport protein J. Clin. Oncol. 2012, 30 (Suppl.) 2536
    194. 194
      Metzger-Filho, O.; Barry, W. T.; Krop, I. E.; Younger, W. J.; Lawler, E. S.; Winer, E. P.; Lin, N. U. Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer J. Clin. Oncol. 2014, 32 (Suppl.) TPS660
    195. 195
      Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oorui, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A.; Miki, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Yano, J.; Aertgeerts, K.; Kamiyama, K. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold J. Med. Chem. 2011, 54, 8030 8050 DOI: 10.1021/jm2008634
    196. 196
      Erdo, F.; Gordon, J.; Wu, J. T.; Sziraki, I. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats Brain Res. Bull. 2012, 87, 413 419 DOI: 10.1016/j.brainresbull.2012.01.002
    197. 197
      Nakayama, A.; Takagi, S.; Yusa, T.; Yaguchi, M.; Hayashi, A.; Tamura, T.; Kawakita, Y.; Ishikawa, T.; Ohta, Y. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model J. Cancer 2013, 4, 557 565 DOI: 10.7150/jca.6689
    198. 198
      Kalous, O.; Conklin, D.; Desai, A. J.; O’Brien, N. A.; Ginther, C.; Anderson, L.; Cohen, D. J.; Britten, C. D.; Taylor, I.; Christensen, J. G.; Slamon, D. J.; Finn, R. S. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib Mol. Cancer Ther. 2012, 11, 1978 1987 DOI: 10.1158/1535-7163.MCT-11-0730
    199. 199
      Wong, T. W.; Lee, F. Y.; Yu, C.; Luo, F. R.; Oppenheimer, S.; Zhang, H.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; Vite, G. D. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling Clin. Cancer Res. 2006, 12, 6186 6193 DOI: 10.1158/1078-0432.CCR-06-0642
    200. 200
      Desjardins, A.; Reardon, D. A.; Vredenburgh, J. J.; Peters, K.; Trikha, M.; James, J.; Gardner, M.; Brickhouse, A.; Herndon, J. E.; Friedman, H. S. A pharmacokinetic study of AC48 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED) J. Clin. Oncol. 2011, 29 (Suppl.) 2070
    201. 201
      Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res. 2004, 64, 4931 4941 DOI: 10.1158/0008-5472.CAN-03-3681
    202. 202
      Meco, D.; Servidei, T.; Zannoni, G. F.; Martinelli, E.; Prisco, M. G.; de Waure, C.; Riccardi, R. Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma Trans. Oncol. 2010, 3, 326 335 DOI: 10.1593/tlo.10163
    203. 203
      Goudar, R. K.; Shi, Q.; Hjelmeland, M. D.; Keir, S. T.; McLendon, R. E.; Wikstrand, C. J.; Reese, E. D.; Conrad, C. A.; Traxler, P.; Lane, H. A.; Reardon, D. A.; Cavenee, W. K.; Wang, X. F.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol. Cancer Ther. 2005, 4, 101 112
    204. 204
      Reardon, D. A.; Conrad, C. A.; Cloughesy, T.; Prados, M. D.; Friedman, H. S.; Aldape, K. D.; Mischel, P.; Xia, J.; DiLea, C.; Huang, J.; Mietlowski, W.; Dugan, M.; Chen, W.; Yung, W. K. A. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients Cancer Chemother. Pharmacol. 2012, 69, 1507 1518 DOI: 10.1007/s00280-012-1854-6
    205. 205
      Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. 2008, 341, 465 477 DOI: 10.1002/ardp.200800009
    206. 206
      Hegedus, C.; Truta-Feles, K.; Antalffy, G.; Varady, G.; Nemet, K.; Ozvegy-Laczka, C.; Keri, G.; Orfi, L.; Szakacs, G.; Settleman, J.; Varadi, A.; Sarkadi, B. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance Biochem. Pharmacol. 2012, 84, 260 267 DOI: 10.1016/j.bcp.2012.04.010
    207. 207
      Jani, J. P.; Finn, R. S.; Campbell, M.; Coleman, K. G.; Connell, R. D.; Currier, N.; Emerson, E. O.; Floyd, E.; Harriman, S.; Kath, J. C.; Morris, J.; Moyer, J. D.; Pustilnik, L. R.; Rafidi, K.; Ralston, S.; Rossi, A. M. K.; Steyn, S. J.; Wagner, L.; Winter, S. M.; Bhattacharya, S. K. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor Cancer Res. 2007, 67, 9887 9893 DOI: 10.1158/0008-5472.CAN-06-3559
    208. 208
      Feng, B.; Xu, J. J.; Bi, Y. A.; Mireles, R.; Davidson, R.; Duignan, D. B.; Campbell, S.; Kostrubsky, V. E.; Dunn, M. C.; Smith, A. R.; Wang, H. F. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714 Toxicol. Sci. 2009, 108, 492 500 DOI: 10.1093/toxsci/kfp033
    209. 209
      Cai, X.; Zhai, H. X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C. J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer J. Med. Chem. 2010, 53, 2000 2009 DOI: 10.1021/jm901453q
    210. 210
      Barlaam, B.; Anderton, J.; Ballard, P.; Bradbury, R. H.; Hennequin, L. F. A.; Hickinson, D. M.; Kettle, J. G.; Kirk, G.; Klinowska, T.; Lambert-van der Brempt, C.; Trigwell, C.; Vincent, J.; Ogilvie, D. Discovery of AZD8931, an equipotent, reversible inhibitor of signaling by EGFR, HER2, and HER3 receptors ACS Med. Chem. Lett. 2013, 4, 742 746 DOI: 10.1021/ml400146c
    211. 211
      Xie, H.; Lin, L.; Tong, L.; Jiang, Y.; Zheng, M.; Chen, Z.; Jiang, X.; Zhang, X.; Ren, X.; Qu, W.; Yang, Y.; Wan, H.; Chen, Y.; Zuo, J.; Jiang, H.; Geng, M.; Ding, J. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo PLoS One 2011, 6, e21487 DOI: 10.1371/journal.pone.0021487
    212. 212
      (a) Fife, K. M.; Colman, M. H.; Stevens, G. N.; Firth, I. C.; Moon, D.; Shannon, K. F.; Harman, R.; Petersen-Schaefer, K.; Zacest, A. C.; Besser, M.; Milton, G. W.; McCarthy, W. H.; Thompson, J. F. Determinants of outcome in melanoma patients with cerebral metastases J. Clin. Oncol. 2004, 22, 1293 1300 DOI: 10.1200/JCO.2004.08.140
      (b) Sampson, J. H.; Carter, J. H.; Friedman, A. H.; Seigler, H. F. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma J. Neurosurg. 1998, 88, 11 20 DOI: 10.3171/jns.1998.88.1.0011
    213. 213
      Flaherty, K. T.; Yasothan, U.; Kirkpatrick, P. Vemurafenib Nat. Rev. Drug Discovery 2011, 10, 811 812 DOI: 10.1038/nrd3579
    214. 214
      Rheault, T. R.; Stellwagen, J. C.; Adjabeng, G. M.; Hornberger, K. R.; Petrov, K. G.; Waterson, A. G.; Dickerson, S. H.; Mook, R. A.; Laquerre, S. G.; King, A. J.; Rossanese, O. W.; Arnone, M. R.; Smitheman, K. N.; Kane-Carson, L. S.; Han, C.; Moorthy, G. S.; Moss, K. G.; Uehling, D. E. Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors ACS Med. Chem. Lett. 2013, 4, 358 362 DOI: 10.1021/ml4000063
    215. 215
      Hoeflich, K. P.; Merchant, M.; Orr, C.; Chan, J.; Den Otter, D.; Berry, L.; Kasman, I.; Koeppen, H.; Rice, K.; Yang, N. Y.; Engst, S.; Johnston, S.; Friedman, L. S.; Belvin, M. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition Cancer Res. 2012, 72, 210 219 DOI: 10.1158/0008-5472.CAN-11-1515
    216. 216
      Abe, H.; Kikuchi, S.; Hayakawa, K.; Iida, T.; Nagahashi, N.; Maeda, K.; Sakamoto, J.; Matsumoto, N.; Miura, T.; Matsumura, K.; Seki, N.; Inaba, T.; Kawasaki, H.; Yamaguchi, T.; Kakefuda, R.; Nanayama, T.; Kurachi, H.; Hori, Y.; Yoshida, T.; Kakegawa, J.; Watanabe, Y.; Gilmartin, A. G.; Richter, M. C.; Moss, K. G.; Laquerre, S. G. Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate) ACS Med. Chem. Lett. 2011, 2, 320 324 DOI: 10.1021/ml200004g
    217. 217
      Myung, J. K.; Cho, H.; Park, C.-K.; Kim, S. K.; Lee, S. H.; Park, S. H. Analysis of the BRAF V600E mutation in central nervous system tumors Transl. Oncol. 2012, 5, 430 436 DOI: 10.1593/tlo.12328
    218. 218
      Kieran, M. W. Targeting BRAF in pediatric brain tumors. In American Society of Clinical Oncology 2014 Educational Book; Dizon, D. S.; Pennell, N.; Burke, L.; Carter, D.; Dottellis, D., Eds.; American Society of Clinical Oncology: Alexandria, VA, 2014; pp e436 e440, DOI:  DOI: 10.14694/EdBook_AM.2014.34.e436 .
    219. 219
      See, W. L.; Tan, I. L.; Mukherjee, J.; Nicolaides, T.; Pieper, R. O. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency Cancer Res. 2012, 72, 3350 3359 DOI: 10.1158/0008-5472.CAN-12-0334
    220. 220
      (a) McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Franklin, R. A.; Montalto, G.; Cervello, M.; Libra, M.; Candido, S.; Malaponte, G.; Mazzarino, M. C.; Fagone, P.; Nicoletti, F.; Basecke, J.; Mijatovic, S.; Maksimovic-Ivanic, D.; Milella, M.; Tafuri, A.; Chiarini, F.; Evangelisti, C.; Cocco, L.; Martelli, A. M. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance Oncotarget 2012, 3, 1068 1111 DOI: 10.18632/oncotarget.659
      (b) Huang, T.; Karsy, M.; Zhuge, J.; Zhong, M.; Liu, D. B-Raf and the inhibitors: from bench to bedside J. Hematol. Oncol. 2013, 6, 30 DOI: 10.1186/1756-8722-6-30
    221. 221
      (a) Zhao, Y.; Adjei, A. A. The clinical development of MEK inhibitors Nat. Rev. Clin. Oncol. 2014, 11, 385 400 DOI: 10.1038/nrclinonc.2014.83
      (b) Akinleye, A.; Furqan, M.; Mukhi, N.; Ravella, P.; Liu, D. MEK and the inhibitors: from bench to bedside J. Hematol. Oncol. 2013, 6, 27 DOI: 10.1186/1756-8722-6-27
      (c) McDermott, L.; Qin, C. Allosteric MEK1/2 Inhibitors for the Treatment of Cancer: An Overview. J. Drug Res. Dev. 2015, 1, DOI:  DOI: 10.16966/2470-1009.101 ; http://dx.doi.org/10.16966/2470-1009.101.
    222. 222
      (a) Rochet, N. M.; Dronca, R. S.; Kottschade, L. A.; Chavan, R. N.; Gorman, B.; Gilbertson, J. R.; Markovic, S. N. Melanoma brain metastases and vemurafenib: need for further investigation Mayo Clin. Proc. 2012, 87, 976 981 DOI: 10.1016/j.mayocp.2012.07.006
      (b) Gummadi, T.; Zhang, B. Y.; Valpione, S.; Kim, C.; Kottschade, L. A.; Mittapalli, R. K.; Chiarion-Sileni, V.; Pigozzo, J.; Elmquist, W. F.; Dudek, A. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases Melanoma Res. 2015, 25, 75 79 DOI: 10.1097/CMR.0000000000000133
      (c) Dummer, R.; Goldinger, S. M.; Turtschi, C. P.; Eggmann, N. B.; Michielin, O.; Mitchell, L.; Veronese, L.; Hilfikeer, P. R.; Felderer, L.; Rinderknecht, J. D. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study Eur. J. Cancer 2014, 50, 611 621 DOI: 10.1016/j.ejca.2013.11.002
      (d) Robinson, G. W.; Orr, B. A.; Gajjar, A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multi-forme after BRAF Inhibitor therapy BMC Cancer 2014, 14, 258 DOI: 10.1186/1471-2407-14-258
    223. 223
      (a) Falchook, G. S.; Long, G. V.; Kurzrock, R.; Kim, K. B.; Arkenau, T. H.; Brown, M. P.; Hamid, O.; Infante, J. R.; Millward, M.; Pavlick, A. C.; O’Day, S. J.; Blackman, S. C.; Curtis, C. M.; Lebowitz, P.; Ma, B.; Ouellet, D.; Kefford, R. F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase I dose-escalation trial Lancet 2012, 379, 1893 1901 DOI: 10.1016/S0140-6736(12)60398-5
      (b) Long, G. V.; Trefzer, U.; Davies, M. A.; Kefford, R. F.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; Mortier, L.; Tawbi, H.; Wilhelm, T.; Zimmer, L.; Switzky, J.; Swann, S.; Martin, A. M.; Guckert, M.; Goodman, V.; Streit, M.; Kirkwood, J. M.; Schadendorf, D. Dabrafenib in patients with Val600Glu or V600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase 2 trial Lancet Oncol. 2012, 13, 1087 1095 DOI: 10.1016/S1470-2045(12)70431-X
    224. 224
      Vaidhyanathan, S.; Mittapalli, R. K.; Sarkaria, J. N.; Elmquist, W. F. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases Drug Metab. Dispos. 2014, 42, 1292 1300 DOI: 10.1124/dmd.114.058339
    225. 225
      (a) Mittapalli, R. K.; Vaidhyanathan, S.; Sane, R.; Elmquist, W. F. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) J. Pharmacol. Exp. Ther. 2012, 342, 33 40 DOI: 10.1124/jpet.112.192195
      (b) Mittapalli, R. K.; Vaidhyanathan, S.; Dudek, A. Z.; Elmquist, W. F. Mechanisms limiting distribution of the threonine-protein kinase B-RafV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases J. Pharmacol. Exp. Ther. 2013, 344, 655 664 DOI: 10.1124/jpet.112.201475
    226. 226
      Williams, T. E.; Subramanian, S.; Verhagen, J.; McBride, C. M.; Costales, A.; Sung, L.; Antonios-McCrea, W.; McKenna, M.; Louie, A. K.; Ramurthy, S.; Levine, B.; Shafer, C. M.; Machajewski, T.; Renhowe, P. A.; Appleton, B. A.; Amiri, P.; Chou, J.; Stuart, D.; Aardalen, K.; Poon, D. Discovery of RAF265: a potent mut-B-Raf inhibitor for the treatment of metastatic melanoma ACS Med. Chem. Lett. 2015, 6, 961 965 DOI: 10.1021/ml500526p
    227. 227
      Liu, X.; Ide, J. L.; Norton, I.; Marchionni, M. A.; Ebling, M. C.; Wang, L. Y.; Davis, E.; Sauvageot, C. M.; Kesari, S.; Kellersberger, K. A.; Easterling, M. L.; Santagata, S.; Stuart, D. D.; Alberta, J.; Agar, J. N.; Stiles, C. D.; Agar, N. Y. R. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging Sci. Rep. 2013, 3, 2859 DOI: 10.1038/srep02859
    228. 228
      Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA. http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/ (ccessed June 10, 2016) .
    229. 229
      Rusconi, P.; Caiola, E.; Broggini, M. Ras/Raf/MEK inhibitors in oncology Curr. Med. Chem. 2012, 19, 1164 1176 DOI: 10.2174/092986712799320510
    230. 230
      Choo, E. F.; Ly, J.; Chan, J.; Shahidi-Latham, S. K.; Messick, K.; Plise, E.; Quiason, C. M.; Yang, L. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib Mol. Pharmaceutics 2014, 11, 4199 4207 DOI: 10.1021/mp500435s
    231. 231
      (a) Choo, E. F.; Belvin, M.; Boggs, J.; Deng, Y.; Hoeflich, K. P.; Ly, J.; Merchant, M.; Orr, C.; Plise, E.; Robarge, K.; Martini, J. F.; Kassees, R.; Aoyama, R. G.; Ramaiya, A.; Johnston, S. H. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions Drug Metab. Dispos. 2012, 40, 919 927 DOI: 10.1124/dmd.111.043778
      (b) Gilmartin, A. G.; Bleam, M. R.; Groy, A.; Moss, K. G.; Minthorn, E. A.; Kulkami, S. G.; Rominger, C. M.; Erskine, S.; Fisher, K. E.; Yang, J.; Azppacosta, F.; Annan, R.; Sutton, D.; Laquerre, S. G. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin. Cancer Res. 2011, 17, 989 1000 DOI: 10.1158/1078-0432.CCR-10-2200
    232. 232
      (a) Widemann, B. C.; Marcus, L. J.; Fisher, M. J.; Weiss, B. D.; Kim, A.; Dombi, E.; Baldwin, A.; Whitcomb, P.; Martin, S.; Gillespie, A.; Doyle, A. Phase I study of the MEK1/2 inhibitor selumetinib (AZ6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs) J. Clin. Oncol. 2014, 32 (Suppl.) 10018
      (b) https://clinicaltrials.gov/ct2/show/NCT01089101 (accessed June 12, 2016) .
    233. 233
      Binimetinib has advanced to a trial enrolling patients with brain cancer: https://clinicaltrials.gov/ct2/show/NCT02285439 (accessed June 10, 2016) .
    234. 234
      Iverson, C.; Larson, G.; Lai, C.; Yeh, L. T.; Dadson, C.; Weingarten, P.; Appleby, T.; Vo, T.; Maderna, A.; Vernier, J. M.; Hamatake, R.; Miner, J. N.; Quart, B. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer Cancer Res. 2009, 69, 6839 6847 DOI: 10.1158/0008-5472.CAN-09-0679
    235. 235
      Isshiki, Y.; Kohchi, Y.; Iikura, H.; Matsubara, Y.; Asoh, K.; Murata, T.; Kohchi, M.; Mizuguchi, E.; Tsujii, S.; Hattori, K.; Miura, T.; Yoshimura, Y.; Aida, S.; Miwa, M.; Saitoh, R.; Murao, N.; Okabe, H.; Belunis, C.; Janson, C.; Lukacs, C.; Schuck, V.; Shimma, N. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent Bioorg. Med. Chem. Lett. 2011, 21, 1795 1801 DOI: 10.1016/j.bmcl.2011.01.062
    236. 236
      Cohen, R. B.; Aamdal, S.; Nyakas, M.; Cavallin, M.; Green, D.; Learoyd, M.; Smith, I.; Kurzrock, R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies Eur. J. Cancer 2013, 49, 1521 1529 DOI: 10.1016/j.ejca.2013.01.013
    237. 237
      Shaw, J. V.; Zhang, H.; Carden, R.; Qiu, D.; Tian, H.; Ma, J.; Clark, A.; Ogden, J.; Goodstal, S. Abstract LB-456: Evaluation of brain pharmacokinetics as a potential differentiation factor for the MEK inhibitors, MSC2015103 and pimasertib Cancer Res. 2012, 72, LB-456 DOI: 10.1158/1538-7445.AM2012-LB-456
    238. 238
      Goutopoulos, A.; Askew, B.; Bankston, D.; Clark, A.; Dhanabal, M.; Dong, R.; Fischer, D.; Healey, B.; Jiang, X.; Josephson, K.; Lin, J.; Ma, J.; Noonan, T.; Qiu, D.; Rocha, C.; Romanelli, A.; Shutes, A.; Spooner, E.; Tian, H.; Yu, H. Abstract 4476: AS703026: a novel allosteric MEK inhibitor Cancer Res. 2009, 69 (Suppl.) 4776
    239. 239
      Shen, Y.; Boivin, R.; Yoneda, N.; Du, H.; Schiller, S.; Matsushima, T.; Goto, M.; Shirota, H.; Gusovsky, F.; Lemelin, C.; Jiang, Y.; Zhang, Z.; Pelletier, R.; Ikemori-Kawada, M.; Kawakami, Y.; Inoue, A. Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III Bioorg. Med. Chem. Lett. 2010, 20, 3155 3157 DOI: 10.1016/j.bmcl.2010.03.087
    240. 240
      Wu, J.; Nomoto, K.; Wang, J.; Kuznetsov, G.; Agoulnik, S.; Shuck, E.; Wong, N.; Towle, M.; Schnaderbeck, M.; Wu, S.; Littlefield, B. Abstract 3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts Cancer Res. 2009, 69 (Suppl.) 3687
    241. 241
      (a) Lee, C.; Fotovati, A.; Triscott, J.; Chen, J.; Venugopal, C.; Singhal, A.; Dunham, C.; Kerr, J. M.; Verreault, M.; Yip, S.; Wakimoto, H.; Jones, C.; Jayanthan, A.; Narendran, A.; Singh, S. K.; Dunn, S. E. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice Stem Cells 2012, 30, 1064 1075 DOI: 10.1002/stem.1081
      (b) Danovi, D.; Folarin, A.; Gogolok, S.; Ender, C.; Elbatsh, A. M. O.; Engström, P. G.; Stricker, S. H.; Gagrica, S.; Georgian, A.; Yu, D.; U, K. P.; Harvey, K. J.; Ferretti, P.; Paddison, P. J.; Preston, J. E.; Abbott, N. J.; Bertone, P.; Smith, A.; Pollard, S. M. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1 PLoS One 2013, 8, e77053 DOI: 10.1371/journal.pone.0077053
      (c) Pezuk, J. A.; Brassesco, M. S.; Morales, A. G.; de Oliveira, J. C.; de Paula Queiroz, R. G.; Machado, H. R.; Carlotti, C. G.; Neder, L.; Scrideli, C. A.; Tone, L. G. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma Cancer Gene Ther. 2013, 20, 499 506 DOI: 10.1038/cgt.2013.46
      (d) Tandle, A. T.; Kramp, T.; Kil, W. J.; Halthore, A.; Gehlhaus, K.; Shankavaram, U.; Tofilon, P. J.; Caplen, N. J.; Camphausen, K. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation Eur. J. Cancer 2013, 49, 3020 3028 DOI: 10.1016/j.ejca.2013.05.013
      (e) Pezuk, J. A.; Brassesco, M. S.; Morales, A. G.; de Oliveira, J. C.; de Oliveira, H. F.; Scrideli, C. A.; Tone, L. G. Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation Cancer Biother.Radiopharm. 2013, 28, 516 522 DOI: 10.1089/cbr.2012.1415
      (f) Triscott, J.; Lee, C.; Foster, C.; Manoranjan, B.; Pamid, M. R.; Berns, R.; Fotovati, A.; Venugopal, C.; O’Halloran, K.; Narendran, A.; Hawkins, C.; Ramaswamy, V.; Bouffet, E.; Taylor, M. D.; Singhal, A.; Hukin, J.; Rassekh, R.; Yip, S.; Northcott, P.; Singh, S. K.; Dunham, C.; Dunn, S. Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children Cancer Res. 2013, 73, 6734 6744 DOI: 10.1158/0008-5472.CAN-12-4331
    242. 242
      (a) Markant, S. L.; Esparza, L. A.; Sun, J.; Barton, K. L.; McCoig, L. M.; Grant, G. A.; Crawford, J. R.; Levy, M. L.; Northcott, P. A.; Shih, D.; Remke, M.; Taylor, M. D.; Wechsler-Reya, R. J. Targeting sonic hedgehog-associated medulloblastoma through inhibition of aurora and polo-like kinases Cancer Res. 2013, 73, 6310 6322 DOI: 10.1158/0008-5472.CAN-12-4258
      (b) Barton, V. N.; Foreman, N. K.; Donson, A. M.; Birks, D. K.; Handler, M. H.; Vibhakar, R. Aurora kinase A as a rational target for therapy in glioblastoma J. Neurosurg. Pediatr. 2010, 6, 98 105 DOI: 10.3171/2010.3.PEDS10120
      (c) Klein, A.; Reichardt, W.; Jung, V.; Zang, K. D.; Meese, E.; Urbschat, S. Overexpression and amplification of STK15 in human gliomas Int. J. Oncol. 2004, 25, 1789 1794 DOI: 10.3892/ijo.25.6.1789
    243. 243
      Li, N.; Maly, D. J.; Chanthery, Y. H.; Sirkis, D. W.; Nakamura, J. L.; Berger, M. S.; James, C. D.; Shokat, K. M.; Weiss, W. A.; Persson, A. I. Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma Mol. Cancer Ther. 2015, 14, 419 428 DOI: 10.1158/1535-7163.MCT-14-0526
    244. 244
      Wu, C.-P.; Hsieh, C.-H.; Hsiao, S.-H.; Luo, S.-Y.; Su, C.-Y.; Li, Y.-Q.; Huang, Y.-H.; Huang, C.-W.; Hsu, S.-C. Human ATP-binding cassette transporter ABCB1 confers resistance to volasertib (BI6727), a selective inhibitor of polo-like kinase 1 Mol. Pharmaceutics 2015, 12, 3885 3895 DOI: 10.1021/acs.molpharmaceut.5b00312
    245. 245
      Wu, C.-P.; Hsiao, S.-H.; Sim, H.-M.; Luo, S.-Y.; Tuo, W.-C.; Cheng, H.-W.; Li, Y.-Q.; Huan, Y.-H.; Ambudkar, S. V. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of polo-like kinase 1 Biochem. Pharmacol. 2013, 86, 904 913 DOI: 10.1016/j.bcp.2013.08.004
    246. 246
      Wu, C.-P.; Hsiao, S.-H.; Luo, S.-Y.; Tuo, W.-C.; Su, C.-Y.; Li, Y.-Q.; Huang, Y.-H.; Hsieh, C. H. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1 Mol. Pharmaceutics 2014, 11, 3727 3736 DOI: 10.1021/mp500492r
    247. 247
      White, M. P.; Babayeva, M.; Taft, D. R.; Maniar, M. Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure J. Pharm. Pharmacol. 2013, 65, 960 969 DOI: 10.1111/jphp.12057
    248. 248
      Sero, V.; Tavanti, E.; Vella, S.; Hattinger, C. M.; Fanelli, M.; Michelacci, F.; Versteeg, R.; Valsasina, B.; Gudeman, B.; Picci, P.; Serra, M. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance Invest. New Drugs 2014, 32, 1167 1180 DOI: 10.1007/s10637-014-0158-6
    249. 249
      Nie, Z.; Feher, V.; Natala, S.; McBride, C.; Kiryanov, A.; Jones, B.; Lam, B.; Liu, Y.; Kaldor, S.; Stafford, J.; Hikami, K.; Uchiyama, N.; Kawamoto, T.; Hikichi, Y.; Matsumoto, S.; Amano, N.; Zhang, L.; Hosfield, D.; Skene, R.; Zou, H.; Cao, X.; Ichikawa, T. Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1) Bioorg. Med. Chem. Lett. 2013, 23, 3662 3666 DOI: 10.1016/j.bmcl.2013.02.083
    250. 250
      Cheung, C. H. A.; Sarvagalla, S.; Lee, J. Y. C.; Huang, Y. C.; Coumar, M. S. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011–2013) Expert Opin. Ther. Pat. 2014, 24, 1021 1038 DOI: 10.1517/13543776.2014.931374
    251. 251
      Van Brocklyn, J. R.; Wojton, J.; Meisen, W. H.; Kellough, D. A.; Ecsedy, J. A.; Kaur, B.; Lehman, N. L. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma Cancer Res. 2014, 74, 5364 5370 DOI: 10.1158/0008-5472.CAN-14-0386
    252. 252
      Sathornsumetee, S.; Reardon, D. A.; Desjardins, A.; Quinn, J. A.; Vredenburgh, J. J.; Rich, J. N. Molecularly targeted therapy for malignant glioma Cancer 2007, 110, 13 24 DOI: 10.1002/cncr.22741
    253. 253
      Mochly-Rosen, D.; Das, K.; Grimes, K. V. Protein kinase C, an elusive target? Nat. Rev. Drug Discovery 2012, 11, 937 957 DOI: 10.1038/nrd3871
    254. 254
      (a) Kreisl, T. N.; Kotliarova, S.; Butman, J. A.; Albert, P. S.; Kim, L.; Musib, L.; Thornton, D.; Fine, H. A. A phase I/II trial of enzastaurin in pateints with recurrent high-grade gliomas Neuro-Oncology 2010, 12, 181 189 DOI: 10.1093/neuonc/nop042
      (b) Wick, W.; Puduvalli, V. K.; Chamberlain, M. C.; van den Bent, M. J.; Carpentier, A. F.; Cher, L. M.; Mason, W.; Weller, M.; Hong, S.; Musib, L.; Liepa, A. M.; Thornton, D. E.; Fine, H. A. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma J. Clin. Oncol. 2010, 28, 1168 1174 DOI: 10.1200/JCO.2009.23.2595
    255. 255
      Gronberg, B. H.; Ciuleanu, T.; Flotten, O.; Knuuttila, A.; Abel, E.; Langer, S. W.; Krejcy, K.; Liepa, A. M.; Munoz, M.; Hahka-Kemppinen, M.; Sundstrom, S. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer Lung Cancer 2012, 78, 63 69 DOI: 10.1016/j.lungcan.2012.07.007
    256. 256
      Yasoshima, K.; Kuwabara, T.; Fuse, E.; Kuramitu, T.; Kurata, N.; Nishiie, H.; Oishi, T.; Kobayashi, H.; Kobayashi, S. Pharmacokinetics, distribution, metabolism and excretion of [3H]UCN-01 in rats and dogs after intravenous administration Cancer Chemother. Pharmacol. 2001, 47, 106 112 DOI: 10.1007/s002800000213
    257. 257
      Budworth, J.; Davies, R.; Malkhandi, J.; Gant, T. W.; Ferry, D. R.; Gescher, A. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistance MCF-7/Adr cells Br. J. Cancer 1996, 73, 1063 1068 DOI: 10.1038/bjc.1996.205
    258. 258
      Capdeville, R.; Buchdunger, E.; Zimmerman, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1, 493 502 DOI: 10.1038/nrd839
    259. 259
      Quintas-Cardama, A.; Kantarjian, H. M.; Cortes, J. E. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia Cancer Control 2009, 16, 122 131
    260. 260
      Leis, J. F.; Stepan, D. E.; Curtin, P. T.; Ford, J. M.; Peng, B.; Schubach, S.; Druker, B. J.; Mariarz, R. T. Central nervous system failure in patients with chroinic mylogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571) Leuk. Lymphoma 2004, 45, 695 698 DOI: 10.1080/10428190310001625728
    261. 261
      (a) Dai, H.; Marbach, P.; Lemaire, M.; Hayes, M.; Elmquist, W. F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux J. Pharmacol. Exp. Ther. 2003, 304, 1085 1092 DOI: 10.1124/jpet.102.045260
      (b) Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen, O.; Schinkel, A. H.; Schellens, J. H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients Cancer Res. 2005, 65, 2577 2582 DOI: 10.1158/0008-5472.CAN-04-2416
      (c) Rajappa, S.; Uppin, S. G.; Raghunadharao, D.; Rao, I. S.; Surath, A. Isolated central nervous system blast crisis in chronic myeloid leukemia Hematol. Oncol. 2004, 22, 179 181 DOI: 10.1002/hon.737
      (d) Neville, K.; Parise, R. A.; Thompson, P.; Aleksic, A.; Egorin, M. J.; Balis, F. M.; McGuffey, L.; McCully, C.; Berg, S. L.; Blaney, S. M. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates Clin. Cancer Res. 2004, 10, 2525 2529 DOI: 10.1158/1078-0432.CCR-03-0155
    262. 262
      Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor J. Med. Chem. 2006, 49, 6819 6832 DOI: 10.1021/jm060727j
    263. 263
      Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Müller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Funga, G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 2009, 23, 477 485 DOI: 10.1038/leu.2008.334
    264. 264
      (a) Du, J.; Bernasconi, P.; Clauser, K. R.; Mani, D. R.; Finn, S. P.; Beroukhim, R.; Burns, M.; Julian, B.; Peng, X. P.; Hieronymus, H.; Maglathin, R. L.; Lewis, T. A.; Liau, L. M.; Nghiemphu, P.; Mellinghoff, I. K.; Louis, D. N.; Loda, M.; Carr, S. A.; Kung, A. L.; Golub, T. R. Bead-based kinase phosphorylation profiling identifies SRC as a therapeutic target in glioblastoma Nat. Biotechnol. 2009, 27, 77 83 DOI: 10.1038/nbt.1513
      (b) Zhang, S.; Huang, W.-C.; Zhang, L.; Zhang, C.; Lowery, F. J.; Ding, Z.; Guo, H.; Wang, H.; Huang, S.; Sahin, A. A.; Aldape, K. D.; Steeg, P. S.; Yu, D. Src family kinases as novel therapeutic targets to treat breast cancer brain metastases Cancer Res. 2013, 73, 5764 5774 DOI: 10.1158/0008-5472.CAN-12-1803
    265. 265
      Chen, Y.; Agarwal, S.; Shaik, N. M.; Chen, C.; Yang, Z.; Elmquist, W. F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib J. Pharmacol. Exp. Ther. 2009, 330, 956 963 DOI: 10.1124/jpet.109.154781
    266. 266
      Porkka, K.; Koskenvesa, P.; Lundan, T.; Rimpilainen, J.; Mustjoki, S.; Smykla, R.; Wild, R.; Luo, R.; Arnan, M.; Brethon, B.; Eccersley, L.; Hjorth-Hansen, H.; Hoglund, M.; Klamova, H.; Knutsen, H.; Parikh, S.; Raffoux, E.; Gruber, F.; Brito-Babapulle, F.; Dombret, H.; Duarte, R. F.; Elonen, E.; Paquette, R.; Zwaan, C. M.; Lee, F. Y. F. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood 2008, 112, 1005 1012 DOI: 10.1182/blood-2008-02-140665
    267. 267
      Hegedus, C.; Özvegy-Laczka, C.; Apati, A.; Magocsi, M.; Nemet, K.; Orfi, L.; Keri, G.; Katona, M.; Takats, Z.; Varadi, A.; Szakacs, G.; Sarkadi, B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties Br. J. Pharmacol. 2009, 158, 1153 1164 DOI: 10.1111/j.1476-5381.2009.00383.x
    268. 268
      Atilla, E.; Ataca, P.; Ozyurek, E.; Erden, I.; Gurman, G. Successful bosutinib experience in an elderly acute lymphoblastic leukemia patient with suspected central nervous system involvement transformed from chronic myeloid leukemia Case Rep. Hematol. 2015, 2015, 689423 DOI: 10.1155/2015/689423
    269. 269
      Taylor, J. W.; Dietrich, J.; Gerstner, E. R.; Norden, A. D.; Rinne, M. L.; Cahill, D. P.; Stemmer-Rachamimov, A.; Wen, P. Y.; Betensky, R. A.; Giorgio, D. H.; Snodgrass, K.; Randall, A. E.; Batchelor, T. T.; Chi, A. S. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma J. Neuro-Oncol. 2015, 121, 557 563 DOI: 10.1007/s11060-014-1667-z
    270. 270
      (a) Kosztyu, P.; Dolezel, P.; Mlejnek, P. Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells? Pharmacol. Res. 2013, 67, 79 83 DOI: 10.1016/j.phrs.2012.10.012
      (b) Yamakawa, Y.; Hamada, A.; Uchida, T.; Sato, D.; Yuki, M.; Hayashi, M.; Kawaguchi, T.; Saito, H. Distinct interaction of nilotinib and imatinib with P-glycoprotein in intracellular accumulation and cytotoxicity in CML cell line K562 cells Biol. Pharm. Bull. 2014, 37, 1330 1335 DOI: 10.1248/bpb.b14-00254
    271. 271
      Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brüggen, J.; Cowan-jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Mohammed, A.; Neuberg, D.; Wright, R. D.; Gilliand, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005, 7, 129 141 DOI: 10.1016/j.ccr.2005.01.007
    272. 272
      Reinwald, M.; Schleyer, E.; Kiewe, P.; Blau, I. W.; Burmeister, T.; Pursche, S.; Neumann, M.; Notter, M.; Thiel, E.; Hofmann, W.-K.; Kolb, H.-J.; Burdach, S.; Bender, H.-U. Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation BioMed Res. Int. 2014, 2014, 637059 DOI: 10.1155/2014/637059
    273. 273

      For example see the following and references therein:

      Lonskaya, I.; Hebron, M. L.; Selby, S. T.; Turner, R. S.; Moussa, C. E.-H. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in alzheimer’s disease models Neuroscience 2015, 304, 316 327 DOI: 10.1016/j.neuroscience.2015.07.070
    274. 274
      Huang, W.-S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J. Med. Chem. 2010, 53, 4701 4719 DOI: 10.1021/jm100395q
    275. 275
      Laramy, J. K.; Parrish, K. E.; Zhang, S.; Bakken, K. K.; Carlson, B. L.; Mladek, A. C.; Ma, D. J.; Sarkaria, J. N.; Elmquist, W. F. Brain distribution of ponatinib, a multi-kinase inhibitor: implications for the treatment of malignant brain tumors Am. Assoc. Pharm. Sci. 2015, W4339
    276. 276
      Niwa, T.; Asaki, T.; Kimura, S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor Anal. Chem. Insights 2007, 2, 93 106
    277. 277
      Portnow, J.; Badie, B.; Markel, S.; Liu, A.; D’Apuzzo, M.; Frankel, P.; Jandial, R.; Synold, T. W. A neuropharmocokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas Eur. J. Cancer 2013, 49, 1634 1640 DOI: 10.1016/j.ejca.2013.01.001
    278. 278
      Yokota, A.; Kimura, S.; Masuda, S.; Ashihara, E.; Kuroda, J.; Sato, K.; Kamitsuji, Y.; Kawata, E.; Deguchi, Y.; Urasaki, Y.; Terui, Y.; Ruthardt, M.; Ueda, T.; Hatake, K.; Inui, K.; Maekawa, T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood 2007, 109, 306 314 DOI: 10.1182/blood-2006-03-013250
    279. 279
      Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R. A.; Olivier, A.; Otterbein, L.; Ple, P. A.; Warin, N.; Costello, G. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor J. Med. Chem. 2006, 49, 6465 6488 DOI: 10.1021/jm060434q
    280. 280
      Kaufman, A. C.; Salazar, S. V.; Haas, L. T.; Yang, J.; Kostylev, M. A.; Jeng, A. T.; Robinson, S. A.; Gunther, E. C.; van Dyck, C. H.; Nygaard, H. B.; Strittmatter, S. M. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice Ann. Neurol. 2015, 77, 953 971 DOI: 10.1002/ana.24394
    281. 281
      Nygaard, H. B.; Wagner, A. F.; Bowen, G. S.; Good, S. P.; MacAvoy, M. G.; Strittmatter, K. A.; Kaufman, A. C.; Rosenberg, B. J.; Sekine-Konno, T.; Varma, P.; Chen, K.; Koleske, A. J.; Reiman, E. M.; Strittmatter, S. M.; van Dyck, C. H. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease Alzheimer's Res. Ther. 2015, 7, 35 DOI: 10.1186/s13195-015-0119-0
    282. 282
      (a) Abounader, R.; Laterra, J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis Neuro-Oncology 2005, 7, 436 451 DOI: 10.1215/S1152851705000050
      (b) Zhang, Y.; Farenholtz, K. E.; Yang, Y.; Guessous, F.; diPierro, C. G.; Calvert, V. S.; Deng, J.; Schiff, D.; Xin, W.; Lee, J. K.; Purow, B.; Christensen, J.; Petricoin, E.; Abounader, R. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition Clin. Cancer Res. 2013, 19, 1433 1444 DOI: 10.1158/1078-0432.CCR-12-2832
    283. 283
      Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K. A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69, 8009 8016 DOI: 10.1158/0008-5472.CAN-08-4889
    284. 284
      Faria, C. C.; Golbourn, B. J.; Dubuc, A. M.; Remke, M.; Diaz, R. J.; Agnihotri, S.; Luck, A.; Sabha, N.; Olsen, S.; Wu, X.; Garzia, L.; Ramaswamy, V.; Mack, S. C.; Wang, X.; Leadley, M.; Reynaud, D.; Ermini, L.; Post, M.; Northcott, P. A.; Pfister, S. M.; Croul, S. E.; Kool, M.; Korshunov, A.; Smith, C. A.; Taylor, M. D.; Rutka, J. T. Foretinib is effective for metastatic sonic hedgehog medulloblastoma Cancer Res. 2015, 75, 134 146 DOI: 10.1158/0008-5472.CAN-13-3629
    285. 285
      Buchanan, S. G.; Hendle, J.; Lee, P. S.; Smith, C. R.; Bounaud, P. Y.; Jessen, K. A.; Tang, C. M.; Huser, N. H.; Felce, J. D.; Froning, K. J.; Peterman, M. C.; Aubol, B. E.; Gessert, S. F.; Sauder, J. M.; Schwinn, K. D.; Russell, M.; Rooney, I. A.; Adams, J.; Leon, B. C.; Do, T. H.; Blaney, J. M.; Sprengeler, P. A.; Thompson, D. A.; Smyth, L.; Pelletier, L. A.; Atwell, S.; Holme, K.; Wasserman, S. R.; Emtage, S.; Burley, S. K.; Reich, S. H. SGX is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo Mol. Cancer Ther. 2009, 8, 3181 3190 DOI: 10.1158/1535-7163.MCT-09-0477
    286. 286
      Guessous, F.; Zhang, Y.; diPierro, C.; Marcinkiewicz, L.; Sarkaria, J.; Schiff, D.; Buchanan, S.; Abounader, R. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth Anti-Cancer Agents Med. Chem. 2010, 10, 28 35 DOI: 10.2174/1871520611009010028
    287. 287
      (a) Underiner, T. L.; Herbertz, T.; Miknyoczki, S. J. Disovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates Anti-Cancer Agents Med. Chem. 2010, 10, 7 27 DOI: 10.2174/1871520611009010007
      (b) Burbridge, M. F.; Bossard, C. J.; Saunier, C.; Fejes, I.; Bruno, I.; Bruno, A.; Leonce, S.; Ferry, G.; Da Violante, G.; Bouzom, F.; Cattan, V.; Jacquet-Bescond, A.; Comoglio, P. M.; Lockhart, B. P.; Boutin, J. A.; Cordi, A.; Ortuno, J. C.; Pierre, A.; Hickman, J. A.; Cruzalegui, F. H.; Depil, S. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab Mol. Cancer Ther. 2013, 12, 1749 1762 DOI: 10.1158/1535-7163.MCT-13-0075
    288. 288

      Literature related to the following c-Met inhibitors was reviewed in an effort to identify any information regarding potential for CNS penetration, including whether the molecules are P-gp substrates: LY2801653, PF-04217903, golvatinib, JNJ-58877605, PHA-66752, tivantinib.

    289. 289
      (a) Gutenberg, A.; Brück, W.; Buchfelder, M.; Ludwig, H. C. Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas Acta Neuropathol. 2004, 108, 224 230 DOI: 10.1007/s00401-004-0886-3
      (b) Rolon-Reyes, K.; Kucheryavykh, Y. V.; Cubano, L. A.; Inyushin, M.; Skatchkov, S. N.; Eaton, M. J.; Harrison, J. K.; Kucheryavykh, L. Y. Microglia activate migration of glioma cells through a Pyk2 intracellular pathway PLoS One 2015, 10, e0131059 DOI: 10.1371/journal.pone.0131059
    290. 290
      Sulzmaier, F. J.; Jean, C.; Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications Nat. Rev. Cancer 2014, 14, 598 610 DOI: 10.1038/nrc3792
    291. 291
      Luzzio, M.; Autry, C.; Berliner, M.; Coleman, K.; Cooper, B.; Desrosiers, E.; Emerson, E.; Griffor, M.; Hulford, C.; Jani, J.; Kath, J.; LaGreca, S.; Lin, J.; Lorenzen, M.; Marr, E.; Martinez-Alsina, L.; Patel, N.; Richter, D.; Ung, E.; Vajdos, F.; Wessel, M.; Whalen, P.; Yao, L.; Roberts, W. Abstract 5432: Design, synthesis, activity and properties of selective focal adhesion kinase inhibitors which are suitable for advanced preclinical evaluation: the discovery of PF-562271 Cancer Res. 2007, 67 (Suppl.) 5432
    292. 292
      Xu, Q.; Pachter, J. A.; Tam, W. Methods and compositions for treating abnormal cell growth (e.g., cancer) using FAK inhibitor and a MEK inhibitor. WO Patent WO2015120289 A1, 2015.
    293. 293
      Schlaepfer, D. Method of promoting apoptosis and inhibiting metastasis. WO Patent WO2011019943 A1, 2011.
    294. 294
      Auger, K. R.; Peddareddigari, V. G. R. Combinations. WO Patent WO2014059095 A1, 2014.
    295. 295
      Mulholland, P.; Williams, M.; Arkenau, H. T.; Fleming, R.; Tolson, J.; Yan, L.; Zhang, J.; Swartz, L.; Singh, R.; Auger, K.; Lenox, L.; Cox, D.; Plisson, C.; Saleem, A.; Searle, G.; Blagden, S. ATNT 06. Evaluation of the safety of GSK2256098 and pharmacokinetics of 11C-GSK2256098 in patients with recurrent glioblastoma by positron emission tomography (PET) imaging Neuro-Oncology 2015, 17 (Suppl. 5) v11 DOI: 10.1093/neuonc/nov205.06
    296. 296
      (a) Han, J.; Alvarez-Breckenridge, C. A.; Wang, Q. E.; Yu, J. TGF-b signaling and its targeting for glioma treatment Am. J. Cancer Res. 2015, 5, 945 955
      (b) Luwor, R. B.; Kaye, A. H.; Zhu, H. J. Transforming growth factor-beta (TGF-b) and brain tumors J. Clin. Neurosci. 2008, 15, 845 855 DOI: 10.1016/j.jocn.2008.01.003
    297. 297
      Herbertz, S.; Sawyer, J. S.; Stauber, A. J.; Gueorguieva, I.; Driscoll, K. E.; Estrem, S. T.; Cleverly, A. L.; Desaiah, D.; Guba, S. C.; Benhadji, K. A.; Slapak, C. A.; Lahn, M. M. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta singaling pathway Drug Des., Dev. Ther. 2015, 9, 4479 4499 DOI: 10.2147/DDDT.S86621
    298. 298
      Herzog, S.; Fink, M. A.; Weitmann, K.; Friedel, C.; Hadlich, S.; Langner, S.; Kindermann, K.; Holm, T.; Bohm, A.; Eskilsson, E.; Miletic, H.; Hildner, M.; Fritsch, M.; Vogelgesang, S.; Havemann, C.; Ritter, C. A.; Meyer zu Schwabedissen, H. E.; Rauch, B.; Hoffmann, W.; Kroemer, H. K.; Schroeder, H.; Bien-Moller, S. Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival Neuro-Oncology 2015, 17, 223 242 DOI: 10.1093/neuonc/nou216
    299. 299
      Chen, L. S.; Redkar, S.; Bearss, D.; Wierda, W. G.; Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Blood 2009, 114, 4150 4157 DOI: 10.1182/blood-2009-03-212852
    300. 300
      Burger, M. T.; Nishiguchi, G.; Han, W.; Lan, J.; Simmons, R.; Atallah, G.; Ding, Y.; Tamez, V.; Zhang, Y.; Mathur, M.; Muller, K.; Bellamacina, C.; Lindvall, M. K.; Zang, R.; Huh, K.; Feucht, P.; Zavorotinskaya, T.; Dai, Y.; Basham, S.; Chan, J.; Ginn, E.; Aycinena, A.; Holash, J.; Castillo, J.; Langowski, J. L.; Wang, Y.; Chen, M. Y.; Lambert, A.; Fritsch, C.; Kauffmann, A.; Pfister, E.; Vanasse, K. G.; Garcia, P. D. Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a potent and selective proviral insertion site of moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitor in clinical trials for hematological malignancies J. Med. Chem. 2015, 58, 8373 8386 DOI: 10.1021/acs.jmedchem.5b01275
    301. 301
      Keeton, E. K.; McEachern, K.; Dillman, K. S.; Palakurthi, S.; Cao, Y.; Grondine, M. R.; Kaur, S.; Wang, S.; Chen, Y.; Wu, A.; Shen, M.; Gibbons, F. D.; Lamb, M. L.; Zheng, X.; Stone, R. M.; DeAngelo, D. J.; Platanias, L. C.; Dakin, L. A.; Chen, H.; Lyne, P. D.; Huszar, D. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia Blood 2014, 123, 905 913 DOI: 10.1182/blood-2013-04-495366
    302. 302
      Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase ChemMedChem 2007, 2, 58 61 DOI: 10.1002/cmdc.200600221
    303. 303
      Bernard, S.; Goldwirt, L.; Amorim, S.; Brice, P.; Bnere, J.; de Kerviller, E.; Mourah, S.; Sauvageon, H.; Thieblemont, C. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse Blood 2015, 126, 1695 1698 DOI: 10.1182/blood-2015-05-647834
    304. 304
      205552 Clinical Pharmacology Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf (accessed June 12, 2016) .
    305. 305
      (a) Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J. M.; Valerie, N. C. K.; Tokarz, M.; Adams, B. R.; Wagner, A. F.; Khalil, A.; Gilfor, D.; Golding, S. E.; Deb, S.; Temesi, D. G.; Lau, A.; O’Connor, M. J.; Choe, K. S.; Parada, L. F.; Lim, S. K.; Mukhopadhyay, N. D.; Valerie, K. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation Clin. Cancer Res. 2013, 19, 3189 3200 DOI: 10.1158/1078-0432.CCR-12-3408
      (b) Nadkarni, A.; Shrivastav, M.; Mladek, A. C.; Schwingler, P. M.; Grogan, P. T.; Chen, J.; Sarkaria, J. N. ATM inhibitor Ku-55993 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells J. Neuro-Oncol. 2012, 110, 349 357 DOI: 10.1007/s11060-012-0979-0
    306. 306
      Linger, R. M. A.; Keating, A. K.; Earp, H. Sh.; Graham, D. K. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors Expert Opin. Ther. Targets 2010, 14, 1073 1090 DOI: 10.1517/14728222.2010.515980
    307. 307

      As an example of the potential importance of inhibiting multiple kinases:

      Joshi, A. D.; Loilome, W.; Siu, I.-M.; Tyler, B.; Gallia, G. L.; Riggins, G. J. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy PLoS One 2012, 7, e44372 DOI: 10.1371/journal.pone.0044372
    308. 308

      See Supporting Information for details of individual inhibitors.

    Cited By


    This article is cited by 59 publications.

    1. Emily Murrell, Junchao Tong, David Smil, Taira Kiyota, Ahmed M. Aman, Methvin B. Isaac, Iain D. G. Watson, Neil Vasdev. Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors. ACS Medicinal Chemistry Letters 2021, 12 (5) , 846-850. https://doi.org/10.1021/acsmedchemlett.1c00127OpenURL HONG KONG UNIV SCIENCE TECHLGY
    2. Jonathan E. Tsang, Lorenz M. Urner, Gyudong Kim, Kingsley Chow, Lynn Baufeld, Kym Faull, Timothy F. Cloughesy, Peter M. Clark, Michael E. Jung, David A. Nathanson. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS Medicinal Chemistry Letters 2020, 11 (10) , 1799-1809. https://doi.org/10.1021/acsmedchemlett.9b00599OpenURL HONG KONG UNIV SCIENCE TECHLGY
    3. David Smil, Jong Fu Wong, Eleanor P. Williams, Roslin J. Adamson, Alison Howarth, David A. McLeod, Ahmed Mamai, Soyoung Kim, Brian J. Wilson, Taira Kiyota, Ahmed Aman, Julie Owen, Gennady Poda, Kurumi Y. Horiuchi, Ekaterina Kuznetsova, Haiching Ma, J. Nicole Hamblin, Sue Cramp, Owen G. Roberts, Aled M. Edwards, David Uehling, Rima Al-awar, Alex N. Bullock, Jeff A. O’Meara, Methvin B. Isaac. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. Journal of Medicinal Chemistry 2020, 63 (17) , 10061-10085. https://doi.org/10.1021/acs.jmedchem.0c01199OpenURL HONG KONG UNIV SCIENCE TECHLGY
    4. Andrea I. Krahn, Carrow Wells, David H. Drewry, Lenore K. Beitel, Thomas M. Durcan, Alison D. Axtman. Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases. ACS Chemical Neuroscience 2020, 11 (13) , 1871-1886. https://doi.org/10.1021/acschemneuro.0c00176OpenURL HONG KONG UNIV SCIENCE TECHLGY
    5. Deeba Ensan, David Smil, Carlos A. Zepeda-Velázquez, Dimitrios Panagopoulos, Jong Fu Wong, Eleanor P. Williams, Roslin Adamson, Alex N. Bullock, Taira Kiyota, Ahmed Aman, Owen G. Roberts, Aled M. Edwards, Jeff A. O’Meara, Methvin B. Isaac, Rima Al-awar. Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma. Journal of Medicinal Chemistry 2020, 63 (9) , 4978-4996. https://doi.org/10.1021/acs.jmedchem.0c00395OpenURL HONG KONG UNIV SCIENCE TECHLGY
    6. Yahui Ding, Qingqing Xue, Shuo Liu, Kai Hu, Da Wang, Tianpeng Wang, Ye Li, Hongyu Guo, Xin Hao, Weizhi Ge, Yan Zhang, Ang Li, Jing Li, Yue Chen, Quan Zhang. Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo. Journal of Medicinal Chemistry 2020, 63 (4) , 1597-1611. https://doi.org/10.1021/acs.jmedchem.9b01328OpenURL HONG KONG UNIV SCIENCE TECHLGY
    7. Leticia Toledo-Sherman, Perla Breccia, Roger Cachope, Jennifer R. Bate, Ivan Angulo-Herrera, Grant Wishart, Kim L. Matthews, Sarah L. Martin, Helen C. Cox, George McAllister, Stephen D. Penrose, Huw Vater, William Esmieu, Amanda Van de Poël, Rhea Van de Bospoort, Annelieke Strijbosch, Marieke Lamers, Philip Leonard, Rebecca E. Jarvis, Wesley Blackaby, Karen Barnes, Maria Eznarriaga, Simon Dowler, Graham D. Smith, David F. Fischer, Ovadia Lazari, Dawn Yates, Mark Rose, Sung-Wook Jang, Ignacio Muñoz-Sanjuan, Celia Dominguez. Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington’s Disease Models. Journal of Medicinal Chemistry 2019, 62 (6) , 2988-3008. https://doi.org/10.1021/acs.jmedchem.8b01819OpenURL HONG KONG UNIV SCIENCE TECHLGY
    8. Robert Dugger Bryan Li Paul Richardson . Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. 2019,,, 27-59. https://doi.org/10.1021/bk-2019-1332.ch002OpenURL HONG KONG UNIV SCIENCE TECHLGY
    9. ChrisTina Okolo, Mohamad Akbar Ali, Matthew Newman, Steven A. Chambers, Jedidiah Whitt, Zakeyah A. Alsharif, Victor W. Day, Mohammad A. Alam. Hexafluoroisopropanol-Mediated Domino Reaction for the Synthesis of Thiazolo-androstenones: Potent Anticancer Agents. ACS Omega 2018, 3 (12) , 17991-18001. https://doi.org/10.1021/acsomega.8b02840OpenURL HONG KONG UNIV SCIENCE TECHLGY
    10. Michael Siu, Arundhati Sengupta Ghosh, Joseph W. Lewcock. Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration. Journal of Medicinal Chemistry 2018, 61 (18) , 8078-8087. https://doi.org/10.1021/acs.jmedchem.8b00370OpenURL HONG KONG UNIV SCIENCE TECHLGY
    11. Peter J. Tonge . Drug–Target Kinetics in Drug Discovery. ACS Chemical Neuroscience 2018, 9 (1) , 29-39. https://doi.org/10.1021/acschemneuro.7b00185OpenURL HONG KONG UNIV SCIENCE TECHLGY
    12. Anne Marie Barrette, Mehdi Bouhaddou, and Marc R. Birtwistle . Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. ACS Chemical Neuroscience 2018, 9 (1) , 118-129. https://doi.org/10.1021/acschemneuro.7b00197OpenURL HONG KONG UNIV SCIENCE TECHLGY
    13. Enza Lacivita, Roberto Perrone, Lucia Margari, and Marcello Leopoldo . Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. Journal of Medicinal Chemistry 2017, 60 (22) , 9114-9141. https://doi.org/10.1021/acs.jmedchem.7b00965OpenURL HONG KONG UNIV SCIENCE TECHLGY
    14. Snahel Patel, William J. Meilandt, Rebecca I. Erickson, Jinhua Chen, Gauri Deshmukh, Anthony A. Estrada, Reina N. Fuji, Paul Gibbons, Amy Gustafson, Seth F. Harris, Jose Imperio, Wendy Liu, Xingrong Liu, Yichin Liu, Joseph P. Lyssikatos, Changyou Ma, Jianping Yin, Joseph W. Lewcock, and Michael Siu . Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer’s Disease. Journal of Medicinal Chemistry 2017, 60 (19) , 8083-8102. https://doi.org/10.1021/acs.jmedchem.7b00843OpenURL HONG KONG UNIV SCIENCE TECHLGY
    15. Zoran Rankovic. CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. Journal of Medicinal Chemistry 2017, 60 (14) , 5943-5954. https://doi.org/10.1021/acs.jmedchem.6b01469OpenURL HONG KONG UNIV SCIENCE TECHLGY
    16. Guiping Zhang, Jianjun Cheng, John D. McCorvy, Paul J. Lorello, Barbara J. Caldarone, Bryan L. Roth, and Alan P. Kozikowski . Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications. Journal of Medicinal Chemistry 2017, 60 (14) , 6273-6288. https://doi.org/10.1021/acs.jmedchem.7b00584OpenURL HONG KONG UNIV SCIENCE TECHLGY
    17. Kevin Peikert, Enrica Federti, Alessandro Matte, Gabriela Constantin, Enrica Caterina Pietronigro, Paolo Francesco Fabene, Paola Defilippi, Emilia Turco, Federico Del Gallo, Pietro Pucci, Angela Amoresano, Anna Illiano, Flora Cozzolino, Maria Monti, Francesca Garello, Enzo Terreno, Seth Leo Alper, Hannes Glaß, Lisann Pelzl, Katja Akgün, Tjalf Ziemssen, Rainer Ordemann, Florian Lang, Anna Maria Brunati, Elena Tibaldi, Immacolata Andolfo, Achille Iolascon, Giuseppe Bertini, Mario Buffelli, Carlo Zancanaro, Erika Lorenzetto, Angela Siciliano, Massimiliano Bonifacio, Adrian Danek, Ruth Helen Walker, Andreas Hermann, Lucia De Franceschi. Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. Acta Neuropathologica Communications 2021, 9 (1) https://doi.org/10.1186/s40478-021-01181-yOpenURL HONG KONG UNIV SCIENCE TECHLGY
    18. Chen He, Ke Xu, Xiaoyan Zhu, Paige S. Dunphy, Brian Gudenas, Wenwei Lin, Nathaniel Twarog, Laura D. Hover, Chang-Hyuk Kwon, Lawryn H. Kasper, Junyuan Zhang, Xiaoyu Li, James Dalton, Barbara Jonchere, Kimberly S. Mercer, Duane G. Currier, William Caufield, Yingzhe Wang, Jia Xie, Alberto Broniscer, Cynthia Wetmore, Santhosh A. Upadhyaya, Ibrahim Qaddoumi, Paul Klimo, Frederick Boop, Amar Gajjar, Jinghui Zhang, Brent A. Orr, Giles W. Robinson, Michelle Monje, Burgess B. Freeman III, Martine F. Roussel, Paul A. Northcott, Taosheng Chen, Zoran Rankovic, Gang Wu, Jason Chiang, Christopher L. Tinkle, Anang A. Shelat, Suzanne J. Baker. Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nature Communications 2021, 12 (1) https://doi.org/10.1038/s41467-021-24168-8OpenURL HONG KONG UNIV SCIENCE TECHLGY
    19. Anmol Gulati, Charles S. Yeung, Blair Lapointe, Solomon D. Kattar, Hakan Gunaydin, Jack D. Scott, Kaleen K. Childers, Joey L. Methot, Vladimir Simov, Ravi Kurukulasuriya, Barbara Pio, Greg J. Morriello, Ping Liu, Haiqun Tang, Santhosh Neelamkavil, Harold B. Wood, Vanessa L. Rada, Michael J. Ardolino, Xin Cindy Yan, Rachel Palte, Karin Otte, Robert Faltus, Janice Woodhouse, Laxminarayan G. Hegde, Paul Ciaccio, Ellen C. Minnihan, Erin F. DiMauro, Matthew J. Fell, Peter H. Fuller, J. Michael Ellis. Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. RSC Medicinal Chemistry 2021, 12 (7) , 1164-1173. https://doi.org/10.1039/D1MD00097GOpenURL HONG KONG UNIV SCIENCE TECHLGY
    20. Chiara Borsari, Martina De Pascale, Matthias P. Wymann. Chemical and Structural Strategies to Selectively Target mTOR Kinase. ChemMedChem 2021, 9 https://doi.org/10.1002/cmdc.202100332OpenURL HONG KONG UNIV SCIENCE TECHLGY
    21. Naseer Maliyakkal, Asmy Appadath Beeran, Nayanabhirama Udupa. Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells. Saudi Pharmaceutical Journal 2021, 95 https://doi.org/10.1016/j.jsps.2021.07.001OpenURL HONG KONG UNIV SCIENCE TECHLGY
    22. Vegard Torp Lien, Sofie Celen, Syed Nuruddin, Bala Attili, Gilles Doumont, Gaetan Van Simaeys, Guy Bormans, Jo Klaveness, Dag Erlend Olberg. Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model. Nuclear Medicine and Biology 2021, 93 , 74-80. https://doi.org/10.1016/j.nucmedbio.2020.12.002OpenURL HONG KONG UNIV SCIENCE TECHLGY
    23. Jinsha Liu, Priyanka Pandya, Sepideh Afshar. Therapeutic Advances in Oncology. International Journal of Molecular Sciences 2021, 22 (4) , 2008. https://doi.org/10.3390/ijms22042008OpenURL HONG KONG UNIV SCIENCE TECHLGY
    24. Dinesh S. Reddy, Manasa Kongot, Vishal Singh, Md. Abrar Siddiquee, Rajan Patel, Nitin K. Singhal, Fernando Avecilla, Amit Kumar. Biscoumarin–pyrimidine conjugates as potent anticancer agents and binding mechanism of hit candidate with human serum albumin. Archiv der Pharmazie 2021, 354 (1) , 2000181. https://doi.org/10.1002/ardp.202000181OpenURL HONG KONG UNIV SCIENCE TECHLGY
    25. Ahmed Elkamhawy, Eslam M. H. Ali, Kyeong Lee. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011–2021) focussing on structure–activity relationship (SAR) and docking insights. Journal of Enzyme Inhibition and Medicinal Chemistry 2021, 36 (1) , 1574-1602. https://doi.org/10.1080/14756366.2021.1937143OpenURL HONG KONG UNIV SCIENCE TECHLGY
    26. Papita Koli, Reena, Rukmankesh Mehra, Deepak K. Sharma. Structure‐Activity Relationship of Indolylkojylmethane Based on Antiproliferative Activity against Breast Cancer. ChemistrySelect 2020, 5 (40) , 12417-12420. https://doi.org/10.1002/slct.202003032OpenURL HONG KONG UNIV SCIENCE TECHLGY
    27. Stuart A Grossman, Carlos G Romo, Michelle A Rudek, Jeffrey Supko, Joy Fisher, L Burt Nabors, Patrick Y Wen, David M Peereboom, Benjamin M Ellingson, William Elmquist, Fred G Barker, David Kamson, Jann N Sarkaria, William Timmer, Ranjit S Bindra, Xiaobu Ye. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery. Neuro-Oncology 2020, 22 (10) , 1422-1424. https://doi.org/10.1093/neuonc/noaa142OpenURL HONG KONG UNIV SCIENCE TECHLGY
    28. Yinliang Qi, Le Xu, Zhiwei Li, Ping Gong, Tao Hu, Bixi Yin, Mingze Qin, Yajing Liu, Yanfang Zhao, Yunlei Hou. Design, synthesis and biological evaluation of novel pteridinone derivatives as potent dual inhibitors of PLK1 and BRD4. New Journal of Chemistry 2020, 44 (38) , 16477-16490. https://doi.org/10.1039/D0NJ03477KOpenURL HONG KONG UNIV SCIENCE TECHLGY
    29. Caroline L. Benn, Lee A. Dawson. Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease. Frontiers in Aging Neuroscience 2020, 12 https://doi.org/10.3389/fnagi.2020.00242OpenURL HONG KONG UNIV SCIENCE TECHLGY
    30. Zilai Wang, Daochun Sun, Yu-Jung Chen, Xuanhua Xie, Yufeng Shi, Viviane Tabar, Cameron W. Brennan, Tejus A. Bale, Chenura D. Jayewickreme, Dan R. Laks, Sheila Alcantara Llaguno, Luis F. Parada. Cell Lineage-Based Stratification for Glioblastoma. Cancer Cell 2020, 38 (3) , 366-379.e8. https://doi.org/10.1016/j.ccell.2020.06.003OpenURL HONG KONG UNIV SCIENCE TECHLGY
    31. Evan K. Day, Nisha G. Sosale, Aizhen Xiao, Qing Zhong, Benjamin Purow, Matthew J. Lazzara. Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling. Cell Reports 2020, 30 (10) , 3383-3396.e7. https://doi.org/10.1016/j.celrep.2020.02.014OpenURL HONG KONG UNIV SCIENCE TECHLGY
    32. Gautham Gampa, Surabhi Talele, Minjee Kim, Afroz Mohammad, Jessica Griffith, William F. Elmquist. Influence of transporters in treating cancers in the CNS. 2020,,, 277-301. https://doi.org/10.1016/B978-0-12-816434-1.00009-7OpenURL HONG KONG UNIV SCIENCE TECHLGY
    33. Burgess B. Freeman, Lei Yang, Zoran Rankovic. Practical approaches to evaluating and optimizing brain exposure in early drug discovery. European Journal of Medicinal Chemistry 2019, 182 , 111643. https://doi.org/10.1016/j.ejmech.2019.111643OpenURL HONG KONG UNIV SCIENCE TECHLGY
    34. Ronilda R. D’Cunha, Daryl J. Murry, Guohua An. Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice. Journal of Pharmaceutical Sciences 2019, 108 (10) , 3434-3442. https://doi.org/10.1016/j.xphs.2019.05.028OpenURL HONG KONG UNIV SCIENCE TECHLGY
    35. Syed Muhammad Usama, Zhengyang Jiang, Kathryn Pflug, Raquel Sitcheran, Kevin Burgess. Conjugation of Dasatinib with MHI‐148 Has a Significant Advantageous Effect in Viability Assays for Glioblastoma Cells. ChemMedChem 2019, 14 (17) , 1575-1579. https://doi.org/10.1002/cmdc.201900356OpenURL HONG KONG UNIV SCIENCE TECHLGY
    36. Hani M. Babiker, Sara A. Byron, William P. D. Hendricks, William F. Elmquist, Gautham Gampa, Jessica Vondrak, Jessica Aldrich, Lori Cuyugan, Jonathan Adkins, Valerie De Luca, Raoul Tibes, Mitesh J. Borad, Katie Marceau, Thomas J. Myers, Linda J. Paradiso, Winnie S. Liang, Ronald L. Korn, Derek Cridebring, Daniel D. Von Hoff, John D. Carpten, David W. Craig, Jeffrey M. Trent, Michael S. Gordon. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Investigational New Drugs 2019, 37 (4) , 636-645. https://doi.org/10.1007/s10637-018-0668-8OpenURL HONG KONG UNIV SCIENCE TECHLGY
    37. Sarah M. Bronner, Karl A. Merrick, Jeremy Murray, Laurent Salphati, John G. Moffat, Jodie Pang, Christopher J. Sneeringer, Nicholas Dompe, Patrick Cyr, Hans Purkey, Gladys de Leon Boenig, Jun Li, Aleksandr Kolesnikov, Robin Larouche-Gauthier, Kwong Wah Lai, Xiaoli Shen, Samuel Aubert-Nicol, Yi-Chen Chen, Jonathan Cheong, James J. Crawford, Marc Hafner, Pouyan Haghshenas, Araz Jakalian, Jean-Philippe Leclerc, Ngiap-Kie Lim, Tom O'Brien, Emile G. Plise, Hadil Shalan, Claudio Sturino, John Wai, Yang Xiao, Jianping Yin, Liang Zhao, Stephen Gould, Alan Olivero, Timothy P. Heffron. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma. Bioorganic & Medicinal Chemistry Letters 2019, 29 (16) , 2294-2301. https://doi.org/10.1016/j.bmcl.2019.06.021OpenURL HONG KONG UNIV SCIENCE TECHLGY
    38. Amreena Suri, Anders W. Bailey, Maurício T. Tavares, Hendra Gunosewoyo, Connor P. Dyer, Alex T. Grupenmacher, David R. Piper, Robert A. Horton, Tadanori Tomita, Alan P. Kozikowski, Saktimayee M. Roy, Simone T. Sredni. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. International Journal of Molecular Sciences 2019, 20 (9) , 2112. https://doi.org/10.3390/ijms20092112OpenURL HONG KONG UNIV SCIENCE TECHLGY
    39. Minjee Kim, Janice K. Laramy, Afroz S. Mohammad, Surabhi Talele, James Fisher, Jann N. Sarkaria, William F. Elmquist. Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2 -Deficient Mice. Drug Metabolism and Disposition 2019, 47 (4) , 393-404. https://doi.org/10.1124/dmd.118.084210OpenURL HONG KONG UNIV SCIENCE TECHLGY
    40. Hamza Saleem, U. Kulsoom Abdul, Asli Küçükosmanoglu, Megan Houweling, Fleur M.G. Cornelissen, Dieter H. Heiland, Monika E. Hegi, Mathilde C.M. Kouwenhoven, David Bailey, Tom Würdinger, Bart A. Westerman. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. Drug Resistance Updates 2019, 43 , 29-37. https://doi.org/10.1016/j.drup.2019.04.002OpenURL HONG KONG UNIV SCIENCE TECHLGY
    41. Sushil K. Kashaw, Shivangi Agarwal, Mitali Mishra, Samaresh Sau, Arun K. Iyer. Molecular Docking Analysis of Caspase-3 Activators as Potential Anticancer Agents. Current Computer-Aided Drug Design 2018, 15 (1) , 55-66. https://doi.org/10.2174/1573409914666181015150731OpenURL HONG KONG UNIV SCIENCE TECHLGY
    42. Minjee Kim, Sani H. Kizilbash, Janice K. Laramy, Gautham Gampa, Karen E. Parrish, Jann N. Sarkaria, William F. Elmquist. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharmaceutical Research 2018, 35 (9) https://doi.org/10.1007/s11095-018-2455-9OpenURL HONG KONG UNIV SCIENCE TECHLGY
    43. Ales Sorf, Jakub Hofman, Radim Kučera, Frantisek Staud, Martina Ceckova. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochemical Pharmacology 2018, 154 , 10-17. https://doi.org/10.1016/j.bcp.2018.04.013OpenURL HONG KONG UNIV SCIENCE TECHLGY
    44. Prashant B. Nigade, Jayasagar Gundu, K. Sreedhara Pai, Kumar V. S. Nemmani. Prediction of Tumor-to-Plasma Ratios of Basic Compounds in Subcutaneous Xenograft Mouse Models. European Journal of Drug Metabolism and Pharmacokinetics 2018, 43 (3) , 331-346. https://doi.org/10.1007/s13318-017-0454-6OpenURL HONG KONG UNIV SCIENCE TECHLGY
    45. Yuan Shi, Mary Mader. Brain penetrant kinase inhibitors: Learning from kinase neuroscience discovery. Bioorganic & Medicinal Chemistry Letters 2018, 28 (11) , 1981-1991. https://doi.org/10.1016/j.bmcl.2018.05.007OpenURL HONG KONG UNIV SCIENCE TECHLGY
    46. Gautham Gampa, Minjee Kim, Nicholas Cook-Rostie, Janice K. Laramy, Jann N. Sarkaria, Linda Paradiso, Louis DePalatis, William F. Elmquist. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. Drug Metabolism and Disposition 2018, 46 (5) , 658-666. https://doi.org/10.1124/dmd.117.079194OpenURL HONG KONG UNIV SCIENCE TECHLGY
    47. Janice K. Laramy, Minjee Kim, Karen E. Parrish, Jann N. Sarkaria, William F. Elmquist. Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics 2018, 365 (2) , 249-261. https://doi.org/10.1124/jpet.117.246116OpenURL HONG KONG UNIV SCIENCE TECHLGY
    48. Victor A Levin. Drug discovery in neuro-oncology: challenges in the path forward. Neuro-Oncology 2018, 20 (4) , 435-436. https://doi.org/10.1093/neuonc/noy004OpenURL HONG KONG UNIV SCIENCE TECHLGY
    49. Timothy P Heffron. Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Neuro-Oncology 2018, 20 (3) , 307-312. https://doi.org/10.1093/neuonc/nox179OpenURL HONG KONG UNIV SCIENCE TECHLGY
    50. Fei Peng, Jin Liu, Lili Li, Zhiwei Chen. Copper-Catalyzed Tandem Reaction of Enamino Esters with ortho -Halogenated Aromatic Carbonyls: One-Pot Approach to Functionalized Quinolines. European Journal of Organic Chemistry 2018, 2018 (5) , 666-672. https://doi.org/10.1002/ejoc.201701472OpenURL HONG KONG UNIV SCIENCE TECHLGY
    51. Alexander C. Conley, Paul A. Newhouse. Advances in Drug Discovery and Development in Geriatric Psychiatry. Current Psychiatry Reports 2018, 20 (2) https://doi.org/10.1007/s11920-018-0871-5OpenURL HONG KONG UNIV SCIENCE TECHLGY
    52. Raviteja Suryadevara, Hassen Fadel, Sharon K. Michelhaugh, Sandeep Mittal, Prahlad Parajuli. Tumors of the Central Nervous System. 2018,,, 1-26. https://doi.org/10.1016/B978-0-12-812218-1.00001-4OpenURL HONG KONG UNIV SCIENCE TECHLGY
    53. Leonid I. Belen’kii, Yulia B. Evdokimenkova. The Literature of Heterocyclic Chemistry, Part XVI, 2016. 2018,,, 173-254. https://doi.org/10.1016/bs.aihch.2018.02.003OpenURL HONG KONG UNIV SCIENCE TECHLGY
    54. Lei Yin, Heng Li, Wenjian Liu, Zhenglin Yao, Zhenzhen Cheng, Huabei Zhang, Hui Zou. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. European Journal of Medicinal Chemistry 2018, 144 , 1-28. https://doi.org/10.1016/j.ejmech.2017.12.003OpenURL HONG KONG UNIV SCIENCE TECHLGY
    55. Muhammad Latif, Zaman Ashraf, Sulman Basit, Abdul Ghaffar, Muhammad Sohail Zafar, Aamer Saeed, Sultan Ayoub Meo. Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. RSC Advances 2018, 8 (30) , 16470-16493. https://doi.org/10.1039/C8RA01934GOpenURL HONG KONG UNIV SCIENCE TECHLGY
    56. Gautham Gampa, Shruthi Vaidhyanathan, Jann N. Sarkaria, William F. Elmquist. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?. Pharmacological Research 2017, 123 , 10-25. https://doi.org/10.1016/j.phrs.2017.06.008OpenURL HONG KONG UNIV SCIENCE TECHLGY
    57. Justin J. Bailey, Ralf Schirrmacher, Kristen Farrell, Vadim Bernard-Gauthier. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II. Expert Opinion on Therapeutic Patents 2017, 27 (7) , 831-849. https://doi.org/10.1080/13543776.2017.1297797OpenURL HONG KONG UNIV SCIENCE TECHLGY
    58. Hendra Gunosewoyo, Lifang Yu, Lenka Munoz, Michael Kassiou. Kinase targets in CNS drug discovery. Future Medicinal Chemistry 2017, 9 (3) , 303-314. https://doi.org/10.4155/fmc-2016-0214OpenURL HONG KONG UNIV SCIENCE TECHLGY
    59. Dan Lindholm, Dan D. Pham, Annunziata Cascone, Ove Eriksson, Krister Wennerberg, Mart Saarma. c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease. Frontiers in Aging Neuroscience 2016, 8 https://doi.org/10.3389/fnagi.2016.00254OpenURL HONG KONG UNIV SCIENCE TECHLGY
    • Abstract

      Figure 1

      Figure 1. Structural modifications upon gefitinib (17), focused on reducing rotatable bonds and effective hydrogen bond donors, led to the freely BBB penetrating inhibitor of EGFR, 22.

      Figure 2

      Figure 2. Modifications of PI3K/mTOR inhibitors that resulted in the discovery of 25, a brain penetrating inhibitor with desirable metabolic stability.

      Figure 3

      Figure 3. Macrocyclization led to improved metabolic stability, potency, and reduced P-gp mediated efflux in this series of ALK inhibitors.

      Figure 4

      Figure 4. Reducing effective HBD count by intramolecular hydrogen bonding reduced P-gp efflux among a set of PLK1 inhibitors.

    • References

      ARTICLE SECTIONS
      Jump To

      This article references 308 other publications.

      1. 1
        Ostrom, Q. T.; Gittleman, H.; Farah, P.; Ondracek, A.; Chen, Y.; Wolinsky, Y.; Stroup, N. E.; Kruchko, C.; Barnholtz-Sloan, J. S. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010 Neuro-Oncology 2013, 15 (Suppl. 2) 1 56 DOI: 10.1093/neuonc/not151
      2. 2
        Krex, D.; Klink, B.; Hartmann, C.; von Deimling, A.; Pietsch, T.; Simon, M.; Sabel, M.; Steinbach, J. P.; Heese, O.; Reifenberger, G.; Weller, M.; Schackert, G. Long-term survival with glioblastoma multiforme Brain 2007, 130, 2596 2606 DOI: 10.1093/brain/awm204
      3. 3
        Patchell, R. A. The management of brain metastases Cancer Treat. Rev. 2003, 29, 533 540 DOI: 10.1016/S0305-7372(03)00105-1
      4. 4
        Swain, S. M.; Baselga, J.; Miles, D.; Im, Y.-H.; Quah, C.; Lee, L. F.; Cortes, J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA Ann. Oncol. 2014, 25, 1116 1121 DOI: 10.1093/annonc/mdu133
      5. 5
        (a) Mehta, M. P.; Paleologos, N. A.; Mikkelsen, T.; Robinson, P. D.; Ammirati, M.; Andrews, D. W.; Asher, A. L.; Burri, S. H.; Cobbs, C. S.; Gaspar, L. E.; Kondziolka, D.; Linskey, M. E.; Loeffler, J. S.; McDermott, M.; Olson, J. J.; Patchell, R. A.; Ryken, T. C.; Kalkanis, S. N. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline J. Neuro-Oncol. 2010, 96, 71 83 DOI: 10.1007/s11060-009-0062-7
        (b) Owonikoko, T. K.; Arbiser, J.; Zelnak, A.; Shu, H.-K. G.; Shim, H.; Robin, A. M.; Kalkanis, S. N.; Whitsett, T. G.; Salhia, B.; Tran, N. L.; Ryken, T.; Moore, M. K.; Egan, K.; Olson, J. J. Current approaches to the treatment of metastatic brain tumors Nat. Rev. Clin. Oncol. 2014, 11, 203 222 DOI: 10.1038/nrclinonc.2014.25
      6. 6
        (a) Steeg, P. S.; Camphausen, K. A.; Smith, Q. R. Brain metastases as preventive and therapeutic targets Nat. Rev. Cancer 2011, 11, 352 363 DOI: 10.1038/nrc3053
        (b) Sledge, G. W. Heading in a new direction: drug permeability in breast cancer brain metastasis Clin. Cancer Res. 2010, 16, 5605 5607 DOI: 10.1158/1078-0432.CCR-10-2502
        (c) Lockman, P. R.; Mittapalli, R. K.; Taskar, K. S.; Rudraraju, V.; Gril, B.; Bohn, K. A.; Adkins, C. E.; Roberts, A.; Thorsheim, H. R.; Gaasch, J. A.; Huang, S.; Palmien, D.; Steeg, P. S.; Smith, Q. R. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer Clin. Cancer Res. 2010, 16, 5664 5678 DOI: 10.1158/1078-0432.CCR-10-1564
        (d) Henson, J. W.; Cordon-Cardo, C.; Posner, J. B. P-glycoprotein expression in brain tumors J. Neuro-Oncol. 1992, 14, 37 43 DOI: 10.1007/BF00170943
        (e) Demeule, M.; Shedid, D.; Beaulieu, E.; Del Maestro, R. F.; Moghrabi, A.; Ghosn, P. B.; Moumdijian, R.; Berthelet, F.; Beliveau, R. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors Int. J. Cancer 2001, 93, 62 66 DOI: 10.1002/ijc.1306
      7. 7
        (a) Claes, A.; Idema, A. J.; Wesseling, P. Diffuse glioma growth: a guerrila war Acta Neuropathol. 2007, 114, 443 448 DOI: 10.1007/s00401-007-0293-7
        (b) Agarwal, S.; Sane, R.; Oberoi, R.; Ohlfest, J. R.; Elmquist, W. F. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain Expert Rev. Mol. Med. 2011, 13, e17 DOI: 10.1017/S1462399411001888
        (c) Kuratsu, J.; Itoyama, Y.; Uemura, S.; Ushio, Y. Regrowth patterns of glioma—cases of glioma regrew away from the original tumor Gan No Rinsho 1989, 35, 1255 1260
        (d) Silbergeld, D. L.; Chicoine, M. R. Isolation and characterization of human malignant glioma cells from histologically normal brain J. Neurosurg. 1997, 86, 525 531 DOI: 10.3171/jns.1997.86.3.0525
        (e) Lucio-Eterovic, A. K.; Piao, Y.; de Groot, J. F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Clin. Cancer Res. 2009, 15, 4589 4599 DOI: 10.1158/1078-0432.CCR-09-0575
      8. 8
        Rankovic, Z. CNS Drug Design: Balancing physicochemical properties for optimal brain exposure J. Med. Chem. 2015, 58, 2584 2608 DOI: 10.1021/jm501535r
      9. 9
        Levin, V. A.; Tonge, P. T.; Gallo, J. M.; Birtwistle, M. R.; Dar, A. C.; Iavarone, A.; Paddison, P. J.; Heffron, T. P.; Elmquist, W. F.; Lachowicz, J. E.; Johnson, T. W.; White, F. M.; Sul, J.; Smith, Q. R.; Shen, W.; Sarkaria, J. N.; Samala, R.; Wen, P. Y.; Berry, D. A.; Petter, R. C. CNS anticancer drug discovery and development conference white paper Neuro-Oncology 2015, 17, vi1 vi26 DOI: 10.1093/neuonc/nov169
      10. 10
        (a) Sun, H.; Dai, H.; Shaik, N.; Elmquist, W. F. Drug efflux transporters in the CNS Adv. Drug Delivery Rev. 2003, 55, 83 105 DOI: 10.1016/S0169-409X(02)00172-2
        (b) He, H.; Lyons, K. A.; Shen, X.; Yao, Z.; Bleasby, K.; Chan, G.; Hafey, M.; Li, X.; Xu, S.; Salituro, G. M.; Cohen, L. H.; Tang, W. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure Xenobiotica 2009, 39, 687 693 DOI: 10.1080/00498250903015402
        (c) Kodaira, H.; Kusuhara, H.; Fujita, T.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate J. Pharmacol. Exp. Ther. 2011, 339, 935 944 DOI: 10.1124/jpet.111.180398
      11. 11
        Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the “gatekeeper door”: exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681 2694 DOI: 10.1021/jm901443h
      12. 12
        (a) Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420 434 DOI: 10.1021/cn100007x
        (b) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435 449 DOI: 10.1021/cn100008c
      13. 13
        (a)

        For inhibitors approved through 2014:

        Wu, P.; Nielsen, T. E.; Clausen, M. H. FDA-approved small-molecule kinase inhibitors Trends Pharmacol. Sci. 2015, 36, 422 439 DOI: 10.1016/j.tips.2015.04.005
        (b)

        For inhibitors approved in 2015:

        http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm (accessed June 12, 2016) .
      14. 14
        Bridges, A. J. Chemical inhibitors of protein kinases Chem. Rev. 2001, 101, 2541 2572 DOI: 10.1021/cr000250y
      15. 15
        Cole, S.; Bagal, S.; El-Kattan, A.; Fenner, K.; Hay, T.; Kempshall, S.; Lunn, G.; Varma, M.; Stupple, P.; Speed, W. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration Xenobiotica 2012, 42, 11 27 DOI: 10.3109/00498254.2011.617847
      16. 16
        Huszthy, P. C.; Daphu, I.; Niclou, S. P.; Stieber, D.; Nigro, J. M.; Sakariassen, P.; Miletic, H.; Thorsen, F.; Bjerkvig, R. In vivo models of primary brain tumors: pitfalls and perspectives Neuro-Oncology 2012, 14, 979 993 DOI: 10.1093/neuonc/nos135
      17. 17
        Lee, J.; Kotilarova, S.; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N. M.; Pastorino, S.; Purow, B. W.; Christopher, N.; Zhang, W.; Park, J. K.; Fine, H. A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 2006, 9, 391 403 DOI: 10.1016/j.ccr.2006.03.030
      18. 18
        Jain, R. K.; di Tomaso, E.; Duda, D. G.; Loeffler, J. S.; Sorensen, A. G.; Batchelor, T. T. Angiogenesis in brain tumors Nat. Rev. Neurosci. 2007, 8, 610 622 DOI: 10.1038/nrn2175
      19. 19
        (a) Huang, H.; Held-Feindt, J.; Buhl, R.; Mehdorn, H. M.; Mentlein, R. Expression of VEGF and its receptors in different brain tumors Neurol. Res. 2005, 27, 371 377 DOI: 10.1179/016164105X39833
        (b) Tuettenberg, J.; Friedel, C.; Vajkoczy, P. Angiogenesis in malignant glioma-a target for antitumor therapy? Crit. Rev. Oncol. Hematol. 2006, 59, 181 193 DOI: 10.1016/j.critrevonc.2006.01.004
      20. 20
        Barrios, C. H.; Viola, F. S.; Coutinho, L. M.; Paglioli, E. Determination of expression of platelet derived growth factor receptors (PDGFR) in astrocytic tumors J. Clin. Oncol. 2006, 24 (Suppl.) 11518
      21. 21
        Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. J.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H. P.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jurgensmeier, J. M.; Ogilvie, D. J. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res. 2005, 65, 4389 4400 DOI: 10.1158/0008-5472.CAN-04-4409
      22. 22
        Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; Hunter, R. N.; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor J. Med. Chem. 2008, 51, 4632 4640 DOI: 10.1021/jm800566m
      23. 23
        Mulholland, P.; Batchelor, T. T.; Neyns, B. A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients Proc. ESMO Ann. Oncol. 2010, 21, LBA7
      24. 24
        Iwamoto, F. M.; Lamborn, K. R.; Robins, H. I.; Mehta, M. P.; Chang, S. M.; Butowski, N. A.; DeAngelis, L. M.; Abrey, L. E.; Zhang, W.-T.; Prados, M. D.; Fine, H. A. Phase II trial of pazopanib (GW786034), and oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06–02) Neuro Oncol. 2010, 12, 855 861 DOI: 10.1093/neuonc/noq025
      25. 25
        Wang, T.; Agarwal, S.; Elmquist, W. F. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier J. Pharmacol. Exp. Ther. 2012, 341, 386 395 DOI: 10.1124/jpet.111.190488
      26. 26
        Minocha, M.; Khurana, V.; Qin, B.; Pal, D.; Mitra, A. K. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib Int. J. Pharm. 2012, 436, 127 134 DOI: 10.1016/j.ijpharm.2012.05.038
      27. 27
        Atkins, M.; Jones, C. A.; Kirkpatrick, P. Sunitinib maleate Nat. Rev. Drug Discovery 2006, 5, 279 280 DOI: 10.1038/nrd2012
      28. 28
        Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discovery 2006, 5, 835 844 DOI: 10.1038/nrd2130
      29. 29
        Roth, G. J.; Binder, R.; Colbatzky, F.; Dallinger, C.; Schlenker-Herceq, R.; Hilberg, F.; Wollin, S. L.; Kaiser, R. Nintedanib: from discovery to the clinic J. Med. Chem. 2015, 58, 1053 1063 DOI: 10.1021/jm501562a
      30. 30
        Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; Suzuki, R.; Kubo, K.; Shibuya, M.; Isae, T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties Cancer Res. 2006, 66, 9134 9142 DOI: 10.1158/0008-5472.CAN-05-4290
      31. 31
        Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.; Jazan, E. M.; Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier, K.; Wiesmann, M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.; Heise, C. C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.; Jansen, J. M.; Wernette-Hammond, M. E.; Harris, A. L. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors J. Med. Chem. 2009, 52, 278 292 DOI: 10.1021/jm800790t
      32. 32
        (a) Balana, C.; Gil, M. J.; Reynes, G.; Capellades, J.; Ribalta, T.; Gallego, O.; Segura, P. P.; Verger, E. A phase II multicentric study of sunitinib administered as upfront therapy in glioblastoma: a study by the GEINO group J. Clin. Oncol. 2012, 30, 2045
        (b) Kreisl, T. N.; Smith, P.; Sul, J.; Salgado, C.; Iwamoto, F. M.; Shih, J. H.; Fine, H. A. Continuous daily sunitinib for recurrent glioblastoma J. Neuro-Oncol. 2013, 111, 41 48 DOI: 10.1007/s11060-012-0988-z
        (c) Reardon, D. A.; Vredenburgh, J. J.; Coan, A.; Desjardins, A.; Peters, K. B.; Gururangan, S.; Sathornsumetee, S.; Rich, J. N.; Herndon, J. E.; Friedman, H. S. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma J. Neuro-Oncol. 2011, 105, 621 627 DOI: 10.1007/s11060-011-0631-4
      33. 33
        (a) Lee, E. Q.; Kuhn, J.; Lamborn, K. R.; Abrey, L.; DeAngelis, L. M.; Lieberman, F.; Robins, H. I.; Chang, S. M.; Yung, W. K. A.; Drappatz, J.; Mehta, M. P.; Levin, V. A.; Aldape, K.; Dancey, J. E.; Wright, J. J.; Prados, M. D.; Cloughesy, T. F.; Gilbert, M. R.; Wen, P. Y. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 Neuro-Oncology 2012, 14, 1511 1518 DOI: 10.1093/neuonc/nos264
        (b) Hainsworth, J. D.; Ervin, T.; Friedman, E.; Priego, V.; Murphy, P. B.; Clark, B. L.; Lamar, R. E. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme Cancer 2010, 116, 3663 3669 DOI: 10.1002/cncr.25275
      34. 34
        Muhic, A.; Poulsen, H. S.; Sorensen, M.; Grunnet, K.; Lassen, U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme J. Neuro-Oncol. 2013, 111, 205 212 DOI: 10.1007/s11060-012-1009-y
      35. 35
        Cai, X.; Chandra, V.; Ou, Y.; Emblem, K. E.; Muzikansky, A.; Evans, J.; Kalpathy-Cramer, J.; Dietrich, J.; Chi, A. S.; Wen, P. Y.; Rosen, B. R.; Batchelor, T.; Gerstner, E. R.; Martinos, A. A. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma J. Clin. Oncol. 2015, 33 (Suppl.) 2025
      36. 36
        Ahluwalia, M. S.; Papadantonakis, N.; Venur, V. A.; Schilero, C.; Peereboom, D. M.; Stevens, G.; Rosenfeld, S.; Vogelbaum, M. A.; Elson, P.; Nixon, A. B.; McCrae, K. Phase II trial of dovitinib in recurrent glioblastoma J. Clin. Oncol. 2015, 33 (Suppl.) 2050
      37. 37
        (a) Oberoi, R. K.; Mittapalli, R. K.; Fisher, J.; Elmquist, W. F. Sunitinib LC-MS/MS assay in mouse plasma and brain tissue: application in CNS distribution studies Chromatographia 2013, 76, 1657 1665 DOI: 10.1007/s10337-013-2528-1
        (b) Tang, S. C.; Lagas, J. S.; Lankheet, N. A. G.; Poller, B.; Hillebrand, M. J.; Rosing, H.; Bejinen, J. H.; Schinkel, A. H. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration Int. J. Cancer 2012, 130, 223 233 DOI: 10.1002/ijc.26000
      38. 38
        (a) Lagas, J. S.; van Waterschoot, R. A. B.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation Mol. Cancer Ther. 2010, 9, 319 326 DOI: 10.1158/1535-7163.MCT-09-0663
        (b) Agarwal, S.; Sane, R.; Ohlfest, J. R.; Elmquist, W. F. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain J. Pharmacol. Exp. Ther. 2011, 336, 223 233 DOI: 10.1124/jpet.110.175034
        (c) Asakawa, C.; Ogawa, M.; Kumata, K.; Fujinaga, M.; Kato, K.; Yamasaki, T.; Yui, J.; Kawamura, K.; Hatori, A.; Fukumura, T.; Zhang, M.-R. [11C]Sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice Bioorg. Med. Chem. Lett. 2011, 21, 2220 2223 DOI: 10.1016/j.bmcl.2011.03.002
      39. 39
        Hussar, D. A.; Jeon, M. M. Naloxegol oxalate, pirfenidone, and nintedanib J. Am. Pharm. Assoc. 2015, 55, 461 463 DOI: 10.1331/JAPhA.2015.15523
      40. 40
        Helgason, H. H.; Mallo, H. A.; Droogendijk, H.; Haanen, J. G.; van der Veldt, A. A. M.; van den Eertwegh, A. J.; Boven, E. Brain metastases in patients with renal cell cancer receiving new targeted treatment J. Clin. Oncol. 2008, 26, 152 154 DOI: 10.1200/JCO.2007.13.5814
      41. 41
        Wilhelm, S. M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C. A.; Schutz, G.; Thierauch, K. H.; Zopf, D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int. J. Cancer 2011, 129, 245 255 DOI: 10.1002/ijc.25864
      42. 42
        EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003722-41 (accessed June 9, 2016) .
      43. 43
        Kort, A.; Durmus, S.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Pharm. Res. 2015, 32, 2205 2216 DOI: 10.1007/s11095-014-1609-7
      44. 44
        Yang, J. J.; Milton, M. N.; Liao, M.; Liu, N.; Wu, J. T.; Gan, L.; Balani, S. K.; Lee, F. W.; Prakash, S.; Xia, C. Q. P-glycloprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor Drug Metab. Lett. 2010, 4, 202 212 DOI: 10.2174/187231210792928279
      45. 45
        Supko, J. G.; Grossman, S. A.; Peereboom, D. M.; Chowdhary, S.; Lesser, G. J.; Nabors, L. B.; Mikkelsen, T.; Desideri, S.; Batchelor, T. T. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma J. Clin. Oncol. 2009, 27 (15s) 2039
      46. 46
        Lu, L.; Saha, D.; Martuza, R. L.; Rabkin, S. D.; Wakimoto, H. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma J. Neuro-Oncol. 2015, 121, 91 100 DOI: 10.1007/s11060-014-1612-1
      47. 47
        Zakharia, Y.; Zakharia, K.; Rixe, O. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma Expert Opin. Drug Discovery 2015, 10, 925 935 DOI: 10.1517/17460441.2015.1045411
      48. 48
        Neyns, B.; Duerinck, J.; Du Four, S.; Bouttens, F.; Verschaeve, V.; Everaert, H.; Van Binst, A. Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma J. Clin. Oncol. 2014, 32 (Suppl.) 2018
      49. 49
        Poller, B.; Iusuf, D.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics Drug Metab. Dispos. 2011, 39, 729 735 DOI: 10.1124/dmd.110.037317
      50. 50
        Sim, M. W.; Cohen, M. S. The discovery and development of vandetanib for the treatment of thyroid cancer Expert Opin. Drug Discovery 2014, 9, 105 114 DOI: 10.1517/17460441.2014.866942
      51. 51
        Matsui, J.; Yamamoto, Y.; Funahashi, Y.; Tsuruoka, A.; Watanabe, T.; Wakabayashi, T.; Uenaka, T.; Asada, M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition Int. J. Cancer 2008, 122, 664 671 DOI: 10.1002/ijc.23131
      52. 52
        (a) Drappatz, J.; Norden, A. D.; Wong, E. T.; Doherty, L. M.; LaFrankie, D. C.; Ciampa, A.; Kesari, S.; Sceppa, C.; Gerard, M.; Phan, P.; Schiff, D.; Batchelor, T. T.; Ligon, K. L.; Young, G.; Muzikansky, A.; Weiss, S. E.; Wen, P. Y. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma Int. J. Radiat. Oncol., Biol., Phys. 2010, 78, 85 90 DOI: 10.1016/j.ijrobp.2009.07.1741
        (b) Chheda, M. G.; Wen, P. Y.; Hochberg, F. H.; Chi, A. S.; Drappatz, J.; Eichler, A. F.; Yang, D.; Beroukhim, R.; Norden, A. D.; Gerstner, E. R.; Betensky, R. A.; Batchelor, T. T. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study J. Neuro-Oncol. 2015, 121, 627 634 DOI: 10.1007/s11060-014-1680-2
        (c) Kreisl, T. N.; McNeill, K. A.; Sul, J.; Iwamoto, F. M.; Shih, J.; Fine, H. A. A phase I/II trial of vandetanib for patients with recurrent malignant glioma Neuro-Oncology 2012, 14, 1519 1526 DOI: 10.1093/neuonc/nos265
        (d) Subbiah, V.; Berry, J.; Roxas, M.; Guha-Thakurta, N.; Subbiah, I. M.; Ali, S. M.; McMahon, C.; Miller, V.; Cascone, T.; Pai, S.; Tang, Z.; Heymach, J. V. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases Lung Cancer 2015, 89, 76 79 DOI: 10.1016/j.lungcan.2015.04.004
      53. 53
        Reardon, D. A.; Pan, E.; Fan, J.; Mink, J.; Barboriak, D. P.; Vrendenburgh, J. J.; Desjardins, A.; Peters, K.; O’Brien, J. P.; Wen, P. Y. A phase 2 trial of the multitargeted kinase inhibitor lenvatinib (E7080) in patients with recurrent glioblastoma (GBM) and disease progression following prior bevacizumab treatment Ann. Oncol. 2012, 23 (Suppl. 9) 417PD
      54. 54
        Minocha, M.; Khurana, V.; Qin, B.; Pal, D.; Mitra, A. K. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors Int. J. Pharm. 2012, 434, 306 314 DOI: 10.1016/j.ijpharm.2012.05.028
      55. 55
        Shumaker, R. C.; Aluri, J.; Fan, J.; Martinez, G.; Thompson, G. A.; Ren, M. Effect of fifampicin on the pharmacokinetics of lenvatinib in healthy adults Clin. Drug Invest. 2014, 34, 651 659 DOI: 10.1007/s40261-014-0217-y
      56. 56
        Banerjee, S.; Zvelebil, M.; Furet, P.; Mueller-Vieira, U.; Evans, D. B.; Dowsett, M.; Martin, L. A. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase Cancer Res. 2009, 69, 4716 4723 DOI: 10.1158/0008-5472.CAN-08-4711
      57. 57
        (a) Gerstner, E. R.; Eichler, A. F.; Plotkin, S. R.; Drappatz; Doyle, C. L.; Xu, L.; Duda, D. G.; Wen, P. Y.; Jain, R. K.; Batchelor, T. T. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide J. Neuro-Oncol. 2011, 103, 325 332 DOI: 10.1007/s11060-010-0390-7
        (b) Brandes, A. A.; Stupp, R.; Hau, P.; Lacombe, D.; Gorlia, T.; Tosoni, A.; Mirimanoff, R. O.; Kros, J. M.; van den Bent, M. J. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma Eur. J. Cancer 2010, 46, 348 354 DOI: 10.1016/j.ejca.2009.10.029
        (c) Reardon, D. A.; Egorin, M. J.; Desjardins, A.; Vredenburgh, J. J.; Beumer, J. H.; Lagattuta, T. F.; Gururangan, S.; Herndon, J. E.; Salvado, A. J.; Friedman, H. S. Phase I pharmacokinetic study of the VEGFR tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma Cancer 2009, 115, 2188 2198 DOI: 10.1002/cncr.24213
      58. 58
        Yakes, F. M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A. D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y. C.; Joly, A. H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol. Cancer Ther. 2011, 10, 2298 2308 DOI: 10.1158/1535-7163.MCT-11-0264
      59. 59
        Bhide, R. S.; Cai, Z. W.; Zhang, Y. Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L. J.; Borzilleri, R. M.; Zheng, X.; Wu, L. I.; Barrish, J. C.; Kim, S. H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R.; Kukral, D.; Hunt, J. T.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D’Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor J. Med. Chem. 2006, 49, 2143 2146 DOI: 10.1021/jm051106d
      60. 60
        Highlights of Prescribing Information. COMETRIQ. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf (accessed June 12, 2016) .
      61. 61
        Marathe, P. H.; Kamath, A. V.; Zhang, Y.; D’Arienzo, C.; Bhide, R.; Fargnoli, J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate Cancer Chemother. Pharmacol. 2009, 65, 55 66 DOI: 10.1007/s00280-009-1002-0
      62. 62
        (a) De Groot, J. F.; Prados, M.; Urquhart, T.; Robertson, S.; Yaron, Y.; Sorensen, A. G.; Norton, A.; Batchelor, T.; Drappatz, J.; Wen, P. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse J. Clin. Oncol. 2009, 27 (15s) 2047
        (b) Wen, P. Y.; Prados, M.; Schiff, D.; Reardon, D. A.; Cloughesy, T.; Mikkelsen, T.; Batchelor, T.; Drappatz, J.; Chamberlain, M. C.; De Groot, J. F. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) J. Clin. Oncol. 2010, 28, 2006
      63. 63
        Dowell, J.; Minna, J. D.; Kirkpatrick, P. Erlotinib hydrochloride Nat. Rev. Drug Discovery 2005, 4, 13 14 DOI: 10.1038/nrd1612
      64. 64
        Muhsin, M.; Graham, J.; Kirkpatrick, P. Gefitinib Nat. Rev. Drug Discovery 2003, 2, 515 516 DOI: 10.1038/nrd1136
      65. 65
        Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gieterma, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors Br. J. Cancer 2008, 98, 80 85 DOI: 10.1038/sj.bjc.6604108
      66. 66
        Finlay, M. R. V.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M. R.; Bradbury, R. H.; Brown, S. J.; Butterworth, S.; Campbell, A.; Chorley, C.; Colclough, N.; Cross, D. A. E.; Currie, G. S.; Grist, M.; Hassall, L.; Hill, G. B.; James, D.; James, M.; Kemmitt, P.; Klinowska, T.; Lamont, G.; Lamont, S. G.; Martin, N.; McFarland, H. L.; Mellor, M. J.; Orme, J. P.; Perkins, D.; Perkins, P.; Richmond, G.; Smith, P.; Ward, R. A.; Waring, M. J.; Whittaker, D.; Wells, S.; Wrigley, G. L. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor J. Med. Chem. 2014, 57, 8249 8267 DOI: 10.1021/jm500973a
      67. 67
        (a) Bartolotti, M.; Franceschi, E.; Brandes, A. A. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer Expert Rev. Anticancer Ther. 2012, 12, 1429 1435 DOI: 10.1586/era.12.121
        (b) Shimato, S.; Mitsudomi, T.; Kosaka, T.; Yatabe, Y.; Wakabayashi, T.; Mizuno, M.; Nakahara, N.; Hatano, H.; Natsume, A.; Ishii, D.; Yoshida, J. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib Neuro-Oncology 2006, 8, 137 144 DOI: 10.1215/15228517-2005-002
        (c) Porta, R.; Sanchez-Torres, J. M.; Paz-Ares, L.; Massuti, B.; Reguart, N.; Mayo, C.; Lianes, P.; Queralt, C.; Guillem, V.; Salinas, P.; Catot, S.; Isla, D.; Pradas, A.; Gurpide, A.; de Castro, J.; Polo, E.; Puig, T.; Taron, M.; Colomer, R.; Rosell, R. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Eur. Respir. J. 2011, 37, 624 631 DOI: 10.1183/09031936.00195609
        (d) Grommes, C.; Oxnard, G. R.; Kris, M. G.; Miller, V. A.; Pao, W.; Holodny, A. I.; Clarke, J. L.; Lassman, A. B. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer Neuro-Oncology 2011, 13, 1364 1369 DOI: 10.1093/neuonc/nor121
        (e) Jackman, D. M.; Holmes, A. J.; Lindeman, N.; Wen, P. Y.; Kesari, S.; Borras, A. M.; Bailey, C.; de Jong, F.; Janne, P. A.; Johnson, B. E. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib J. Clin. Oncol. 2006, 24, 4517 4520 DOI: 10.1200/JCO.2006.06.6126
        (f) Park, S. J.; Kim, H. T.; Lee, D. H.; Kim, K. P.; Kim, S.-W.; Suh, C.; Lee, J. S. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer. 2012, 77, 556 560 DOI: 10.1016/j.lungcan.2012.05.092
      68. 68
        Noronha, V.; Joshi, A.; Gokarn, A.; Sharma, V.; Patil, V.; Janu, A.; Purandare, N.; Chougule, A.; Jambhekar, N.; Prabhash, K. The importance of brain metastasis in EGFR mutation positive NSCLC patients Chemother. Res. Pract. 2014, 2014, 856156 DOI: 10.1155/2014/856156
      69. 69
        Weber, B.; Winterdahl, M.; Memon, A.; Sorensen, B. S.; Keiding, S.; Sorensen, L.; Nexo, E.; Meldgaard, P. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor J. Thorac. Oncol. 2011, 6, 1287 1289 DOI: 10.1097/JTO.0b013e318219ab87
      70. 70
        Agarwal, S.; Manchanda, P.; Vogelbaum, M. A.; Ohlfest, J. R.; Elmquist, W. F. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma Drug Metab. Dispos. 2013, 41, 33 39 DOI: 10.1124/dmd.112.048322
      71. 71
        Agarwal, S.; Sane, R.; Gallardo, J. L.; Ohlfest, J. R.; Elmquist, W. F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux J. Pharmacol. Exp. Ther. 2010, 334, 147 155 DOI: 10.1124/jpet.110.167601
      72. 72
        Peters, S.; Zimmerman, S.; Adjei, A. A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions Cancer Treat. Rev. 2014, 40, 917 926 DOI: 10.1016/j.ctrv.2014.06.010
      73. 73
        Highlights of Prescribing Information. TAGRISSO. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf Accessed June 12, 2016.
      74. 74
        Hoffknecht, P.; Tufman, A.; Wehler, T.; Pelzer, T.; Wiewrodt, R.; Schutz, M.; Serke, M.; Stohlmacher-Williams, J.; Marten, A.; Huber, R. M.; Dickgreber, N. J. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease J. Thorac. Oncol. 2015, 10, 156 163 DOI: 10.1097/JTO.0000000000000380
      75. 75
        Hatanpaa, K. J.; Burma, S.; Zhao, D.; Habib, A. A. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance Neoplasia 2010, 12, 675 684 DOI: 10.1593/neo.10688
      76. 76
        (a) Mellinghoff, I. K.; Wang, M. Y.; Vivanco, I.; Haas-Kogan, D. A.; Zhu, S.; Dia, E. Q.; Lu, K. V.; Yoshimoto, K.; Huang, J. H. Y.; Chute, D. J.; Riggs, B. L.; Horvatch, S.; Liau, L. M.; Cavanee, W. K.; Rao, P. N.; Beroukhim, R.; Peck, T. C.; Lee, J. C.; Sellers, W. R.; Stokoe, D.; Prados, M.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N. Engl. J. Med. 2005, 353, 2012 2024 DOI: 10.1056/NEJMoa051918
        (b) Rich, J. N.; Reardon, D. A.; Peery, T.; Dowell, J. M.; Quinn, J. A.; Penne, K. L.; Wikstrand, C. J.; Van Duyn, L. B.; Dancey, J. E.; McLendon, R. E.; Kao, J. C.; Stenzel, T. T.; Rasheed, B. K. A.; Tourt-Uhlig, S. E.; Herndon, J. E.; Vredenburgh, J. J.; Sampson, J. H.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S. Phase II trial of gefitinib in recurrent glioblastoma J. Clin. Oncol. 2004, 22, 133 142 DOI: 10.1200/JCO.2004.08.110
      77. 77
        Walter, A. O.; Sjin, R. T.; Haringsma, H. J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovsky, A.; Labenski, M.; Zhu, Z.; Wang, Z.; Sheets, M.; St Martin, T.; Karp, R.; van Kalken, D.; Chaturvedi, P.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W.; Lin, K.; Jaw-Tsai, S.; Raponi, M.; Van Dyke, T.; Etter, J.; Weaver, Z.; Pao, W.; Singh, J.; Simmons, A. D.; Harding, T. C.; Allen, A. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discovery 2013, 3, 1404 1415 DOI: 10.1158/2159-8290.CD-13-0314
      78. 78
        (a) Yoshida, Y.; Ozawa, T.; Butowski, N.; Shen, W.; Brown, D.; Pederson, H.; James, D. Preclinical evaluation of NT-113, a novel ERBB inhibitor optimized for CNS biodistribution Neuro-Oncology 2013, 15 (Suppl.) ET-00
        (b) Yoshida, Y.; Ozawa, T.; Yao, T.-W.; Shen, W.; Brown, D.; Parsa, A. T.; Raizer, J. J.; Cheng, S.-Y.; Stegh, A. H.; Mazar, A. P.; Giles, F. J.; Sarkaria, J. N.; Butowski, N.; Nicolaides, T.; James, C. D. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification Mol. Cancer Ther. 2014, 13, 2919 2929 DOI: 10.1158/1535-7163.MCT-14-0306
      79. 79
        Zeng, Q.; Wang, J.; Cheng, Z.; Chen, K.; Johnstrom, P.; Varnas, K.; Li, D. Y.; Yang, Z. F.; Zhang, X. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor J. Med. Chem. 2015, 58, 8200 8215 DOI: 10.1021/acs.jmedchem.5b01073
      80. 80
        Ströbele, S.; Schneider, M.; Schneele, L.; Siegelin, M. D.; Nonnenmacher, L.; Zhou, S.; Karpel-Massle, G.; Westhoff, M.-A.; Halatsch, M.-E.; Debatin, K.-M. A potential role for the inhibition of PI3K signaling in glioblastoma therapy PLoS One 2015, 10, e0131670 DOI: 10.1371/journal.pone.0131670
      81. 81
        Akhavan, D.; Cloughesy, T. F.; Mischel, P. S. mTOR signaling in glioblastoma: lessons learned from bench to bedside Neuro-Oncology 2010, 12, 882 889 DOI: 10.1093/neuonc/noq052
      82. 82
        The Cancer Genome Atlas Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 2008, 455, 1061 1068 DOI: 10.1038/nature07385
      83. 83
        Westhoff, M.-A.; Karpel-Massler, G.; Brühl, O.; Enzenmüller, S.; La Ferla-Brühl, K.; Siegelin, M. D.; Nonnenmacher, L.; Debatin, K.-M. A critical evaluation of PI3K inhibition in glioblastoma and neruoblastoma therapy Mol. Cell. Ther. 2014, 2, 32 DOI: 10.1186/2052-8426-2-32
      84. 84
        Mohd Sharial, M. S. N.; Crown, J.; Hennessy, B. T. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer Ann. Oncol. 2012, 23, 3007 3016 DOI: 10.1093/annonc/mds200
      85. 85
        Wen, P. Y.; Lee, E. Q.; Reardon, D. A.; Ligon, K. L.; Yung, W. K. A. Current clinical development of PI3K pathway inhibitors in glioblastoma Neuro-Oncology 2012, 14, 819 829 DOI: 10.1093/neuonc/nos117
      86. 86
        Heffron, T. P.; Ndubaku, C. O.; Salphati, L.; Alicke, B.; Cheong, J.; Drobnick, J.; Edgar, K.; Gould, S. E.; Lee, L. B.; Lesnick, J. D.; Lewis, C.; Nonomiya, J.; Pang, J.; Plise, E. G.; Sideris, S.; Wallin, J.; Wang, L.; Zhang, X.; Olivero, A. G. Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR ACS Med. Chem. Lett. 2016, 7, 351 356 DOI: 10.1021/acsmedchemlett.6b00005
      87. 87
        Burger, M. T.; Pecchi, S.; Wagman, A.; Ni, Z.-J.; Knapp, M.; Hendrickson, T.; Atallah, G.; Pfister, K.; Zhang, Y.; Bartulis, S.; Frazier, K.; Ng, S.; Smith, A.; Verhagen, J.; Haznedar, J.; Huh, K.; Iwanowicz, E.; Xin, X.; Menezes, D.; Merritt, H.; Lee, I.; Wiesmann, M.; Kaufman, S.; Crawford, K.; Chin, M.; Bussiere, D.; Shoemaker, K.; Zaror, I.; Maira, S.-M.; Voliva, C. F. Identification of NVP-BKM120 as a potent, selective, orally bioavailable Class I PI3 kinase inhibitor for treating cancer ACS Med. Chem. Lett. 2011, 2, 774 779 DOI: 10.1021/ml200156t
      88. 88
        Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol. Cancer Ther. 2004, 3, 763 772
      89. 89
        Foster, P.; Yamaguchi, K.; Hsu, P. P.; Qian, F.; Du, X.; Wu, J.; Won, K. A.; Yu, P.; Jaeger, C. T.; Zhang, W.; Marlowe, C. K.; Keast, P.; Abulafia, W.; Chen, J.; Young, J.; Plonowski, A.; Yakes, F. M.; Chu, F.; Engell, K.; Bentzien, F.; Lam, S. T.; Dale, S.; Yturralde, O.; Matthews, D. J.; Lamb, P.; Laird, A. D. The selective PI3K inhibitor XL147 (SAR245408) inhibits tumor growth and survival and potentiates the activity of chemotherapeutic agents in preclinical models Mol. Cancer Ther. 2015, 14, 931 940 DOI: 10.1158/1535-7163.MCT-14-0833
      90. 90
        Yu, P.; Laird, A. D.; Du, X.; Wu, J.; Won, K.; Yamaguchi, K.; Hsu, P. P.; Qian, F.; Jaeger, C. T.; Zhang, W.; Buhr, C. A.; Shen, P.; Abulafia, W.; Chen, J.; Young, J.; Plonowski, A.; Yakes, F. M.; Chu, F.; Lee, M.; Bentzien, F.; Lam, S. T.; Dale, S.; Matthews, D. J.; Lamb, P.; Foster, P. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway Mol. Cancer Ther. 2014, 13, 1078 1091 DOI: 10.1158/1535-7163.MCT-13-0709
      91. 91
        Lin, N. U. Targeted therapies in brain metastases Curr. Treat. Options Neurol. 2014, 16, 276 DOI: 10.1007/s11940-013-0276-z
      92. 92
        Sutherlin, D. P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W. W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V.; Wan, N. C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B.-Y. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer J. Med. Chem. 2010, 53, 1086 1097 DOI: 10.1021/jm901284w
      93. 93
        Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J. Med. Chem. 2008, 51, 5522 5532 DOI: 10.1021/jm800295d
      94. 94
        (a) Heffron, T. P.; Salphati, L.; Alicke, B.; Cheong, J.; Dotson, J.; Edgar, K.; Goldsmith, R.; Gould, S. E.; Lee, L. B.; Lesnick, J. D.; Lewis, C.; Ndubaku, C. O.; Nonomiya, J.; Olivero, A. G.; Pang, J.; Plise, E. G.; Sideris, S.; Trapp, S.; Wallin, J.; Wang, L.; Zhang, X. The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase a J. Med. Chem. 2012, 55, 8007 8020 DOI: 10.1021/jm300867c
        (b) Salphati, L.; Heffron, T. P.; Alicke, B.; Nishimura, M.; Barck, K.; Carano, R. A.; Cheong, J.; Edgar, K.; Greve, J.; Kharbanda, S.; Koeppen, H.; Lau, S.; Lee, L. B.; Pang, J.; Plise, E. G.; Pokorny, J. L.; Reslan, H. B.; Sarkaria, J. N.; Wallin, J. J.; Zhang, X.; Gould, S. E.; Olivero, A. G.; Phillips, H. S. Targeting the PI3K pathway in the brain – efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier Clin. Cancer Res. 2012, 18, 6239 6248 DOI: 10.1158/1078-0432.CCR-12-0720
      95. 95
        Maira, M.; Schnell, C.; Lollini, P.; Chouaid, C.; Schmid, P.; Nanni, P.; Lam, D.; Di Tomaso, E.; C. Massacesi, C.; Rodon, J. Preclinical and preliminary clinical activity of NVP-BKM-120, an oral pan-class I PI3K inhibitor, in the brain Ann. Oncol. 2012, 23 (Suppl.) 1675
      96. 96
        Wen, P. Y.; Yung, W. K. A.; Mellinghoff, I. K.; Ramkissoon, S.; Alexander, B. M.; Rinne, M. L.; Colman, H.; Omuro, A. M. P.; DeAngelis, L. M.; Gilbert, M. R.; De Groot, J. F.; Cloughesy, T. F.; Chi, A. S.; Lee, E. Q.; Nayak, L.; Betchelor, T.; Chang, S. M.; Prados, M.; Reardon, D. A.; Ligon, K. Phase II trial of the phosphatidylinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma J. Clin. Oncol. 2014, 32 (Suppl.) 2019
      97. 97
        Cmiljanovic, V.; Cmiljanovic, N.; Marone, R.; Beaufils, F.; Zhang, X.; Zvelebil, M.; Hebeisen, P.; Lang, M.; Mestan, J.; Melone, A.; Bohnacker, T.; Gaudio, E.; Tarantelli, C.; Bertoni, F.; Ritschard, R.; Pretre, V.; Wicki, A.; Fabbro, D.; Hillmann, P.; Williams, R.; Giese, B.; Wymann, M. P. Abstract 2664: PQR309: structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor Cancer Res. 2015, 75 (Suppl.) 2664 DOI: 10.1158/1538-7445.AM2015-2664
      98. 98
        Cmiljanovic, V.; Ettlin, R. A.; Beaufils, F.; Dieterle, W.; Hillmann, P.; Mestan, J.; Melone, A.; Bohnacker, T.; Lang, M.; Cmiljanovic, N.; Giese, B.; Hebeisen, P.; Wymann, M. P.; Fabbro, D. Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability Cancer Res. 2015, 75 (Suppl.) 4514 DOI: 10.1158/1538-7445.AM2015-4514
      99. 99
        Lannutti, B. J.; Meadows, S. A.; Herman, S. E. M.; Kashishian, A.; Steiner, B.; Johnson, A. J.; Byrd, J. C.; Tyner, J. W.; Loriaux, M. M.; Deininger, M.; Druker, B. J.; Puri, K. D.; Ulrich, R. G.; Giese, N. A. CAL-101, a p100d selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 2011, 117, 591 594 DOI: 10.1182/blood-2010-03-275305
      100. 100
        Janssens, A. Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice Belg. J. Hematol. 2015, 6, 216 224
      101. 101
        Highlights of Prescribing Information. Zydelig. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf (accessed June 12, 2016) .
      102. 102
        Benjamin, D.; Colombi, M.; Moroni, C.; Hall, M. H. Rapamycin passes the torch: a new generation of mTOR inhibitors Nat. Rev. Drug Discovery 2011, 10, 868 880 DOI: 10.1038/nrd3531
      103. 103
        Crowe, A.; Lemaire, M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin Pharm. Res. 1998, 15, 1666 1672 DOI: 10.1023/A:1011940108365
      104. 104
        Pike, K. G.; Malagu, K.; Hummersone, M. G.; Menear, K. A.; Duggan, H. M.; Gomez, S.; Martin, N. M.; Ruston, L.; Pass, S. L.; Pass, M. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014 Bioorg. Med. Chem. Lett. 2013, 23, 1212 1216 DOI: 10.1016/j.bmcl.2013.01.019
      105. 105
        Mortensen, D. S.; Perrin-Ninkovic, S. M.; Shevlin, G.; Zhao, J.; Packard, G.; Bahmanyar, S.; Correa, M.; Elsner, J.; Harris, R.; Lee, B. G. S.; Papa, P.; Parnes, J. S.; Riggs, J. R.; Sapienza, J.; Tehrani, L.; Whitefield, B.; Apuy, J.; Bisonette, R. R.; Gamez, J. C.; Hickman, M.; Khambatta, G.; Leisten, J.; Peng, S. X.; Richardson, S. J.; Cathers, B. E.; Canan, S. S.; Moghaddam, M. F.; Raymon, H. K.; Worland, P.; Narla, R. K.; Fultz, K. E.; Sankar, S. Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223 J. Med. Chem. 2015, 58, 5323 5333 DOI: 10.1021/acs.jmedchem.5b00626
      106. 106
        https://clinicaltrials.gov/ct2/show/NCT02619864 (accessed June 12, 2016) .
      107. 107
        Varga, A.; Mita, M. M.; Wu, J. J.; Nemunaitis, J. J.; Cloughesy, T. F.; Mischel, P. S.; Bendell, J. C.; Shih, K. C.; Paz-Ares, L. G.; Mahipal, A.; Delord, J.-P.; Kelley, R. K.; Soria, J.-C.; Wong, L.; Xu, S.; James, A.; Wu, X.; Chopra, R.; Hege, K.; Muster, P. N. Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors J. Clin. Oncol. 2013, 31 (Suppl.) 2606
      108. 108
        Basu, B.; Dean, E.; Puglisi, M.; Greystoke, A.; Ong, M.; Burke, W.; Cavallin, M.; Bigley, G.; Womack, C.; Harrington, E. A.; Green, S.; Oelmann, E.; de Bono, J. S.; Ranson, M.; Banerji, U. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014 Clin. Cancer Res. 2015, 21, 3412 3419 DOI: 10.1158/1078-0432.CCR-14-2422
      109. 109
        Lin, F.; Buil, L.; Sherris, D.; Beijnen, J. H.; van Tellingen, O. Dual mTORC1 and mTORC2 inhibitor Palmoid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2 Int. J. Cancer 2013, 133, 1222 1234 DOI: 10.1002/ijc.28126
      110. 110

        For AKT inhibitors that have entered clinical studies see the following:

        (a) Pal, S. K.; Reckamp, K.; Yu, H.; Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer Expert Opin. Invest. Drugs 2010, 19, 1355 1366 DOI: 10.1517/13543784.2010.520701
        (b) Rodon, J.; Dienstmann, R.; Serra, V.; Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials Nat. Rev. Clin. Oncol. 2013, 10, 143 153 DOI: 10.1038/nrclinonc.2013.10
      111. 111
        Hilgard, P.; Klenner, T.; Stekar, J.; Nossner, G.; Kutscher, B.; Engel, J. D-21266, a new heterocyclic alkylphospholipid with antitumor activity Eur. J. Cancer 1997, 33, 442 446 DOI: 10.1016/S0959-8049(97)89020-X
      112. 112
        Hirai, H.; Sootome, H.; Nakatsuru, Y.; Miyama, K.; Taguchi, S.; Tsujioka, K.; Ueno, Y.; Hatch, H.; Majumder, P. K.; Pan, B. S.; Kotani, H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo Mol. Cancer Ther. 2010, 9, 1956 1967 DOI: 10.1158/1535-7163.MCT-09-1012
      113. 113
        Dunn, D. E.; He, D. N.; Yang, P.; Johansen, M.; Newman, R. A.; Lo, D. C. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models J. Neurochem. 2011, 119, 805 814 DOI: 10.1111/j.1471-4159.2011.07439.x
      114. 114
        Heerding, D. A.; Rhodes, N.; Leber, J. D.; Clark, T. J.; Keenan, R. M.; Lafrance, L. V.; Li, M.; Safonov, I. G.; Takata, D. T.; Venslavsky, J. W.; Yamashita, D. S.; Choudhry, A. E.; Copeland, R. A.; Lai, Z.; Schaber, M. D.; Tummino, P. J.; Strum, S. L.; Wood, E. R.; Duckett, D. R.; Eberwein, D.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Zhang, S.; Minthorn, E. A.; Concha, N. O.; Warren, G. L.; Kumar, R. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase J. Med. Chem. 2008, 51, 5663 5679 DOI: 10.1021/jm8004527
      115. 115
        Dumble, M.; Crouthamel, M.; Zhang, S.; Schaber, M.; Levy, D.; Robell, K.; Liu, Q.; Figueroa, D. J.; Minthorn, E. A.; Seefeld, M. A.; Rouse, M. B.; Rabindran, S. K.; Heerding, D. A.; Kumar, R. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor PLoS One 2014, 9, e100880 DOI: 10.1371/journal.pone.0100880
      116. 116
        Blake, J. F.; Xu, R.; Bencsik, J. R.; Xiao, D.; Kallan, N. C.; Schlachter, S.; Mitchell, I. S.; Spencer, K. L.; Banka, A. L.; Wallace, E. M.; Gloor, S. L.; Martinson, M.; Woessner, R. D.; Vigers, G. P.; Brandhuber, B. J.; Liang, J.; Safina, B. S.; Li, J.; Zhang, B.; Chabot, C.; Do, S.; Lee, L.; Oeh, J.; Sampath, D.; Lee, B. B.; Lin, K.; Liederer, B. M.; Skelton, N. J. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors J. Med. Chem. 2012, 55, 8110 8127 DOI: 10.1021/jm301024w
      117. 117
        Lapierre, J.-M.; Eathiraj, S.; Vensel, D.; Liu, Y.; Bull, C. O.; Cornell-Kennon, S.; Iimura, S.; Kelleher, E. W.; Kizer, D. E.; Koerner, S.; Makhija, S.; Matsuda, A.; Moussa, M.; Namdev, N.; Savage, R. E.; Szwaya, J.; Volckova, E.; Westlund, N.; Wu, H.; Schwartz, B. Discovery of 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor J. Med. Chem. 2016, 59, 6455 6469 DOI: 10.1021/acs.jmedchem.6b00619
      118. 118
        Vink, S. R.; Schellens, J. H.; van Blitterswijk, W. J.; Verheij, M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid Invest. New Drugs 2005, 23, 279 286 DOI: 10.1007/s10637-005-1436-0
      119. 119
        Dunn, D. E.; He, D. N.; Yang, P.; Johansen, M.; Newman, R. A.; Lo, D. C. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models J. Neurochem. 2011, 119, 805 814 DOI: 10.1111/j.1471-4159.2011.07439.x
      120. 120
        Newton, H. B. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors Expert Rev. Anticancer Ther. 2003, 3, 595 614 DOI: 10.1586/14737140.3.5.595
      121. 121
        Singh, D.; Chan, J. M.; Zoppoli, P.; Niola, F.; Sullivan, R.; Castano, A.; Liu, E. M.; Reichel, J.; Porrati, P.; Pellegatta, S.; Qiu, K.; Gao, Z.; Ceccarelli, M.; Riccardi, R.; Brat, D. J.; Guha, A.; Aldape, K.; Golfinos, J. G.; Zagzag, D.; Mikkelsen, T.; Finocchiaro, G.; Lasorella, A.; Rabadan, R.; Iavarone, A. Transofrming fusions of FGFR and TACC genes in human glioblastoma Science 2012, 337, 1231 1235 DOI: 10.1126/science.1220834
      122. 122
        (a) Shaw, A. T.; Hsu, P. P.; Awad, M. M.; Engleman, J. A. Tyrosine kinase gene rearrangements in epithelial malignancies Nat. Rev. Cancer 2013, 13, 772 787 DOI: 10.1038/nrc3612
        (b) Dieci, M. V.; Arnedos, M.; Andre, F.; Soria, J. C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives Cancer Discovery 2013, 3, 264 279 DOI: 10.1158/2159-8290.CD-12-0362
      123. 123
        Brooks, A. N.; Kilgour, E.; Smith, P. D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer Clin. Cancer Res. 2012, 18, 1855 1862 DOI: 10.1158/1078-0432.CCR-11-0699
      124. 124
        Gavine, P. R.; Mooney, L.; Kilgour, E.; Thomas, A. P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M. J.; Brooks, A. N.; Klinowska, T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family Cancer Res. 2012, 72, 2045 2056 DOI: 10.1158/0008-5472.CAN-11-3034
      125. 125
        Guagnano, V.; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M. R.; Schnell, C.; Schmid, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Graus Porta, D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase J. Med. Chem. 2011, 54, 7066 7083 DOI: 10.1021/jm2006222
      126. 126
        Angibaud, P. R.; Mevellec, L.; Saxty, G.; Adelinet, C.; Akkari, R.; Berdini, V.; Bonnet, P.; Bourgeois, M.; Bourdrez, X.; Cleasby, A.; Colombel, H.; Csoka, I.; Embrechts, W.; Freyne, E.; Gilissen, R.; Jovcheva, E.; King, P.; Lacrampe, J.; Lardeau, D.; Ligny, Y.; Mcclue, S.; Meerpoel, L.; Newell, D. R.; Page, M.; Papanikos, A.; Pasquier, E.; Pilatte, I.; Poncelet, V.; Querolle, O.; Rees, D. C.; Rich, S.; Roux, B.; Sement, E.; Simonnet, Y.; Squires, M.; Tronel, V.; Verhulst, T.; Vialard, J.; Willems, M.; Woodhead, S. J.; Wroblowski, B.; Murray, C. W.; Perera, T. Abstract 4748: Discovery of JNJ-42756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment based approach Cancer Res. 2014, 74 (Suppl.) 4748 DOI: 10.1158/1538-7445.AM2014-4748
      127. 127
        Nakanishi, Y.; Akiyama, N.; Tsukaguchi, T.; Fujii, T.; Sakata, K.; Sase, H.; Isobe, T.; Morikami, K.; Shindoh, H.; Mio, T.; Ebiike, H.; Taka; Naoki, N.; Aoki, Y.; Ishii, N. The fibroblast growth factor receptor genetic status as a potential predictor for the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor Mol. Cancer Ther. 2014, 13, 2547 2558 DOI: 10.1158/1535-7163.MCT-14-0248
      128. 128
        https://clinicaltrials.gov/ct2/show/NCT01975701 (accessed June 12, 2016) .
      129. 129
        Savage, R. E.; Hall, T.; Schwartz, B. ARQ 087, a novel pan FGFR-inhibitor crosses the BBB (blood brain barrier) and distributes to the brain of rats Eur. J. Cancer 2014, 50 (Suppl. 6) 50 DOI: 10.1016/S0959-8049(14)70271-0
      130. 130
        Elmlinger, M. W.; Deininger, M. H.; Schuett, B. S.; Meyermann, R.; Duffner, F.; Grote, E. H.; Ranke, M. B. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade Endocrinology 2001, 142, 1652 1658 DOI: 10.1210/endo.142.4.8084
      131. 131
        Chen, H. X.; Sharon, E. IGF-1R as an anti-cancer target—trials and tribulations Aizheng 2013, 32, 242 252 DOI: 10.5732/cjc.012.10263
      132. 132
        Mulvihill, M. J.; Cooke, A.; Rosenfeld-Franklin, M.; Buck, E.; Foreman, K.; Landfair, D.; O’Connor, M.; Pirritt, C.; Sun, Y.; Yao, Y.; Arnold, L. D.; Gibson, N. W.; Ji, Q. S. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor Future Med. Chem. 2009, 1, 1153 1171 DOI: 10.4155/fmc.09.89
      133. 133
        Carboni, J. M.; Wittman, M.; Yang, Z.; Lee, F.; Greer, A.; Hurlburt, W.; Hillerman, S.; Cao, C.; Cantor, G. H.; Dell-John, J.; Chen, C.; Discenza, L.; Menard, K.; Li, A.; Trainor, G.; Vyas, D.; Kramer, R.; Attar, R. M.; Gottardis, M. M. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR Mol. Cancer Ther. 2009, 8, 3341 3349 DOI: 10.1158/1535-7163.MCT-09-0499
      134. 134
        Vasilcanu, D.; Girnita, A.; Girnita, L.; Vasilcanu, R.; Axelson, A.; Larsson, O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway Oncogene 2004, 23, 7854 7862 DOI: 10.1038/sj.onc.1208065
      135. 135
        Guz, N. R.; Leuser, H.; Goldman, E. Process development and multikilogram syntheses of XL228 utilizing a regioselective isoxazole formation and a selective SNAr reaction to a pyrimidine core Org. Process Res. Dev. 2013, 17, 1066 1073 DOI: 10.1021/op400137m
      136. 136
        Rodon, J.; De Santos, V.; Ferry, R. J.; Kurzrock, R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials Mol. Cancer Ther. 2008, 7, 2575 2588 DOI: 10.1158/1535-7163.MCT-08-0265
      137. 137
        Halvorson, K. G.; Barton, K. L.; Schroeder, K.; Misuraca, K. L.; Hoeman, C.; Chung, A.; Crabtree, D. M.; Cordero, F. J.; Singh, R.; Spasojevic, I.; Berlow, N.; Pal, R.; Becher, O. J. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent PLoS One 2015, 10, e0118926 DOI: 10.1371/journal.pone.0118926
      138. 138
        Boston-Howes, W.; Williams, E. O.; Bogush, A.; Scolere, M.; Pasinelli, P.; Trotti, D. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis Exp. Neurol. 2008, 213, 229 237 DOI: 10.1016/j.expneurol.2008.06.010
      139. 139
        Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.-H.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.-M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K. N.; Shinjo, S. M. O.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmiqiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme Science 2008, 321, 1807 1812 DOI: 10.1126/science.1164382
      140. 140
        (a) Paugh, B. S.; Broniscer, A.; Qu, C.; Miller, C. P.; Zhang, J.; Tatevossian, R. G.; Olson, J. M.; Geyer, J. R.; Chi, S. N.; da Silva, N. S.; Onar-Thomas, A.; Baker, J. N.; Gajjar, A.; Ellison, D. W.; Baker, Z. J. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma J. Clin. Oncol. 2011, 29, 3999 4006 DOI: 10.1200/JCO.2011.35.5677
        (b) Warren, K. E.; Killian, K.; Suuriniemi, M.; Wang, Y.; Quezado, M.; Meltzer, P. S. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas Neuro-Oncology 2012, 14, 326 332 DOI: 10.1093/neuonc/nor190
      141. 141
        Toogood, P. L.; Harvey, P. J.; Repine, J. T.; Sheehan, D. J.; VanderWel, S. N.; Zhou, H.; Keller, P. R.; McNamara, D. J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M. R.; Fry, D. W. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 J. Med. Chem. 2005, 48, 2388 2406 DOI: 10.1021/jm049354h
      142. 142
        Barton, K. L.; Misuraca, K.; Cordero, F.; Dobrikova, E.; Min, H. D.; Gromeier, M.; Kirsch, D. G.; Becher, O. J. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma PLoS One 2013, 8, e77639 DOI: 10.1371/journal.pone.0077639
      143. 143
        Michaud, K.; Solomon, D. A.; Oermann, E.; Kim, J.-S.; Zhong, W.-Z.; Prados, M. D.; Ozawa, T.; James, C. D.; Waldman, T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts Cancer Res. 2010, 70, 3228 3238 DOI: 10.1158/0008-5472.CAN-09-4559
      144. 144
        Parrish, K. E.; Pokorny, J. L.; Mittapalli, R. K.; Bakken, K.; Sarkaria, J. N.; Elmquist, W. F. Efflux transporters at the blood-brain barrier limit delivery and efficacy of CDK4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model J. Pharmacol. Exp. Ther. 2015, 355, 264 271 DOI: 10.1124/jpet.115.228213
      145. 145
        Gelbert, L. M.; Cai, S.; Lin, X.; Sanchez-Martinez, C.; del Prado, M.; Lallena, M. J.; Torres, R.; Ajamie, R. T.; Wishart, G. N.; Flack, R. S.; Neubauer, B. L.; Young, J.; Chan, E. M.; Iversen, P.; Cronier, D.; Kreklau, E.; de Dios, A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Invest. New Drugs 2014, 32, 825 837 DOI: 10.1007/s10637-014-0120-7
      146. 146
        Raub, T. J.; Wishart, G. N.; Kulanthaivel, P.; Staton, B. A.; Ajamie, R. T.; Sawada, G. A.; Gelbert, L. M.; Shannon, H. E.; Sanchez-Martinez, C.; De Dios, A. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft Drug Metab. Dispos. 2015, 43, 1360 1371 DOI: 10.1124/dmd.114.062745
      147. 147
        Sanchez-Martinez, C.; Gelbert, L. M.; Shannon, H.; De Dios, A.; Staton, B. A.; Ajamie, R. T.; Sawada, G.; Wishart, G. N.; Raub, T. J. Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts Mol. Cancer Ther. 2011, 10, B234 DOI: 10.1158/1535-7163.TARG-11-B234
      148. 148
        https://clinicaltrials.gov/ct2/show/NCT02308020 (accessed June 12, 2016) .
      149. 149
        Asghar, U.; Witkiewicz, A. K.; Turner, N. C.; Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy Nat. Rev. Drug Discovery 2015, 14, 130 146 DOI: 10.1038/nrd4504
      150. 150
        Cheng, C. K.; Gustafson, W. C.; Charron, E.; Houseman, B. T.; Zunder, E.; Goga, A.; Gray, N. S.; Pollok, B.; Oakes, S. A.; James, C. D.; Shokat, K. M.; Weiss, W. A.; Fan, Q. W. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 12722 12727 DOI: 10.1073/pnas.1202492109
      151. 151
        Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials Invest. New Drugs 1999, 17, 313 320 DOI: 10.1023/A:1006353008903
      152. 152
        Newcomb, E. W.; Tamasdan, C.; Entzminger, Y.; Arena, E.; Schnee, T.; Kim, M.; Crisan, D.; Lukyanov, Y.; Miller, D. C.; Zagzag, D. Flavopiridol inhibits the growth of GL261 gliomas in vivo Cell Cycle 2004, 3, 218 222 DOI: 10.4161/cc.3.2.667
      153. 153
        Zhou, L.; Schmidt, K.; Nelson, F. R.; Zelesky, V.; Troutman, M. D.; Feng, B. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice Drug Metab. Dispos. 2009, 37, 946 955 DOI: 10.1124/dmd.108.024489
      154. 154
        Vita, M.; Abdel-Rehim, M.; Olofsson, S.; Hassan, Z.; Meurling, L.; Siden, A.; Siden, M.; Pettersson, T.; Hassan, M. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat Eur. J. Pharm. Sci. 2005, 25, 91 103 DOI: 10.1016/j.ejps.2005.02.001
      155. 155
        Rajnai, Z.; Mehn, D.; Beery, E.; Okyar, A.; Jani, M.; Toth, G. K.; Fulop, F.; Levi, F.; Krajcsi, P. ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor Drug Metab. Dispos. 2010, 38, 2000 2006 DOI: 10.1124/dmd.110.032805
      156. 156
        Paruch, K.; Dwyer, M. P.; Alvarez, C.; Brown, C.; Chan, T. Y.; Doll, R. J.; Keertikar, K.; Knutson, C.; McKittrick, B.; Rivera, J.; Rossman, R.; Tucker, G.; Fischmann, T.; Hruza, A.; Madison, V.; Nomeir, A. A.; Wang, Y.; Kirschmeier, P.; Lees, E.; Parry, D.; Sqambellone, N.; Seghezzi, W.; Schultz, L.; Shanahan, F.; Wiswell, D.; Xu, X.; Zhou, Q.; James, R. A.; Paradkar, V. M.; Park, H.; Rokosz, L. R.; Stauffer, T. M.; Guzi, T. J. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases ACS Med. Chem. Lett. 2010, 1, 204 208 DOI: 10.1021/ml100051d
      157. 157
        Jane, E. P.; Premkumar, D. R.; Cavaleri, J. M.; Sutera, P. A.; Rajasekar, T.; Pollack, I. F. Dinaciclib, a cyclin-dependent kinase inhibitor promotes proteasomal degradation of Mcl-1 and enhances glioma cell lines J. Pharmacol. Exp. Ther. 2016, 356, 354 365 DOI: 10.1124/jpet.115.230052
      158. 158
        Loschmann, N.; Michaelis, M.; Rothweiler, F.; Zehner, R.; Cinati, J.; Voges, Y.; Sharifi, M.; Riecken, K.; Meyer, J.; von Deimling, A.; Fichter, I.; Ghafourian, T.; Westermann, F.; Cinatl, J. Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs Transl. Oncol. 2013, 6, 685 696 DOI: 10.1593/tlo.13544
      159. 159
        Kamath, A. V.; Chong, S.; Chang, M.; Marthe, P. H. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats Cancer Chemother. Pharmacol. 2005, 55, 110 116 DOI: 10.1007/s00280-004-0873-3
      160. 160
        Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.; Feltell, R. E.; Lewis, E. J.; McMenamin, R. L.; Navarro, E. F.; O’Brien, M. A.; O’Reilly, M.; Reule, M.; Saxty, G.; Seavers, L. C.; Smith, D. M.; Squires, M. S.; Trewartha, G.; Walker, M. T.; Woolford, A. J. Identification of N-(4-piperidinyl)-4-(2,6-dichlorbenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design J. Med. Chem. 2008, 51, 4986 4999 DOI: 10.1021/jm800382h
      161. 161
        Cihalova, D.; Staud, F.; Ceckova, M. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 trasporters and their potential to overcome multidrug resistance in vitro Cancer Chemother. Pharmacol. 2015, 76, 105 116 DOI: 10.1007/s00280-015-2772-1
      162. 162
        Chu, X. J.; DePinto, W.; Bartkovitz, D.; So, S. S.; Vu, B. T.; Packman, K.; Lukacs, C.; Ding, Q.; Jiang, N.; Wang, K.; Goelzer, P.; Yin, X.; Smith, M. A.; Higgins, B. X.; Chen, Y.; Xiang, Q.; Moliterni, J.; Kaplan, G.; Graves, B.; Lovey, A.; Fotouhi, N. Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity J. Med. Chem. 2006, 49, 6549 6560 DOI: 10.1021/jm0606138
      163. 163
        Byth, K. F.; Thomas, A.; Hughes, G.; Forder, C.; McGregor, A.; Geh, C.; Oakes, S.; Green, C.; Walker, M.; Newcombe, N.; Green, S.; Growcott, J.; Barker, A.; Wilkinson, R. W. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts Mol. Cancer Ther. 2009, 8, 1856 1866 DOI: 10.1158/1535-7163.MCT-08-0836
      164. 164
        Zhang, I.; Zaorsky, N. G.; Palmer, J. D.; Mehra, R.; Lu, B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer Lancet Oncol. 2015, 16, e510 e521 DOI: 10.1016/S1470-2045(15)00013-3
      165. 165
        Cui, J. J.; Tran-Dube, M.; Shen, H.; Nambu, M.; Kung, P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342 6363 DOI: 10.1021/jm2007613
      166. 166
        Camidge, D. R.; Bang, Y.-J.; Kwak, E. L.; Iafrate, A. J.; Varella-Garcia, M.; Fox, S. B.; Riely, G. J.; Solomon, B.; Ou, S.-H. I.; Kim, D.-W.; Salgia, R.; Fidias, P.; Engelman, J. A.; Gandhi, L.; Janne, P. A.; Costa, D. B.; Shapiro, G. I.; LoRusso, P.; Ruffner, K.; Stephenson, P.; Tang, Y.; Wilner, K.; Clark, J. W.; Shaw, A. T. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol. 2012, 13, 1011 1019 DOI: 10.1016/S1470-2045(12)70344-3
      167. 167
        Otterson, G. A.; Riely, G. J.; Shaw, A. T.; Crino, L.; Kim, D.-W.; Marins, R.; Salgia, R.; Zhou, C.; Solomon, B. J.; Wilner, K. D.; Polli, A.; Tang, Y.; Bartlett, C. H.; Ou, S.-H. I. Clinical characteristics of ALK+ NSCLC patients treated with crizotnib beyond disease progression: potential implications for management J. Clin. Oncol. 2012, 30 (Suppl.) 7600
      168. 168
        Costa, D. B.; Kobayashi, S.; Pandya, S. S.; Yeo, W.-L.; Shen, Z.; Tan, W.; Wilner, K. D. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib J. Clin. Oncol. 2011, 29, e443 445 DOI: 10.1200/JCO.2010.34.1313
      169. 169
        Johnson, T. W.; Richardson, P. F.; Bailey, S.; Brooun, A.; Burke, B. J.; Collins, M. R.; Cui, J. J.; Deal, J. G.; Deng, Y.-L.; Dinh, D.; Engstrom, L. D.; He, M.; Hoffman, J.; Hoffman, R. L.; Huang, Q.; Kania, R. S.; Kath, J. C.; Lam, H.; Lam, J. L.; Le, P. T.; Lingardo, L.; Liu, W.; McTigue, M.; Palmer, C. L.; Sach, N. W.; Smeal, T.; Smith, G. L.; Stewart, A. E.; Timofeevski, S.; Zhu, H.; Zhu, J.; Zou, H. Y.; Edwards, M. P. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations J. Med. Chem. 2014, 57, 4720 4744 DOI: 10.1021/jm500261q
      170. 170
        Awad, M. M.; Shaw, A. T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond Clin. Adv. Hematol. Oncol. 2014, 12, 429 439
      171. 171
        Marsilje, T. H.; Pei, W.; Chen, B.; Lu, W.; Uno, T.; Jin, Y.; Jiang, T.; Kim, S.; Li, N.; Warmuth, M.; Sarkisova, Y.; Sun, F.; Steffy, A.; Pferdekamper, A. C.; Li, A. G.; Joseph, S. B.; Kim, Y.; Liu, B.; Tuntland, T.; Cui, X.; Gray, N. S.; Steensma, R.; Wan, Y.; Jiang, J.; Chopiuk, G.; Li, J.; Gordon, W. P.; Richmond, W.; Johnson, K.; Chang, J.; Groessl, T.; He, Y.-Q.; Phimister, A.; Aycinena, A.; Lee, C. C.; Bursulaya, B.; Karanewsky, D. S.; Seidel, H. M.; Harris, J. L.; Michellys, P.-Y. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J. Med. Chem. 2013, 56, 5675 5690 DOI: 10.1021/jm400402q
      172. 172
        (a) Shaw, A. T.; Kim, D. W.; Mehra, R.; Tan, D. S. W.; Felip, E.; Chow, L. Q. M.; Camidge, D. R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, M.; Liu, G.; Santoro, A.; Lau, Y. Y.; Goldwasser, M.; Boral, A. L.; Engelman, J. A. Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med. 2014, 370, 1189 1197 DOI: 10.1056/NEJMoa1311107
        (b) Kim, D.-W.; Mehra, R.; Tan, D. S.-W.; Felip, E.; Chow, L. Q. M.; Camidge, D. R.; Vansteenkiste, J. F.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, M. H.; Liu, G.; Santoro, A.; Geraldes, M.; Boral, A.; Yovine, A. J.; Shaw, A. T. Ceritinib in advanced anaplastic lymphoma (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial J. Clin. Oncol. 2014, 32 (Suppl.) 8003
        (c) Shaw, A.; Mehra, R.; Tan, D. S. W.; Felip, E.; Chow, L. Q.; Camidge, D. R.; Vansteenkiste, J. R.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B.; Wolf, J.; Thomas, M.; Schuler, M.; Liu, G.; Santoro, A.; Geraldes, M.; Boral, A. L.; Yovine, A.; Kim, D. Evaluation of ceritinib-treated patients (pts) with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 Study Ann. Oncol. 2014, 25 (Suppl. 4) iv455 iv456
      173. 173
        Kinoshita, K.; Asoh, K.; Furuichi, N.; Ito, T.; Kawada, H.; Hara, S.; Ohwada, J.; Miyagi, T.; Kobayashi, T.; Takanashi, K.; Tsukaguchi, T.; Sakamoto, H.; Tsukuda, T.; Oikawa, N. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802) Bioorg. Med. Chem. 2012, 20, 1271 1280 DOI: 10.1016/j.bmc.2011.12.021
      174. 174
        Kodama, T.; Hasegawa, M.; Takanashi, K.; Sakurai, Y.; Kondoh, O.; Sakamoto, H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases Cancer Chemother. Pharmacol. 2014, 74, 1023 1028 DOI: 10.1007/s00280-014-2578-6
      175. 175
        (a) Gadgeel, S. M.; Gandhi, L.; Riely, G. J.; Chiappori, A. A.; West, H. L.; Azada, M. C.; Morcos, P. N.; Lee, R.-M.; Garcia, L.; Yu, L.; Boisserie, F.; Di Laurenzio, L.; Golding, S.; Sato, J.; Yokoyama, S.; Tanaka, T.; Ou, S.-H. I. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Lancet Oncol. 2014, 15, 1119 1128 DOI: 10.1016/S1470-2045(14)70362-6
        (b) Ajimizu, H.; Kim, Y. H.; Mishima, M. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib Med. Oncol. 2015, 32, 3 DOI: 10.1007/s12032-014-0477-7
        (c) Gainor, J. F.; Sherman, C. A.; Willoughby, K.; Logan, J.; Kennedy, E.; Brastianos, P. K.; Chi, A. S.; Shaw, A. T. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib J. Thorac. Oncol. 2015, 10, 232 236 DOI: 10.1097/JTO.0000000000000455
      176. 176
        Menichincheri, M.; Ardini, E.; Magnaghi, P.; Avanzi, N.; Banfi, P.; Bossi, R.; Buffa, L.; Canevari, G.; Ceriani, L.; Colombo, M.; Corti, L.; Donati, D.; Fasolini, M.; Felder, E.; Fiorelli, C.; Fiorentini, F.; Galvani, A.; Isacchi, A.; Borgia, A. L.; Marchionni, C.; Nesi, M.; Orrenius, C.; Panzeri, A.; Pesenti, E.; Rusconi, L.; Saccardo, M. B.; Vanotti, E.; Perrone, E.; Orsini, P. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor J. Med. Chem. 2016, 59, 3392 3408 DOI: 10.1021/acs.jmedchem.6b00064
      177. 177
        Farago, A. F.; Le, L. P.; Zheng, Z.; Muzikansky, A.; Drilon, A.; Patel, M.; Bauer, T. M.; Liu, S. V.; Ou, S. I.; Jackman, D.; Costa, D. B.; Multani, P. S.; Li, G. G.; Hornby, Z.; Chow-Maneval, E.; Luo, D.; Lim, J. E.; Iafrate, A. J.; Shaw, A. T. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer J. Thorac. Oncol. 2015, 10, 1670 1674 DOI: 10.1097/01.JTO.0000473485.38553.f0
      178. 178
        Mori, M.; Ueno, Y.; Konagai, S.; Fushiki, H.; Shimada, I.; Kondoh, Y.; Saito, R.; Mori, K.; Shindou, N.; Soga, T.; Sakagami, H.; Furutani, T.; Doihara, H.; Kudoh, M.; Kuromitsu, S. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice Mol. Cancer Ther. 2014, 13, 329 340 DOI: 10.1158/1535-7163.MCT-13-0395
      179. 179
        Fushiki, H.; Saito, R.; Jitsuoka, M.; Shimada, I.; Kondoh, Y.; Sakagami, H.; Funatsu, Y.; Noda, A.; Murakami, Y.; Miyoshi, S.; Ueon, Y.; Konagai, S.; Soga, T.; Nishimura, S.; Mori, M.; Kuromitsu, S. Abstract 2678: First demonstration of in vivo PET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor Cancer Res. 2013, 73 (Suppl.) 2678 DOI: 10.1158/1538-7445.AM2013-2678
      180. 180
        Huang, W. S.; Liu, S.; Zou, D.; Thomas, M.; Wang, Y.; Zhou, T.; Romero, J.; Kohlmann, A.; Li, F.; Qi, J.; Cai, L.; Dwight, T. A.; Xu, Y.; Xu, R.; Dodd, R.; Toms, A.; Parillon, L.; Lu, X.; Anjum, R.; Zhang, S.; Wang, F.; Keats, J.; Wardwell, S. D.; Ning, Y.; Xu, Q.; Moran, L. E.; Mohemmad, Q. K.; Jang, H. G.; Clackson, T.; Narashimhan, N. I.; Rivera, V. M.; Zhu, X.; Dalgarno, D.; Shakespeare, W. C. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of analplastic lymphoma kinase J. Med. Chem. 2016, 59, 4948 4964 DOI: 10.1021/acs.jmedchem.6b00306
      181. 181
        Gettinger, S. N.; Bazhenova, L.; Salgia, R.; Langer, C. J.; Gold, K. A.; Rosell, R.; Shaw, A. T.; Weiss, G. J.; Narasimhan, N. I.; Dorer, D. J.; Rivera, V. M.; Clackson, T.; Haluska, F. G.; Camidge, D. R. Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer J. Thorac. Oncol. 2013, 8 (Suppl. 2) S296
      182. 182
        Camidge, D. R.; Bazhenova, L.; Salgia, R.; Langer, C. J.; Gold, K. A.; Rosell, R.; Shaw, A. T.; Weiss, G. J.; Narasimhan, N. I.; Dorer, D. J.; Rivera, V. M.; Clackson, T. P.; Conlan, M. G.; Kerstein, D.; Haluska, F. G.; Gettinger, S. N. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC) J. Clin. Oncol. 2015, 33 (Suppl.) 8062
      183. 183
        Lovly, C. M.; Heuckmann, J. M.; de Stanchina, E.; Chen, H.; Thomas, R. K.; Liang, C.; Pao, W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Cancer Res. 2011, 71, 4920 4931 DOI: 10.1158/0008-5472.CAN-10-3879
      184. 184
        Lin, N. U.; Dieras, V.; Paul, D.; Lossignol, D.; Christodoulou, C.; Stemmler, H.-J.; Roche, H.; Liu, M. C.; Greil, R.; Ciruelos, E.; Loibl, S.; Gori, S.; Wardley, A.; Yardley, D.; Brufsky, A.; Blum, J. L.; Rubin, S. D.; Dharan, B.; Steplewski, K.; Zembryki, D.; Oliva, C.; Roychowdhury, D.; Paoletti, P.; Winer, E. P. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin. Cancer Res. 2009, 15, 1452 1459 DOI: 10.1158/1078-0432.CCR-08-1080
      185. 185
        Medina, P. J.; Goodin, S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin. Ther. 2008, 30, 1426 1447 DOI: 10.1016/j.clinthera.2008.08.008
      186. 186
        Taskar, K. S.; Rudraraju, V.; Mittapalli, R. K.; Samala, R.; Thorsheim, H. R.; Lockman, J.; Gril, B.; Hua, E.; Palmieri, D.; Polli, J. W.; Castellino, S.; Rubin, S. D.; Lockman, P. R.; Steeg, P. S.; Smith, Q. R. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer Pharm. Res. 2012, 29, 770 781 DOI: 10.1007/s11095-011-0601-8
      187. 187
        Polli, J. W.; Olson, K. L.; Chism, J. P.; St. John-Williams, L.; Yeager, R. L.; Woodard, S. M.; Otto, V.; Castellino, S.; Demby, V. E. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016 Drug Metab. Dispos. 2009, 37, 439 442 DOI: 10.1124/dmd.108.024646
      188. 188
        Morikawa, A.; Peereboom, D. M.; Thorsheim, H. R.; Samala, R.; Balyan, R.; Murphy, C. G.; Lockman, P. R.; Simmons, A.; Weil, R. J.; Tabar, V.; Steeg, P. S.; Smith, Q. R.; Seidman, A. D. Capcitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study Neuro-Oncology 2015, 17, 289 295 DOI: 10.1093/neuonc/nou141
      189. 189
        Schroeder, R. L.; Stevens, C. L.; Sridhar, J. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer Molecules 2014, 19, 15196 15212 DOI: 10.3390/molecules190915196
      190. 190
        Feldinger, K.; Kong, A. Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer: Targets Ther. 2015, 7, 147 162 DOI: 10.2147/BCTT.S54414
      191. 191
        Dinkel, V.; Anderson, D.; Winski, S.; Winkler, J.; Koch, K.; Lee, P. A. Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice Cancer Res. 2012, 72 (Suppl.) 852 DOI: 10.1158/1538-7445.AM2012-852
      192. 192
        Freedman, R. A.; Gelman, R. S.; Wefel, J. S.; Melisko, M. E.; Hess, K. R.; Connolly, R. M.; Van Poznak, C. H.; Niravath, P. A.; Puhalla, S. L.; Ibrahim, N.; Blackwell, K. L.; Liu, M. C.; Lowe, A.; Agar, N. Y. R.; Ryabin, N.; Farooq, S.; Lawler, E.; Rimawi, M. F.; Krop, I. E.; Wolff, A. C.; Winer, E. P.; Lin, N. U. Translational Breast Cancer Research Consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases J. Clin. Oncol. 2016, 34, 945 952 DOI: 10.1200/JCO.2015.63.0343
      193. 193
        Roche, S.; Pedersen, K.; Dunne, G.; Collins, D.; Devery, A.; Crown, J.; Clynes, M.; O’Connor, R. Pharmacological interactions of TKIs with the P-gp drug transport protein J. Clin. Oncol. 2012, 30 (Suppl.) 2536
      194. 194
        Metzger-Filho, O.; Barry, W. T.; Krop, I. E.; Younger, W. J.; Lawler, E. S.; Winer, E. P.; Lin, N. U. Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer J. Clin. Oncol. 2014, 32 (Suppl.) TPS660
      195. 195
        Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oorui, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A.; Miki, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Yano, J.; Aertgeerts, K.; Kamiyama, K. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold J. Med. Chem. 2011, 54, 8030 8050 DOI: 10.1021/jm2008634
      196. 196
        Erdo, F.; Gordon, J.; Wu, J. T.; Sziraki, I. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats Brain Res. Bull. 2012, 87, 413 419 DOI: 10.1016/j.brainresbull.2012.01.002
      197. 197
        Nakayama, A.; Takagi, S.; Yusa, T.; Yaguchi, M.; Hayashi, A.; Tamura, T.; Kawakita, Y.; Ishikawa, T.; Ohta, Y. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model J. Cancer 2013, 4, 557 565 DOI: 10.7150/jca.6689
      198. 198
        Kalous, O.; Conklin, D.; Desai, A. J.; O’Brien, N. A.; Ginther, C.; Anderson, L.; Cohen, D. J.; Britten, C. D.; Taylor, I.; Christensen, J. G.; Slamon, D. J.; Finn, R. S. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib Mol. Cancer Ther. 2012, 11, 1978 1987 DOI: 10.1158/1535-7163.MCT-11-0730
      199. 199
        Wong, T. W.; Lee, F. Y.; Yu, C.; Luo, F. R.; Oppenheimer, S.; Zhang, H.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; Vite, G. D. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling Clin. Cancer Res. 2006, 12, 6186 6193 DOI: 10.1158/1078-0432.CCR-06-0642
      200. 200
        Desjardins, A.; Reardon, D. A.; Vredenburgh, J. J.; Peters, K.; Trikha, M.; James, J.; Gardner, M.; Brickhouse, A.; Herndon, J. E.; Friedman, H. S. A pharmacokinetic study of AC48 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED) J. Clin. Oncol. 2011, 29 (Suppl.) 2070
      201. 201
        Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res. 2004, 64, 4931 4941 DOI: 10.1158/0008-5472.CAN-03-3681
      202. 202
        Meco, D.; Servidei, T.; Zannoni, G. F.; Martinelli, E.; Prisco, M. G.; de Waure, C.; Riccardi, R. Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma Trans. Oncol. 2010, 3, 326 335 DOI: 10.1593/tlo.10163
      203. 203
        Goudar, R. K.; Shi, Q.; Hjelmeland, M. D.; Keir, S. T.; McLendon, R. E.; Wikstrand, C. J.; Reese, E. D.; Conrad, C. A.; Traxler, P.; Lane, H. A.; Reardon, D. A.; Cavenee, W. K.; Wang, X. F.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol. Cancer Ther. 2005, 4, 101 112
      204. 204
        Reardon, D. A.; Conrad, C. A.; Cloughesy, T.; Prados, M. D.; Friedman, H. S.; Aldape, K. D.; Mischel, P.; Xia, J.; DiLea, C.; Huang, J.; Mietlowski, W.; Dugan, M.; Chen, W.; Yung, W. K. A. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients Cancer Chemother. Pharmacol. 2012, 69, 1507 1518 DOI: 10.1007/s00280-012-1854-6
      205. 205
        Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. 2008, 341, 465 477 DOI: 10.1002/ardp.200800009
      206. 206
        Hegedus, C.; Truta-Feles, K.; Antalffy, G.; Varady, G.; Nemet, K.; Ozvegy-Laczka, C.; Keri, G.; Orfi, L.; Szakacs, G.; Settleman, J.; Varadi, A.; Sarkadi, B. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance Biochem. Pharmacol. 2012, 84, 260 267 DOI: 10.1016/j.bcp.2012.04.010
      207. 207
        Jani, J. P.; Finn, R. S.; Campbell, M.; Coleman, K. G.; Connell, R. D.; Currier, N.; Emerson, E. O.; Floyd, E.; Harriman, S.; Kath, J. C.; Morris, J.; Moyer, J. D.; Pustilnik, L. R.; Rafidi, K.; Ralston, S.; Rossi, A. M. K.; Steyn, S. J.; Wagner, L.; Winter, S. M.; Bhattacharya, S. K. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor Cancer Res. 2007, 67, 9887 9893 DOI: 10.1158/0008-5472.CAN-06-3559
      208. 208
        Feng, B.; Xu, J. J.; Bi, Y. A.; Mireles, R.; Davidson, R.; Duignan, D. B.; Campbell, S.; Kostrubsky, V. E.; Dunn, M. C.; Smith, A. R.; Wang, H. F. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714 Toxicol. Sci. 2009, 108, 492 500 DOI: 10.1093/toxsci/kfp033
      209. 209
        Cai, X.; Zhai, H. X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C. J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer J. Med. Chem. 2010, 53, 2000 2009 DOI: 10.1021/jm901453q
      210. 210
        Barlaam, B.; Anderton, J.; Ballard, P.; Bradbury, R. H.; Hennequin, L. F. A.; Hickinson, D. M.; Kettle, J. G.; Kirk, G.; Klinowska, T.; Lambert-van der Brempt, C.; Trigwell, C.; Vincent, J.; Ogilvie, D. Discovery of AZD8931, an equipotent, reversible inhibitor of signaling by EGFR, HER2, and HER3 receptors ACS Med. Chem. Lett. 2013, 4, 742 746 DOI: 10.1021/ml400146c
      211. 211
        Xie, H.; Lin, L.; Tong, L.; Jiang, Y.; Zheng, M.; Chen, Z.; Jiang, X.; Zhang, X.; Ren, X.; Qu, W.; Yang, Y.; Wan, H.; Chen, Y.; Zuo, J.; Jiang, H.; Geng, M.; Ding, J. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo PLoS One 2011, 6, e21487 DOI: 10.1371/journal.pone.0021487
      212. 212
        (a) Fife, K. M.; Colman, M. H.; Stevens, G. N.; Firth, I. C.; Moon, D.; Shannon, K. F.; Harman, R.; Petersen-Schaefer, K.; Zacest, A. C.; Besser, M.; Milton, G. W.; McCarthy, W. H.; Thompson, J. F. Determinants of outcome in melanoma patients with cerebral metastases J. Clin. Oncol. 2004, 22, 1293 1300 DOI: 10.1200/JCO.2004.08.140
        (b) Sampson, J. H.; Carter, J. H.; Friedman, A. H.; Seigler, H. F. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma J. Neurosurg. 1998, 88, 11 20 DOI: 10.3171/jns.1998.88.1.0011
      213. 213
        Flaherty, K. T.; Yasothan, U.; Kirkpatrick, P. Vemurafenib Nat. Rev. Drug Discovery 2011, 10, 811 812 DOI: 10.1038/nrd3579
      214. 214
        Rheault, T. R.; Stellwagen, J. C.; Adjabeng, G. M.; Hornberger, K. R.; Petrov, K. G.; Waterson, A. G.; Dickerson, S. H.; Mook, R. A.; Laquerre, S. G.; King, A. J.; Rossanese, O. W.; Arnone, M. R.; Smitheman, K. N.; Kane-Carson, L. S.; Han, C.; Moorthy, G. S.; Moss, K. G.; Uehling, D. E. Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors ACS Med. Chem. Lett. 2013, 4, 358 362 DOI: 10.1021/ml4000063
      215. 215
        Hoeflich, K. P.; Merchant, M.; Orr, C.; Chan, J.; Den Otter, D.; Berry, L.; Kasman, I.; Koeppen, H.; Rice, K.; Yang, N. Y.; Engst, S.; Johnston, S.; Friedman, L. S.; Belvin, M. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition Cancer Res. 2012, 72, 210 219 DOI: 10.1158/0008-5472.CAN-11-1515
      216. 216
        Abe, H.; Kikuchi, S.; Hayakawa, K.; Iida, T.; Nagahashi, N.; Maeda, K.; Sakamoto, J.; Matsumoto, N.; Miura, T.; Matsumura, K.; Seki, N.; Inaba, T.; Kawasaki, H.; Yamaguchi, T.; Kakefuda, R.; Nanayama, T.; Kurachi, H.; Hori, Y.; Yoshida, T.; Kakegawa, J.; Watanabe, Y.; Gilmartin, A. G.; Richter, M. C.; Moss, K. G.; Laquerre, S. G. Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate) ACS Med. Chem. Lett. 2011, 2, 320 324 DOI: 10.1021/ml200004g
      217. 217
        Myung, J. K.; Cho, H.; Park, C.-K.; Kim, S. K.; Lee, S. H.; Park, S. H. Analysis of the BRAF V600E mutation in central nervous system tumors Transl. Oncol. 2012, 5, 430 436 DOI: 10.1593/tlo.12328
      218. 218
        Kieran, M. W. Targeting BRAF in pediatric brain tumors. In American Society of Clinical Oncology 2014 Educational Book; Dizon, D. S.; Pennell, N.; Burke, L.; Carter, D.; Dottellis, D., Eds.; American Society of Clinical Oncology: Alexandria, VA, 2014; pp e436 e440, DOI:  DOI: 10.14694/EdBook_AM.2014.34.e436 .
      219. 219
        See, W. L.; Tan, I. L.; Mukherjee, J.; Nicolaides, T.; Pieper, R. O. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency Cancer Res. 2012, 72, 3350 3359 DOI: 10.1158/0008-5472.CAN-12-0334
      220. 220
        (a) McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Franklin, R. A.; Montalto, G.; Cervello, M.; Libra, M.; Candido, S.; Malaponte, G.; Mazzarino, M. C.; Fagone, P.; Nicoletti, F.; Basecke, J.; Mijatovic, S.; Maksimovic-Ivanic, D.; Milella, M.; Tafuri, A.; Chiarini, F.; Evangelisti, C.; Cocco, L.; Martelli, A. M. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance Oncotarget 2012, 3, 1068 1111 DOI: 10.18632/oncotarget.659
        (b) Huang, T.; Karsy, M.; Zhuge, J.; Zhong, M.; Liu, D. B-Raf and the inhibitors: from bench to bedside J. Hematol. Oncol. 2013, 6, 30 DOI: 10.1186/1756-8722-6-30
      221. 221
        (a) Zhao, Y.; Adjei, A. A. The clinical development of MEK inhibitors Nat. Rev. Clin. Oncol. 2014, 11, 385 400 DOI: 10.1038/nrclinonc.2014.83
        (b) Akinleye, A.; Furqan, M.; Mukhi, N.; Ravella, P.; Liu, D. MEK and the inhibitors: from bench to bedside J. Hematol. Oncol. 2013, 6, 27 DOI: 10.1186/1756-8722-6-27
        (c) McDermott, L.; Qin, C. Allosteric MEK1/2 Inhibitors for the Treatment of Cancer: An Overview. J. Drug Res. Dev. 2015, 1, DOI:  DOI: 10.16966/2470-1009.101 ; http://dx.doi.org/10.16966/2470-1009.101.
      222. 222
        (a) Rochet, N. M.; Dronca, R. S.; Kottschade, L. A.; Chavan, R. N.; Gorman, B.; Gilbertson, J. R.; Markovic, S. N. Melanoma brain metastases and vemurafenib: need for further investigation Mayo Clin. Proc. 2012, 87, 976 981 DOI: 10.1016/j.mayocp.2012.07.006
        (b) Gummadi, T.; Zhang, B. Y.; Valpione, S.; Kim, C.; Kottschade, L. A.; Mittapalli, R. K.; Chiarion-Sileni, V.; Pigozzo, J.; Elmquist, W. F.; Dudek, A. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases Melanoma Res. 2015, 25, 75 79 DOI: 10.1097/CMR.0000000000000133
        (c) Dummer, R.; Goldinger, S. M.; Turtschi, C. P.; Eggmann, N. B.; Michielin, O.; Mitchell, L.; Veronese, L.; Hilfikeer, P. R.; Felderer, L.; Rinderknecht, J. D. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study Eur. J. Cancer 2014, 50, 611 621 DOI: 10.1016/j.ejca.2013.11.002
        (d) Robinson, G. W.; Orr, B. A.; Gajjar, A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multi-forme after BRAF Inhibitor therapy BMC Cancer 2014, 14, 258 DOI: 10.1186/1471-2407-14-258
      223. 223
        (a) Falchook, G. S.; Long, G. V.; Kurzrock, R.; Kim, K. B.; Arkenau, T. H.; Brown, M. P.; Hamid, O.; Infante, J. R.; Millward, M.; Pavlick, A. C.; O’Day, S. J.; Blackman, S. C.; Curtis, C. M.; Lebowitz, P.; Ma, B.; Ouellet, D.; Kefford, R. F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase I dose-escalation trial Lancet 2012, 379, 1893 1901 DOI: 10.1016/S0140-6736(12)60398-5
        (b) Long, G. V.; Trefzer, U.; Davies, M. A.; Kefford, R. F.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; Mortier, L.; Tawbi, H.; Wilhelm, T.; Zimmer, L.; Switzky, J.; Swann, S.; Martin, A. M.; Guckert, M.; Goodman, V.; Streit, M.; Kirkwood, J. M.; Schadendorf, D. Dabrafenib in patients with Val600Glu or V600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase 2 trial Lancet Oncol. 2012, 13, 1087 1095 DOI: 10.1016/S1470-2045(12)70431-X
      224. 224
        Vaidhyanathan, S.; Mittapalli, R. K.; Sarkaria, J. N.; Elmquist, W. F. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases Drug Metab. Dispos. 2014, 42, 1292 1300 DOI: 10.1124/dmd.114.058339
      225. 225
        (a) Mittapalli, R. K.; Vaidhyanathan, S.; Sane, R.; Elmquist, W. F. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) J. Pharmacol. Exp. Ther. 2012, 342, 33 40 DOI: 10.1124/jpet.112.192195
        (b) Mittapalli, R. K.; Vaidhyanathan, S.; Dudek, A. Z.; Elmquist, W. F. Mechanisms limiting distribution of the threonine-protein kinase B-RafV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases J. Pharmacol. Exp. Ther. 2013, 344, 655 664 DOI: 10.1124/jpet.112.201475
      226. 226
        Williams, T. E.; Subramanian, S.; Verhagen, J.; McBride, C. M.; Costales, A.; Sung, L.; Antonios-McCrea, W.; McKenna, M.; Louie, A. K.; Ramurthy, S.; Levine, B.; Shafer, C. M.; Machajewski, T.; Renhowe, P. A.; Appleton, B. A.; Amiri, P.; Chou, J.; Stuart, D.; Aardalen, K.; Poon, D. Discovery of RAF265: a potent mut-B-Raf inhibitor for the treatment of metastatic melanoma ACS Med. Chem. Lett. 2015, 6, 961 965 DOI: 10.1021/ml500526p
      227. 227
        Liu, X.; Ide, J. L.; Norton, I.; Marchionni, M. A.; Ebling, M. C.; Wang, L. Y.; Davis, E.; Sauvageot, C. M.; Kesari, S.; Kellersberger, K. A.; Easterling, M. L.; Santagata, S.; Stuart, D. D.; Alberta, J.; Agar, J. N.; Stiles, C. D.; Agar, N. Y. R. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging Sci. Rep. 2013, 3, 2859 DOI: 10.1038/srep02859
      228. 228
        Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA. http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/ (ccessed June 10, 2016) .
      229. 229
        Rusconi, P.; Caiola, E.; Broggini, M. Ras/Raf/MEK inhibitors in oncology Curr. Med. Chem. 2012, 19, 1164 1176 DOI: 10.2174/092986712799320510
      230. 230
        Choo, E. F.; Ly, J.; Chan, J.; Shahidi-Latham, S. K.; Messick, K.; Plise, E.; Quiason, C. M.; Yang, L. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib Mol. Pharmaceutics 2014, 11, 4199 4207 DOI: 10.1021/mp500435s
      231. 231
        (a) Choo, E. F.; Belvin, M.; Boggs, J.; Deng, Y.; Hoeflich, K. P.; Ly, J.; Merchant, M.; Orr, C.; Plise, E.; Robarge, K.; Martini, J. F.; Kassees, R.; Aoyama, R. G.; Ramaiya, A.; Johnston, S. H. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions Drug Metab. Dispos. 2012, 40, 919 927 DOI: 10.1124/dmd.111.043778
        (b) Gilmartin, A. G.; Bleam, M. R.; Groy, A.; Moss, K. G.; Minthorn, E. A.; Kulkami, S. G.; Rominger, C. M.; Erskine, S.; Fisher, K. E.; Yang, J.; Azppacosta, F.; Annan, R.; Sutton, D.; Laquerre, S. G. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin. Cancer Res. 2011, 17, 989 1000 DOI: 10.1158/1078-0432.CCR-10-2200
      232. 232
        (a) Widemann, B. C.; Marcus, L. J.; Fisher, M. J.; Weiss, B. D.; Kim, A.; Dombi, E.; Baldwin, A.; Whitcomb, P.; Martin, S.; Gillespie, A.; Doyle, A. Phase I study of the MEK1/2 inhibitor selumetinib (AZ6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs) J. Clin. Oncol. 2014, 32 (Suppl.) 10018
        (b) https://clinicaltrials.gov/ct2/show/NCT01089101 (accessed June 12, 2016) .
      233. 233
        Binimetinib has advanced to a trial enrolling patients with brain cancer: https://clinicaltrials.gov/ct2/show/NCT02285439 (accessed June 10, 2016) .
      234. 234
        Iverson, C.; Larson, G.; Lai, C.; Yeh, L. T.; Dadson, C.; Weingarten, P.; Appleby, T.; Vo, T.; Maderna, A.; Vernier, J. M.; Hamatake, R.; Miner, J. N.; Quart, B. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer Cancer Res. 2009, 69, 6839 6847 DOI: 10.1158/0008-5472.CAN-09-0679
      235. 235
        Isshiki, Y.; Kohchi, Y.; Iikura, H.; Matsubara, Y.; Asoh, K.; Murata, T.; Kohchi, M.; Mizuguchi, E.; Tsujii, S.; Hattori, K.; Miura, T.; Yoshimura, Y.; Aida, S.; Miwa, M.; Saitoh, R.; Murao, N.; Okabe, H.; Belunis, C.; Janson, C.; Lukacs, C.; Schuck, V.; Shimma, N. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent Bioorg. Med. Chem. Lett. 2011, 21, 1795 1801 DOI: 10.1016/j.bmcl.2011.01.062
      236. 236
        Cohen, R. B.; Aamdal, S.; Nyakas, M.; Cavallin, M.; Green, D.; Learoyd, M.; Smith, I.; Kurzrock, R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies Eur. J. Cancer 2013, 49, 1521 1529 DOI: 10.1016/j.ejca.2013.01.013
      237. 237
        Shaw, J. V.; Zhang, H.; Carden, R.; Qiu, D.; Tian, H.; Ma, J.; Clark, A.; Ogden, J.; Goodstal, S. Abstract LB-456: Evaluation of brain pharmacokinetics as a potential differentiation factor for the MEK inhibitors, MSC2015103 and pimasertib Cancer Res. 2012, 72, LB-456 DOI: 10.1158/1538-7445.AM2012-LB-456
      238. 238
        Goutopoulos, A.; Askew, B.; Bankston, D.; Clark, A.; Dhanabal, M.; Dong, R.; Fischer, D.; Healey, B.; Jiang, X.; Josephson, K.; Lin, J.; Ma, J.; Noonan, T.; Qiu, D.; Rocha, C.; Romanelli, A.; Shutes, A.; Spooner, E.; Tian, H.; Yu, H. Abstract 4476: AS703026: a novel allosteric MEK inhibitor Cancer Res. 2009, 69 (Suppl.) 4776
      239. 239
        Shen, Y.; Boivin, R.; Yoneda, N.; Du, H.; Schiller, S.; Matsushima, T.; Goto, M.; Shirota, H.; Gusovsky, F.; Lemelin, C.; Jiang, Y.; Zhang, Z.; Pelletier, R.; Ikemori-Kawada, M.; Kawakami, Y.; Inoue, A. Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III Bioorg. Med. Chem. Lett. 2010, 20, 3155 3157 DOI: 10.1016/j.bmcl.2010.03.087
      240. 240
        Wu, J.; Nomoto, K.; Wang, J.; Kuznetsov, G.; Agoulnik, S.; Shuck, E.; Wong, N.; Towle, M.; Schnaderbeck, M.; Wu, S.; Littlefield, B. Abstract 3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts Cancer Res. 2009, 69 (Suppl.) 3687
      241. 241
        (a) Lee, C.; Fotovati, A.; Triscott, J.; Chen, J.; Venugopal, C.; Singhal, A.; Dunham, C.; Kerr, J. M.; Verreault, M.; Yip, S.; Wakimoto, H.; Jones, C.; Jayanthan, A.; Narendran, A.; Singh, S. K.; Dunn, S. E. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice Stem Cells 2012, 30, 1064 1075 DOI: 10.1002/stem.1081
        (b) Danovi, D.; Folarin, A.; Gogolok, S.; Ender, C.; Elbatsh, A. M. O.; Engström, P. G.; Stricker, S. H.; Gagrica, S.; Georgian, A.; Yu, D.; U, K. P.; Harvey, K. J.; Ferretti, P.; Paddison, P. J.; Preston, J. E.; Abbott, N. J.; Bertone, P.; Smith, A.; Pollard, S. M. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1 PLoS One 2013, 8, e77053 DOI: 10.1371/journal.pone.0077053
        (c) Pezuk, J. A.; Brassesco, M. S.; Morales, A. G.; de Oliveira, J. C.; de Paula Queiroz, R. G.; Machado, H. R.; Carlotti, C. G.; Neder, L.; Scrideli, C. A.; Tone, L. G. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma Cancer Gene Ther. 2013, 20, 499 506 DOI: 10.1038/cgt.2013.46
        (d) Tandle, A. T.; Kramp, T.; Kil, W. J.; Halthore, A.; Gehlhaus, K.; Shankavaram, U.; Tofilon, P. J.; Caplen, N. J.; Camphausen, K. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation Eur. J. Cancer 2013, 49, 3020 3028 DOI: 10.1016/j.ejca.2013.05.013
        (e) Pezuk, J. A.; Brassesco, M. S.; Morales, A. G.; de Oliveira, J. C.; de Oliveira, H. F.; Scrideli, C. A.; Tone, L. G. Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation Cancer Biother.Radiopharm. 2013, 28, 516 522 DOI: 10.1089/cbr.2012.1415
        (f) Triscott, J.; Lee, C.; Foster, C.; Manoranjan, B.; Pamid, M. R.; Berns, R.; Fotovati, A.; Venugopal, C.; O’Halloran, K.; Narendran, A.; Hawkins, C.; Ramaswamy, V.; Bouffet, E.; Taylor, M. D.; Singhal, A.; Hukin, J.; Rassekh, R.; Yip, S.; Northcott, P.; Singh, S. K.; Dunham, C.; Dunn, S. Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children Cancer Res. 2013, 73, 6734 6744 DOI: 10.1158/0008-5472.CAN-12-4331
      242. 242
        (a) Markant, S. L.; Esparza, L. A.; Sun, J.; Barton, K. L.; McCoig, L. M.; Grant, G. A.; Crawford, J. R.; Levy, M. L.; Northcott, P. A.; Shih, D.; Remke, M.; Taylor, M. D.; Wechsler-Reya, R. J. Targeting sonic hedgehog-associated medulloblastoma through inhibition of aurora and polo-like kinases Cancer Res. 2013, 73, 6310 6322 DOI: 10.1158/0008-5472.CAN-12-4258
        (b) Barton, V. N.; Foreman, N. K.; Donson, A. M.; Birks, D. K.; Handler, M. H.; Vibhakar, R. Aurora kinase A as a rational target for therapy in glioblastoma J. Neurosurg. Pediatr. 2010, 6, 98 105 DOI: 10.3171/2010.3.PEDS10120
        (c) Klein, A.; Reichardt, W.; Jung, V.; Zang, K. D.; Meese, E.; Urbschat, S. Overexpression and amplification of STK15 in human gliomas Int. J. Oncol. 2004, 25, 1789 1794 DOI: 10.3892/ijo.25.6.1789
      243. 243
        Li, N.; Maly, D. J.; Chanthery, Y. H.; Sirkis, D. W.; Nakamura, J. L.; Berger, M. S.; James, C. D.; Shokat, K. M.; Weiss, W. A.; Persson, A. I. Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma Mol. Cancer Ther. 2015, 14, 419 428 DOI: 10.1158/1535-7163.MCT-14-0526
      244. 244
        Wu, C.-P.; Hsieh, C.-H.; Hsiao, S.-H.; Luo, S.-Y.; Su, C.-Y.; Li, Y.-Q.; Huang, Y.-H.; Huang, C.-W.; Hsu, S.-C. Human ATP-binding cassette transporter ABCB1 confers resistance to volasertib (BI6727), a selective inhibitor of polo-like kinase 1 Mol. Pharmaceutics 2015, 12, 3885 3895 DOI: 10.1021/acs.molpharmaceut.5b00312
      245. 245
        Wu, C.-P.; Hsiao, S.-H.; Sim, H.-M.; Luo, S.-Y.; Tuo, W.-C.; Cheng, H.-W.; Li, Y.-Q.; Huan, Y.-H.; Ambudkar, S. V. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of polo-like kinase 1 Biochem. Pharmacol. 2013, 86, 904 913 DOI: 10.1016/j.bcp.2013.08.004
      246. 246
        Wu, C.-P.; Hsiao, S.-H.; Luo, S.-Y.; Tuo, W.-C.; Su, C.-Y.; Li, Y.-Q.; Huang, Y.-H.; Hsieh, C. H. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1 Mol. Pharmaceutics 2014, 11, 3727 3736 DOI: 10.1021/mp500492r
      247. 247
        White, M. P.; Babayeva, M.; Taft, D. R.; Maniar, M. Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure J. Pharm. Pharmacol. 2013, 65, 960 969 DOI: 10.1111/jphp.12057
      248. 248
        Sero, V.; Tavanti, E.; Vella, S.; Hattinger, C. M.; Fanelli, M.; Michelacci, F.; Versteeg, R.; Valsasina, B.; Gudeman, B.; Picci, P.; Serra, M. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance Invest. New Drugs 2014, 32, 1167 1180 DOI: 10.1007/s10637-014-0158-6
      249. 249
        Nie, Z.; Feher, V.; Natala, S.; McBride, C.; Kiryanov, A.; Jones, B.; Lam, B.; Liu, Y.; Kaldor, S.; Stafford, J.; Hikami, K.; Uchiyama, N.; Kawamoto, T.; Hikichi, Y.; Matsumoto, S.; Amano, N.; Zhang, L.; Hosfield, D.; Skene, R.; Zou, H.; Cao, X.; Ichikawa, T. Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1) Bioorg. Med. Chem. Lett. 2013, 23, 3662 3666 DOI: 10.1016/j.bmcl.2013.02.083
      250. 250
        Cheung, C. H. A.; Sarvagalla, S.; Lee, J. Y. C.; Huang, Y. C.; Coumar, M. S. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011–2013) Expert Opin. Ther. Pat. 2014, 24, 1021 1038 DOI: 10.1517/13543776.2014.931374
      251. 251
        Van Brocklyn, J. R.; Wojton, J.; Meisen, W. H.; Kellough, D. A.; Ecsedy, J. A.; Kaur, B.; Lehman, N. L. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma Cancer Res. 2014, 74, 5364 5370 DOI: 10.1158/0008-5472.CAN-14-0386
      252. 252
        Sathornsumetee, S.; Reardon, D. A.; Desjardins, A.; Quinn, J. A.; Vredenburgh, J. J.; Rich, J. N. Molecularly targeted therapy for malignant glioma Cancer 2007, 110, 13 24 DOI: 10.1002/cncr.22741
      253. 253
        Mochly-Rosen, D.; Das, K.; Grimes, K. V. Protein kinase C, an elusive target? Nat. Rev. Drug Discovery 2012, 11, 937 957 DOI: 10.1038/nrd3871
      254. 254
        (a) Kreisl, T. N.; Kotliarova, S.; Butman, J. A.; Albert, P. S.; Kim, L.; Musib, L.; Thornton, D.; Fine, H. A. A phase I/II trial of enzastaurin in pateints with recurrent high-grade gliomas Neuro-Oncology 2010, 12, 181 189 DOI: 10.1093/neuonc/nop042
        (b) Wick, W.; Puduvalli, V. K.; Chamberlain, M. C.; van den Bent, M. J.; Carpentier, A. F.; Cher, L. M.; Mason, W.; Weller, M.; Hong, S.; Musib, L.; Liepa, A. M.; Thornton, D. E.; Fine, H. A. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma J. Clin. Oncol. 2010, 28, 1168 1174 DOI: 10.1200/JCO.2009.23.2595
      255. 255
        Gronberg, B. H.; Ciuleanu, T.; Flotten, O.; Knuuttila, A.; Abel, E.; Langer, S. W.; Krejcy, K.; Liepa, A. M.; Munoz, M.; Hahka-Kemppinen, M.; Sundstrom, S. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer Lung Cancer 2012, 78, 63 69 DOI: 10.1016/j.lungcan.2012.07.007
      256. 256
        Yasoshima, K.; Kuwabara, T.; Fuse, E.; Kuramitu, T.; Kurata, N.; Nishiie, H.; Oishi, T.; Kobayashi, H.; Kobayashi, S. Pharmacokinetics, distribution, metabolism and excretion of [3H]UCN-01 in rats and dogs after intravenous administration Cancer Chemother. Pharmacol. 2001, 47, 106 112 DOI: 10.1007/s002800000213
      257. 257
        Budworth, J.; Davies, R.; Malkhandi, J.; Gant, T. W.; Ferry, D. R.; Gescher, A. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistance MCF-7/Adr cells Br. J. Cancer 1996, 73, 1063 1068 DOI: 10.1038/bjc.1996.205
      258. 258
        Capdeville, R.; Buchdunger, E.; Zimmerman, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1, 493 502 DOI: 10.1038/nrd839
      259. 259
        Quintas-Cardama, A.; Kantarjian, H. M.; Cortes, J. E. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia Cancer Control 2009, 16, 122 131
      260. 260
        Leis, J. F.; Stepan, D. E.; Curtin, P. T.; Ford, J. M.; Peng, B.; Schubach, S.; Druker, B. J.; Mariarz, R. T. Central nervous system failure in patients with chroinic mylogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571) Leuk. Lymphoma 2004, 45, 695 698 DOI: 10.1080/10428190310001625728
      261. 261
        (a) Dai, H.; Marbach, P.; Lemaire, M.; Hayes, M.; Elmquist, W. F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux J. Pharmacol. Exp. Ther. 2003, 304, 1085 1092 DOI: 10.1124/jpet.102.045260
        (b) Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen, O.; Schinkel, A. H.; Schellens, J. H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients Cancer Res. 2005, 65, 2577 2582 DOI: 10.1158/0008-5472.CAN-04-2416
        (c) Rajappa, S.; Uppin, S. G.; Raghunadharao, D.; Rao, I. S.; Surath, A. Isolated central nervous system blast crisis in chronic myeloid leukemia Hematol. Oncol. 2004, 22, 179 181 DOI: 10.1002/hon.737
        (d) Neville, K.; Parise, R. A.; Thompson, P.; Aleksic, A.; Egorin, M. J.; Balis, F. M.; McGuffey, L.; McCully, C.; Berg, S. L.; Blaney, S. M. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates Clin. Cancer Res. 2004, 10, 2525 2529 DOI: 10.1158/1078-0432.CCR-03-0155
      262. 262
        Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor J. Med. Chem. 2006, 49, 6819 6832 DOI: 10.1021/jm060727j
      263. 263
        Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Müller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Funga, G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 2009, 23, 477 485 DOI: 10.1038/leu.2008.334
      264. 264
        (a) Du, J.; Bernasconi, P.; Clauser, K. R.; Mani, D. R.; Finn, S. P.; Beroukhim, R.; Burns, M.; Julian, B.; Peng, X. P.; Hieronymus, H.; Maglathin, R. L.; Lewis, T. A.; Liau, L. M.; Nghiemphu, P.; Mellinghoff, I. K.; Louis, D. N.; Loda, M.; Carr, S. A.; Kung, A. L.; Golub, T. R. Bead-based kinase phosphorylation profiling identifies SRC as a therapeutic target in glioblastoma Nat. Biotechnol. 2009, 27, 77 83 DOI: 10.1038/nbt.1513
        (b) Zhang, S.; Huang, W.-C.; Zhang, L.; Zhang, C.; Lowery, F. J.; Ding, Z.; Guo, H.; Wang, H.; Huang, S.; Sahin, A. A.; Aldape, K. D.; Steeg, P. S.; Yu, D. Src family kinases as novel therapeutic targets to treat breast cancer brain metastases Cancer Res. 2013, 73, 5764 5774 DOI: 10.1158/0008-5472.CAN-12-1803
      265. 265
        Chen, Y.; Agarwal, S.; Shaik, N. M.; Chen, C.; Yang, Z.; Elmquist, W. F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib J. Pharmacol. Exp. Ther. 2009, 330, 956 963 DOI: 10.1124/jpet.109.154781
      266. 266
        Porkka, K.; Koskenvesa, P.; Lundan, T.; Rimpilainen, J.; Mustjoki, S.; Smykla, R.; Wild, R.; Luo, R.; Arnan, M.; Brethon, B.; Eccersley, L.; Hjorth-Hansen, H.; Hoglund, M.; Klamova, H.; Knutsen, H.; Parikh, S.; Raffoux, E.; Gruber, F.; Brito-Babapulle, F.; Dombret, H.; Duarte, R. F.; Elonen, E.; Paquette, R.; Zwaan, C. M.; Lee, F. Y. F. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood 2008, 112, 1005 1012 DOI: 10.1182/blood-2008-02-140665
      267. 267
        Hegedus, C.; Özvegy-Laczka, C.; Apati, A.; Magocsi, M.; Nemet, K.; Orfi, L.; Keri, G.; Katona, M.; Takats, Z.; Varadi, A.; Szakacs, G.; Sarkadi, B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties Br. J. Pharmacol. 2009, 158, 1153 1164 DOI: 10.1111/j.1476-5381.2009.00383.x
      268. 268
        Atilla, E.; Ataca, P.; Ozyurek, E.; Erden, I.; Gurman, G. Successful bosutinib experience in an elderly acute lymphoblastic leukemia patient with suspected central nervous system involvement transformed from chronic myeloid leukemia Case Rep. Hematol. 2015, 2015, 689423 DOI: 10.1155/2015/689423
      269. 269
        Taylor, J. W.; Dietrich, J.; Gerstner, E. R.; Norden, A. D.; Rinne, M. L.; Cahill, D. P.; Stemmer-Rachamimov, A.; Wen, P. Y.; Betensky, R. A.; Giorgio, D. H.; Snodgrass, K.; Randall, A. E.; Batchelor, T. T.; Chi, A. S. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma J. Neuro-Oncol. 2015, 121, 557 563 DOI: 10.1007/s11060-014-1667-z
      270. 270
        (a) Kosztyu, P.; Dolezel, P.; Mlejnek, P. Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells? Pharmacol. Res. 2013, 67, 79 83 DOI: 10.1016/j.phrs.2012.10.012
        (b) Yamakawa, Y.; Hamada, A.; Uchida, T.; Sato, D.; Yuki, M.; Hayashi, M.; Kawaguchi, T.; Saito, H. Distinct interaction of nilotinib and imatinib with P-glycoprotein in intracellular accumulation and cytotoxicity in CML cell line K562 cells Biol. Pharm. Bull. 2014, 37, 1330 1335 DOI: 10.1248/bpb.b14-00254
      271. 271
        Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brüggen, J.; Cowan-jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Mohammed, A.; Neuberg, D.; Wright, R. D.; Gilliand, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005, 7, 129 141 DOI: 10.1016/j.ccr.2005.01.007
      272. 272
        Reinwald, M.; Schleyer, E.; Kiewe, P.; Blau, I. W.; Burmeister, T.; Pursche, S.; Neumann, M.; Notter, M.; Thiel, E.; Hofmann, W.-K.; Kolb, H.-J.; Burdach, S.; Bender, H.-U. Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation BioMed Res. Int. 2014, 2014, 637059 DOI: 10.1155/2014/637059
      273. 273

        For example see the following and references therein:

        Lonskaya, I.; Hebron, M. L.; Selby, S. T.; Turner, R. S.; Moussa, C. E.-H. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in alzheimer’s disease models Neuroscience 2015, 304, 316 327 DOI: 10.1016/j.neuroscience.2015.07.070
      274. 274
        Huang, W.-S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J. Med. Chem. 2010, 53, 4701 4719 DOI: 10.1021/jm100395q
      275. 275
        Laramy, J. K.; Parrish, K. E.; Zhang, S.; Bakken, K. K.; Carlson, B. L.; Mladek, A. C.; Ma, D. J.; Sarkaria, J. N.; Elmquist, W. F. Brain distribution of ponatinib, a multi-kinase inhibitor: implications for the treatment of malignant brain tumors Am. Assoc. Pharm. Sci. 2015, W4339
      276. 276
        Niwa, T.; Asaki, T.; Kimura, S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor Anal. Chem. Insights 2007, 2, 93 106
      277. 277
        Portnow, J.; Badie, B.; Markel, S.; Liu, A.; D’Apuzzo, M.; Frankel, P.; Jandial, R.; Synold, T. W. A neuropharmocokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas Eur. J. Cancer 2013, 49, 1634 1640 DOI: 10.1016/j.ejca.2013.01.001
      278. 278
        Yokota, A.; Kimura, S.; Masuda, S.; Ashihara, E.; Kuroda, J.; Sato, K.; Kamitsuji, Y.; Kawata, E.; Deguchi, Y.; Urasaki, Y.; Terui, Y.; Ruthardt, M.; Ueda, T.; Hatake, K.; Inui, K.; Maekawa, T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood 2007, 109, 306 314 DOI: 10.1182/blood-2006-03-013250
      279. 279
        Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R. A.; Olivier, A.; Otterbein, L.; Ple, P. A.; Warin, N.; Costello, G. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor J. Med. Chem. 2006, 49, 6465 6488 DOI: 10.1021/jm060434q
      280. 280
        Kaufman, A. C.; Salazar, S. V.; Haas, L. T.; Yang, J.; Kostylev, M. A.; Jeng, A. T.; Robinson, S. A.; Gunther, E. C.; van Dyck, C. H.; Nygaard, H. B.; Strittmatter, S. M. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice Ann. Neurol. 2015, 77, 953 971 DOI: 10.1002/ana.24394
      281. 281
        Nygaard, H. B.; Wagner, A. F.; Bowen, G. S.; Good, S. P.; MacAvoy, M. G.; Strittmatter, K. A.; Kaufman, A. C.; Rosenberg, B. J.; Sekine-Konno, T.; Varma, P.; Chen, K.; Koleske, A. J.; Reiman, E. M.; Strittmatter, S. M.; van Dyck, C. H. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease Alzheimer's Res. Ther. 2015, 7, 35 DOI: 10.1186/s13195-015-0119-0
      282. 282
        (a) Abounader, R.; Laterra, J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis Neuro-Oncology 2005, 7, 436 451 DOI: 10.1215/S1152851705000050
        (b) Zhang, Y.; Farenholtz, K. E.; Yang, Y.; Guessous, F.; diPierro, C. G.; Calvert, V. S.; Deng, J.; Schiff, D.; Xin, W.; Lee, J. K.; Purow, B.; Christensen, J.; Petricoin, E.; Abounader, R. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition Clin. Cancer Res. 2013, 19, 1433 1444 DOI: 10.1158/1078-0432.CCR-12-2832
      283. 283
        Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K. A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69, 8009 8016 DOI: 10.1158/0008-5472.CAN-08-4889
      284. 284
        Faria, C. C.; Golbourn, B. J.; Dubuc, A. M.; Remke, M.; Diaz, R. J.; Agnihotri, S.; Luck, A.; Sabha, N.; Olsen, S.; Wu, X.; Garzia, L.; Ramaswamy, V.; Mack, S. C.; Wang, X.; Leadley, M.; Reynaud, D.; Ermini, L.; Post, M.; Northcott, P. A.; Pfister, S. M.; Croul, S. E.; Kool, M.; Korshunov, A.; Smith, C. A.; Taylor, M. D.; Rutka, J. T. Foretinib is effective for metastatic sonic hedgehog medulloblastoma Cancer Res. 2015, 75, 134 146 DOI: 10.1158/0008-5472.CAN-13-3629
      285. 285
        Buchanan, S. G.; Hendle, J.; Lee, P. S.; Smith, C. R.; Bounaud, P. Y.; Jessen, K. A.; Tang, C. M.; Huser, N. H.; Felce, J. D.; Froning, K. J.; Peterman, M. C.; Aubol, B. E.; Gessert, S. F.; Sauder, J. M.; Schwinn, K. D.; Russell, M.; Rooney, I. A.; Adams, J.; Leon, B. C.; Do, T. H.; Blaney, J. M.; Sprengeler, P. A.; Thompson, D. A.; Smyth, L.; Pelletier, L. A.; Atwell, S.; Holme, K.; Wasserman, S. R.; Emtage, S.; Burley, S. K.; Reich, S. H. SGX is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo Mol. Cancer Ther. 2009, 8, 3181 3190 DOI: 10.1158/1535-7163.MCT-09-0477
      286. 286
        Guessous, F.; Zhang, Y.; diPierro, C.; Marcinkiewicz, L.; Sarkaria, J.; Schiff, D.; Buchanan, S.; Abounader, R. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth Anti-Cancer Agents Med. Chem. 2010, 10, 28 35 DOI: 10.2174/1871520611009010028
      287. 287
        (a) Underiner, T. L.; Herbertz, T.; Miknyoczki, S. J. Disovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates Anti-Cancer Agents Med. Chem. 2010, 10, 7 27 DOI: 10.2174/1871520611009010007
        (b) Burbridge, M. F.; Bossard, C. J.; Saunier, C.; Fejes, I.; Bruno, I.; Bruno, A.; Leonce, S.; Ferry, G.; Da Violante, G.; Bouzom, F.; Cattan, V.; Jacquet-Bescond, A.; Comoglio, P. M.; Lockhart, B. P.; Boutin, J. A.; Cordi, A.; Ortuno, J. C.; Pierre, A.; Hickman, J. A.; Cruzalegui, F. H.; Depil, S. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab Mol. Cancer Ther. 2013, 12, 1749 1762 DOI: 10.1158/1535-7163.MCT-13-0075
      288. 288

        Literature related to the following c-Met inhibitors was reviewed in an effort to identify any information regarding potential for CNS penetration, including whether the molecules are P-gp substrates: LY2801653, PF-04217903, golvatinib, JNJ-58877605, PHA-66752, tivantinib.

      289. 289
        (a) Gutenberg, A.; Brück, W.; Buchfelder, M.; Ludwig, H. C. Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas Acta Neuropathol. 2004, 108, 224 230 DOI: 10.1007/s00401-004-0886-3
        (b) Rolon-Reyes, K.; Kucheryavykh, Y. V.; Cubano, L. A.; Inyushin, M.; Skatchkov, S. N.; Eaton, M. J.; Harrison, J. K.; Kucheryavykh, L. Y. Microglia activate migration of glioma cells through a Pyk2 intracellular pathway PLoS One 2015, 10, e0131059 DOI: 10.1371/journal.pone.0131059
      290. 290
        Sulzmaier, F. J.; Jean, C.; Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications Nat. Rev. Cancer 2014, 14, 598 610 DOI: 10.1038/nrc3792
      291. 291
        Luzzio, M.; Autry, C.; Berliner, M.; Coleman, K.; Cooper, B.; Desrosiers, E.; Emerson, E.; Griffor, M.; Hulford, C.; Jani, J.; Kath, J.; LaGreca, S.; Lin, J.; Lorenzen, M.; Marr, E.; Martinez-Alsina, L.; Patel, N.; Richter, D.; Ung, E.; Vajdos, F.; Wessel, M.; Whalen, P.; Yao, L.; Roberts, W. Abstract 5432: Design, synthesis, activity and properties of selective focal adhesion kinase inhibitors which are suitable for advanced preclinical evaluation: the discovery of PF-562271 Cancer Res. 2007, 67 (Suppl.) 5432
      292. 292
        Xu, Q.; Pachter, J. A.; Tam, W. Methods and compositions for treating abnormal cell growth (e.g., cancer) using FAK inhibitor and a MEK inhibitor. WO Patent WO2015120289 A1, 2015.
      293. 293
        Schlaepfer, D. Method of promoting apoptosis and inhibiting metastasis. WO Patent WO2011019943 A1, 2011.
      294. 294
        Auger, K. R.; Peddareddigari, V. G. R. Combinations. WO Patent WO2014059095 A1, 2014.
      295. 295
        Mulholland, P.; Williams, M.; Arkenau, H. T.; Fleming, R.; Tolson, J.; Yan, L.; Zhang, J.; Swartz, L.; Singh, R.; Auger, K.; Lenox, L.; Cox, D.; Plisson, C.; Saleem, A.; Searle, G.; Blagden, S. ATNT 06. Evaluation of the safety of GSK2256098 and pharmacokinetics of 11C-GSK2256098 in patients with recurrent glioblastoma by positron emission tomography (PET) imaging Neuro-Oncology 2015, 17 (Suppl. 5) v11 DOI: 10.1093/neuonc/nov205.06
      296. 296
        (a) Han, J.; Alvarez-Breckenridge, C. A.; Wang, Q. E.; Yu, J. TGF-b signaling and its targeting for glioma treatment Am. J. Cancer Res. 2015, 5, 945 955
        (b) Luwor, R. B.; Kaye, A. H.; Zhu, H. J. Transforming growth factor-beta (TGF-b) and brain tumors J. Clin. Neurosci. 2008, 15, 845 855 DOI: 10.1016/j.jocn.2008.01.003
      297. 297
        Herbertz, S.; Sawyer, J. S.; Stauber, A. J.; Gueorguieva, I.; Driscoll, K. E.; Estrem, S. T.; Cleverly, A. L.; Desaiah, D.; Guba, S. C.; Benhadji, K. A.; Slapak, C. A.; Lahn, M. M. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta singaling pathway Drug Des., Dev. Ther. 2015, 9, 4479 4499 DOI: 10.2147/DDDT.S86621
      298. 298
        Herzog, S.; Fink, M. A.; Weitmann, K.; Friedel, C.; Hadlich, S.; Langner, S.; Kindermann, K.; Holm, T.; Bohm, A.; Eskilsson, E.; Miletic, H.; Hildner, M.; Fritsch, M.; Vogelgesang, S.; Havemann, C.; Ritter, C. A.; Meyer zu Schwabedissen, H. E.; Rauch, B.; Hoffmann, W.; Kroemer, H. K.; Schroeder, H.; Bien-Moller, S. Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival Neuro-Oncology 2015, 17, 223 242 DOI: 10.1093/neuonc/nou216
      299. 299
        Chen, L. S.; Redkar, S.; Bearss, D.; Wierda, W. G.; Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Blood 2009, 114, 4150 4157 DOI: 10.1182/blood-2009-03-212852
      300. 300
        Burger, M. T.; Nishiguchi, G.; Han, W.; Lan, J.; Simmons, R.; Atallah, G.; Ding, Y.; Tamez, V.; Zhang, Y.; Mathur, M.; Muller, K.; Bellamacina, C.; Lindvall, M. K.; Zang, R.; Huh, K.; Feucht, P.; Zavorotinskaya, T.; Dai, Y.; Basham, S.; Chan, J.; Ginn, E.; Aycinena, A.; Holash, J.; Castillo, J.; Langowski, J. L.; Wang, Y.; Chen, M. Y.; Lambert, A.; Fritsch, C.; Kauffmann, A.; Pfister, E.; Vanasse, K. G.; Garcia, P. D. Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a potent and selective proviral insertion site of moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitor in clinical trials for hematological malignancies J. Med. Chem. 2015, 58, 8373 8386 DOI: 10.1021/acs.jmedchem.5b01275
      301. 301
        Keeton, E. K.; McEachern, K.; Dillman, K. S.; Palakurthi, S.; Cao, Y.; Grondine, M. R.; Kaur, S.; Wang, S.; Chen, Y.; Wu, A.; Shen, M.; Gibbons, F. D.; Lamb, M. L.; Zheng, X.; Stone, R. M.; DeAngelo, D. J.; Platanias, L. C.; Dakin, L. A.; Chen, H.; Lyne, P. D.; Huszar, D. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia Blood 2014, 123, 905 913 DOI: 10.1182/blood-2013-04-495366
      302. 302
        Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase ChemMedChem 2007, 2, 58 61 DOI: 10.1002/cmdc.200600221
      303. 303
        Bernard, S.; Goldwirt, L.; Amorim, S.; Brice, P.; Bnere, J.; de Kerviller, E.; Mourah, S.; Sauvageon, H.; Thieblemont, C. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse Blood 2015, 126, 1695 1698 DOI: 10.1182/blood-2015-05-647834
      304. 304
        205552 Clinical Pharmacology Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf (accessed June 12, 2016) .
      305. 305
        (a) Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J. M.; Valerie, N. C. K.; Tokarz, M.; Adams, B. R.; Wagner, A. F.; Khalil, A.; Gilfor, D.; Golding, S. E.; Deb, S.; Temesi, D. G.; Lau, A.; O’Connor, M. J.; Choe, K. S.; Parada, L. F.; Lim, S. K.; Mukhopadhyay, N. D.; Valerie, K. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation Clin. Cancer Res. 2013, 19, 3189 3200 DOI: 10.1158/1078-0432.CCR-12-3408
        (b) Nadkarni, A.; Shrivastav, M.; Mladek, A. C.; Schwingler, P. M.; Grogan, P. T.; Chen, J.; Sarkaria, J. N. ATM inhibitor Ku-55993 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells J. Neuro-Oncol. 2012, 110, 349 357 DOI: 10.1007/s11060-012-0979-0
      306. 306
        Linger, R. M. A.; Keating, A. K.; Earp, H. Sh.; Graham, D. K. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors Expert Opin. Ther. Targets 2010, 14, 1073 1090 DOI: 10.1517/14728222.2010.515980
      307. 307

        As an example of the potential importance of inhibiting multiple kinases:

        Joshi, A. D.; Loilome, W.; Siu, I.-M.; Tyler, B.; Gallia, G. L.; Riggins, G. J. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy PLoS One 2012, 7, e44372 DOI: 10.1371/journal.pone.0044372
      308. 308

        See Supporting Information for details of individual inhibitors.

    • Supporting Information

      Supporting Information

      ARTICLE SECTIONS
      Jump To

      The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.6b00618.

      • Calculated physicochemical properties of FDA approved kinase inhibitors and of discussed inhibitors that are capable of penetrating the BBB or have limited CNS penetration (PDF)



      Terms & Conditions

      Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect

    This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. Read the ACS privacy policy.

    CONTINUE